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1
GENERAL INTRODUCTION
Osteoporosis-related fractures represent a major health care problem demanding 
immediate attention from the physician. Osteoporosis is defined as a chronic disease 
characterized by low bone mass and a deterioration in bone microarchitecture and 
material properties of bone leading to decreased bone strength and increased risk of 
fracture (1). A fracture is the single most important clinical consequence of osteoporo-
sis, the majority of which occur in postmenopausal women and old age. It is estimated 
that 3.5 million fractures occur each year in Europe (2). In the Netherlands, there are 
more than 800,000 women and men diagnosed with osteoporosis, with an estimated 
number of 49,000 fractures in women and 27,000 in men likely to occur each year 
(3). It is thus estimated that one in three women and one in five men aged 50 years 
or older will sustain a fracture in their lifetime. All fractures have been shown to be 
associated with increased morbidity and mortality and with a decrease in quality of life, 
all reflected in personal, societal and economic burdens (2, 4, 5).
And yet, despite accumulating evidence for the detrimental consequences of frac-
tures, the number of patients who do not receive adequate attention after a recently 
sustained fracture remains alarming (6, 7). This issue has been clearly recognized by 
the International Osteoporosis Foundation leading to the launch of the global initiative 
of “Capture the Fracture” to increase awareness and attention for post-fracture care 
(8). This post-fracture care includes a number of facets ideally bundled in a Fracture 
Liaison Service (FLS), which consist primarily of a multidisciplinary care trajectory offer-
ing screening for osteoporosis using Dual Energy X-ray Absorptiometry (DXA), and for 
possible underlying secondary factors for increased fracture risk in the form of a panel 
of laboratory investigations in patients at high risk for fractures. Establishment of an 
FLS has clearly been shown to be associated with a decrease in the incidence of new 
fractures and in mortality (5). This approach has thus proven to be a successful formula 
in the management of osteoporosis by providing secondary fracture prevention in 
patients with a recent fracture in a cost-effective approach (9, 10).
In daily clinical practice, Bone Mineral Density (BMD) measurements using DXA remain 
the corner stone for the diagnosis of osteoporosis. BMD is measured at two main 
representative sites of the skeleton: the lumbar spine (L1-L4) and the femoral neck. 
T-scores are calculated using country-specific reference values obtained in groups 
of healthy young female subjects. The diagnosis of a normal BMD (T-score ≥ -1.0 
SD), osteopenia (T-score > -2.5 and ≤ -1.0 SD) or osteoporosis (T-score ≤ -2.5 SD) is 
based on established World Health Organization criteria (11, 12). BMD has been shown 
to be a strong predictor for fractures, and the combination of BMD and age further 
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strengthens the predictive value of BMD for fractures (13, 14). Although the incidence 
of fractures increases with age, the majority of fractures in elderly patients has been 
shown to occur in the presence of osteopenia (13, 15).
There is increasing evidence that factors other than BMD determine bone fragility 
and thus fracture risk. These underlying secondary risk factors for fractures should be 
taken into account in the assessment of an individual’s fracture risk. Several studies 
have shown that these other secondary factors for increased bone fragility are com-
mon in patients with osteoporosis (16–18), but evidence is also accumulating for a high 
prevalence of these factors in patients with osteopenia (16, 17). Secondary factors for 
fractures are numerous and may be identified by a detailed medical history including 
smoking and drug use particularly glucocorticoids, and evaluated and confirmed using 
appropriate laboratory investigations including thyroid and gonadal function, which 
may be expanded to include less common causes potentially contributing to bone fra-
gility. It is important to identify these factors as a number may be reversible. Evaluation 
of secondary factors for fracture risk is included in the FRAX algorithm, a computer-
based algorithm, accessible online (http://www.sheffield.ac.uk/FRAX/index.aspx), that 
makes use of the presence or absence of independent risk factors to generate a 10-
year probability for a major osteoporotic fracture (clinical spine, hip, distal radius and 
humerus) and for a hip fracture (19, 20). The model input includes an individual’s age, 
gender and BMI, and information on the presence or absence of the following risk fac-
tors: prior fracture, parental history of hip fracture, ever use of glucocorticoids, current 
smoking, excessive use of alcohol, rheumatoid arthritis and other secondary causes 
for osteoporosis (Table 1). Fracture risk prediction has been shown to be improved by 
including data on femoral neck BMD in the calculation although FRAX can also provide 
adequate fracture risk prediction without the inclusion of femoral neck BMD (21). A 
number of significant limitations has been identified, however, with the use of FRAX. 
There is thus no weight given for a likely dose response effect of glucocorticoid use, 
of smoking and other factors in the algorithm. In addition, FRAX does not take into 
account a number of risk factors significantly associated with fracture risk such as falls 
and frailty, biochemical markers of bone turnover and the presence of morphometric 
vertebral fractures (19).
The presence of one or more vertebral fractures has been thus shown to represent a 
strong independent predictor for future vertebral and for non-vertebral fractures (22, 
23), and vertebral fractures have been shown to be associated with increased morbid-
ity and mortality (24, 25). Assessment of vertebral fractures should therefore be incor-
porated in the evaluation of all patients with osteoporosis. Conventional radiographs 
of the spine remain the gold standard for screening for the presence of vertebral 
fractures. However, Vertebral Fracture Assessment (VFA) is advocated as a surrogate 
11
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screening method for the presence of vertebral fractures and has been increasingly 
used in clinical practice although its value is as yet to be formally validated (26). VFA is 
a technique available on the DXA machine using a software programme, which allows 
the patient-friendly evaluation of the presence of vertebral fractures in the same ses-
sion as a BMD measurement. Lower radiation exposure, better time-management and 
possible lowers costs are considered to be potential benefits of using VFA compared 
with conventional spine radiographs (27, 28).
Over the past two decades, there has been accumulating evidence for a contribu-
tory role of factors other than BMD, such as bone structure, bone composition and 
material properties of bone to bone strength, although these factors have been so far 
difficult to assess. An increasingly used method for the evaluation of disturbances in 
bone architecture in clinical trials is High Resolution peripheral Quantitative Computed 
Tomography (HRpQCT), a non-invasive 3-dimensional imaging technique (29). This 
method can distinguish trabecular from cortical bone and is used to assess volumetric 
BMD at the distal radius and at the tibia. A number of studies, all conducted in post-
menopausal women with osteoporosis, showed a relationship between poor bone 
microarchitecture and fracture risk (29–31). These studies also demonstrated that 
postmenopausal women with osteopenia and fractures had worse microarchitecture 













Alcohol 3 or more U/day yes/no
Bone Mineral Density:
Femoral neck …g/cm2
kg kilograms; cm centimetres; U unit; g/cm2 grams per square centimetres.
* Disorders strongly related with osteoporosis; type I diabetes mellitus, osteogenesis imperfecta, untreated 
long-standing hyperthyroidism, hypogonadism or premature menopause (<  45 years), chronic malnutrition, 
malabsorption and chronic liver disease.
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than women without fractures (29, 32). A further study, also conducted in postmeno-
pausal women with osteopenia, demonstrated a relationship between cortical porosity 
and fractures of the distal radius (33).
Another tool used to assess structural characteristics of bone is the Trabecular Bone 
Score (TBS), a non-invasive technique that uses DXA-generated lumbar spine images 
(34–36), to produce 3-dimensional microarchitectural parameters of bone (37, 38). TBS 
has been found to be predictive of fracture risk in several prospective studies, also 
showing improvement of the predictive value of TBS when combined with BMD data 
(39–42).
Despite the promising advances made possible with the use of these novel technolo-
gies, it remains difficult to assess material properties of bone. The gold standard for 
the assessment of these properties have so far been the compression test and the 
three-point bending test, but these are ex vivo methods undertaken on transiliac bone 
biopsy material and not otherwise applicable for use in vivo in the clinic. Reference 
Point Indentation is a relatively new microindentation technique that assesses bone’s 
resistance to fracture in a minimally invasive manner (43, 44). The first clinical stud-
ies using cyclic microindentation (44), an earlier version of the technique, and impact 
microindentation (45, 46), the most recently improved version of the technique that 
is now increasingly used in clinical studies, have provided interesting insights into 
the material properties of bone, which are further discussed in Chapter 5. In short, 
impact microindentation makes use of a single impact device called the OsteoProbe, 
to indent the bone surface of the tibia, allowing the evaluation of material properties 
of bone at the cortical level. The distance covered by the test probe after impact is the 
Indentation Distance Increase (IDI), which is used to calculate the outcome parameter: 
Bone Material Strength index (BMSi) defined as the radio of the harmonic mean of the 
IDI from a polymethylmethacrylate calibration phantom, to the mean IDI from the bone 
surface of the tibia (45). Over the past few years, this exciting field of investigation of 
bone material properties at the tissue level has gained increased momentum, particu-
larly with increased evidence about the ability of this tool to capture aspects of bone 
fragility which are independent of BMD (47–51)(this thesis). Despite further technical 
improvements of the RPI device, a number of questions still remain to be answered 
before the use of this tool could be widely advocated in the routine management of 
patients with high fracture risk with or without osteoporosis.
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OUTLINE OF THE THESIS
The first part of this thesis focuses on different aspects of the screening programme 
included in the Leiden University Medical Center’s FLS. Chapter 2 describes the 
prevalence of underlying secondary factors for increased bone fragility in patients 
who have recently sustained a fracture. In Chapter 3, we compared low-radiation VFA 
with conventional radiography of the spine in the identification of vertebral fractures. 
We were interested in the performance of VFA to identify vertebral fractures as this 
tool is being increasingly implemented in the clinic. Laboratory investigations are also 
part of the screening programme in our FLS to assess the presence of underlying 
secondary factors for increased bone fragility but bone turnover markers (BTMs) can 
also be easily measured from serum collected in the screening visit. Chapter 4 reports 
on the predictive value of BTMs for treatment outcome after starting treatment with 
antiresorptive drugs.
Over a decade ago, Reference Point Indentation (RPI) was introduced as a new 
method for the in vivo evaluation of tissue-level material properties of bone. Impact 
microindentation (IMI) is the RPI technique currently used in humans in vivo, Chapter 5 
provides a detailed and up-to-date review on all published in vivo clinical studies using 
the IMI technique in humans. In Chapter 6, we assessed the relationship between 
the IMI technique and prevalent fragility fractures in patients with low bone mass. We 
further expanded studies in this cohort in Chapter 7, as we were interested in the 
relationship between IMI and different types of fragility fractures, especially vertebral 
fractures. It has been shown that patients with acromegaly have an increased risk for 
vertebral fractures in the presence of relatively normal BMD values. In Chapter 8, we 
evaluated Bone Material Strength index (BMSi) values as measured by IMI in patients 
with acromegaly compared to control patients. We also compared BMSi values in pa-
tients with acromegaly, with or without vertebral fractures. Although multiple studies 
have been published on IMI since its introduction, a number of questions remains 
unanswered, including the number of measurements necessary to calculate BMSi, the 
identification of correctly obtained measurements, insights on the variability of these 
measurements, and the preferred measurement site. In Chapter 9, we address these 
questions by using IMI to evaluate patients with Paget’s disease of bone localized in 
the tibia compared to patients without tibia pathology.
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In this study we demonstrate a high prevalence of secondary factors in patients with a 
recent fracture independently of BMD. Our results suggest that patients with a recent 
fracture should be screened for secondary factors for bone fragility regardless of BMD 
values.
Introduction:
Secondary factors for bone fragility are common in patients with osteoporosis who 
have sustained a fracture. The majority of fragility fractures occurs, however, in pa-
tients with osteopenia and it is not known whether secondary factors may contribute 
to fracture risk in these patients or in those with normal BMD.
Methods:
Prospective cohort study evaluating the prevalence of secondary factors for bone 
fragility in consecutive patients referred to our Fracture Liaison Service from June 
2012 to June 2014 after a recent fracture.
Results:
709 patients were included, 201 (28 %) with osteoporosis, 391 (55 %) with osteopenia 
and 117 (17 %) with normal BMD. Mean age was 66.0 ± 9.8 years, 504 (73 %) were women 
and 390 (57 %) had one or more underlying secondary factor. Evaluation of clinical risk 
factors using FRAX identified 38 % of patients with ≥ 1 secondary factor including smok-
ing (18 %), excessive alcohol use (12 %), glucocorticoid use (12 %) and rheumatoid arthritis 
(3 %). Laboratory investigations revealed chronic kidney disease in 13 %, monoclonal 
gammopathy also in 13 %, and primary or secondary hyperparathyroidism in 1 % and 6 %, 
respectively. Secondary factors for bone fragility were equally prevalent in patients 
with osteoporosis, osteopenia, or normal BMD.
Conclusions:
Our findings demonstrate a high prevalence of secondary factors for bone fragility in 
patients who have sustained a recent fracture, independently of BMD. The significant 
number of documented factors, which were treatable suggest that patients who sus-
tained a fracture should be screened for secondary factors for bone fragility regardless 
of BMD values to optimize secondary fracture prevention.
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INTRODUCTION
Osteoporotic fragility fractures are associated with increased morbidity and mortality 
and growing personal, societal and economic burdens [1–4]. The presence of a fragil-
ity fracture has also been shown to significantly increase the risk of future fractures 
[5, 6]. Over the past decade, Fracture Liaison Services (FLS) have been globally 
implemented to improve the identification and treatment of patients at risk for a new 
fracture in a cost-effective approach [7, 8]. Patients who sustain a fracture and who 
have osteoporosis are offered treatment with bone-modifying agents, but a significant 
number of patients who sustain a fracture have Bone Mineral Density (BMD) in the 
osteopenia range [9,10] and in the Netherlands, these are not generally screened for 
secondary factors for bone fragility and are not routinely offered anti-osteoporosis 
treatment [11, 12].
Secondary factors for bone fragility are common in patients with osteoporosis and 
a fragility fracture [13–15], but data on the prevalence of these factors in patients with 
osteopenia or normal BMD and a fragility fracture are scarce[13, 15]. Postmenopausal 
women with osteopenia and fragility fractures have been shown to have poor bone mi-
croarchitecture and altered material properties of bone, which may also be influenced 
by secondary factors for bone fragility [16–19]. To assess the potential contribution of 
secondary factors for bone fragility to fracture risk, we set out to evaluate the preva-
lence of these factors in a cohort of patients who had recently sustained a fracture and 
who were referred to the FLS for further investigation and management.
PATIENTS AND METHODS
Study design
Prospective cohort study in which all patients ≥ 50 years with a recent fracture, who 
were referred to the FLS of the Leiden University Medical Center from June 2012 to 
June 2014 were screened for secondary factors for bone fragility.
Patients
Patients were informed of their referral to the FLS during their follow-up visit for pri-
mary fracture care at the Outpatient Clinics of the Departments of Traumatology or 
Orthopaedic Surgery. Excluded from the study were patients with an isolated fracture 
of the skull, hands or feet, patients with pathological fractures or those with fractures 
resulting from failure of prosthesis. Patients who had undergone screening for osteo-
porosis in another hospital were also not included in the study. Patients with impaired 




The following data were collected in all patients: age, gender, height and weight 
(from which Body Mass Index (BMI) was calculated), a full medical history including 
detailed fracture history, family history of osteoporosis, dietary calcium intake, age 
at menopause (early menopause was defined as menopause at age ≤  45 years), 
parental history of hip fracture, alcohol use, corticosteroid use, smoking, current use 
of medication, including vitamin D supplementation, past or present use of hormone 
replacement therapy and past or present use of bone modifying agents. The 10-year 
probability for a major osteoporotic fracture and for a hip fracture were calculated 
using the FRAX algorithm using reference values for the Dutch population [20]. The 
10-year fracture probabilities were calculated with and without inclusion of values for 
femoral neck BMD.
Bone Mineral Density
Bone Mineral Density was measured at the lumbar spine (L1-L4), and at the left and 
right femoral neck by Dual-energy X-ray Absorptiometry (DXA) using Hologic QDR 
Discovery A (Hologic, Bedford, MA, USA). T-scores were calculated using NHANES 
III reference values compatible with reference values for the Dutch population. The 
World Health Organization criteria were used to define osteoporosis, osteopenia and 
normal BMD. Average values of right and left femoral neck BMD were used in the 
analysis of data, except when both sides could not be measured due to the presence 
of a prosthesis.
Laboratory investigations
Serum was measured for calcium, albumin, inorganic phosphate, alkaline phosphatase, 
potassium, sodium, ureum, creatinine, TSH, PTH, 25-OH vitamin D and P1NP. Vitamin 
D deficiency was defined as serum levels of 25-OH vitamin D < 50nmol/L. Renal func-
tion was assessed by calculating the estimated glomerular filtration rate (eGFR) using 
the modification of diet in renal disease (MDRD) formula. Stages of chronic kidney 
disease were defined as I to V according to the classification of the National Kidney 
Foundation KDOQI [21]. Primary hyperparathyroidism was diagnosed by hypercalce-
mia (albumin corrected calcium > 2.55mmol/L) in the presence of an inappropriately 
normal or elevated PTH level (PTH > 8.0pmol/L), in the absence of thiazide use. Hy-
perthyroidism was diagnosed by a repeated TSH level < 0.300mU/L in the presence 
of a free T4 (fT4) level > 22.0 pmol/L and subclinical hyperthyroidism by a TSH level 
< 0.300mU/L in the presence of a fT4 level between 10.0–24.0 pmol/L, without use 
of interfering medication. Hypogonadism was screened for in men < 70 years of age 
and was diagnosed by a total testosterone level of < 8nmol/L in a morning sample. 
Screening for a monoclonal gammopathy using immunofixation was undertaken at the 
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discretion of the treating physician, mostly in case of unexpected osteoporosis and/
or multiple fractures, also in the presence of osteopenia. Monoclonal Gammopathy 
of Undetermined Significance (MGUS) was defined by the presence of M-protein in 
serum at a concentration of up to 10g/L, with no signs of organ damage in the form of 
anemia, hypercalcemia, kidney insufficiency or bone lesions [22].
Statistical analysis
All analyses were performed using the SPSS software for Windows (Version 20.0; SPSS 
Inc., Chicago, IL, USA). Between group differences in baseline characteristics were 
assessed using ANOVA, a Chi-square test or a Kruskall Wallis test. The prevalence of 
secondary factors for bone fragility according to the recently sustained fracture type 
was assessed using a Chi-square test. Pearson correlation coefficients were used to 
express correlations between the 10-year FRAX probability calculated with and without 
femoral neck BMD values (after logarithmic transformation), lumbar spine and mean 
femoral neck BMD, and the number of secondary factors for bone fragility. Partial 
correlation coefficients were calculated to assess the correlation between number of 
secondary factors and lumbar spine and mean femoral neck BMD after adjusting for 
age, gender and BMI. Multivariate logistic regression analysis was used to assess the 
contribution of BMD: normal, osteopenia and osteoporosis (variable) to the prevalence 
of secondary factors for bone fragility (outcome), adjusted for age, gender and BMI.
Differences were considered to be significant at p < 0.05.
RESULTS
In the 2-year study period, 1562 patients presented to the Emergency Room of the 
Leiden University Medical Center with a recent fracture. 706 patients were not referred 
to the Fracture Liaison Service for a variety of reasons detailed in Fig. 1. Compared to 
this group, the 856 patients who were referred were younger (68.6 ±  11.2 years vs. 
72.2 ± 12.9 years, p < 0.001), predominantly female (71 % vs. 69 %), and had sustained 
less hip fractures (hip fracture/vertebral fracture/non-hip non-vertebral fracture 9 %/ 6 %/ 
85 % vs. 22 %/ 8 %/ 70 %; p < 0.001). There was no significant difference in the number of 
female patients who were referred to the FLS or not, p = 0.229.
Of these 856 patients referred, 709 agreed to be further investigated for the pres-
ence of secondary factors for bone fragility and were included in the study. These 
were 196 men and 513 women, with a mean age of 67.1 ± 10.2 years (range 50.0 – 94.0 
years). Sixty-one (9 %) had a hip fracture, 40 (6 %) a clinical vertebral fracture, and 608 
(86 %) a non-hip/non-vertebral (NH/NV) fracture.
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Two-hundred and one patients (28 %) had osteoporosis, 391 (55 %) had osteopenia and 
117 (17 %) had normal Bone Mineral Density (BMD). Data on FRAX clinical risk factors for 
fracture and/or laboratory data were incomplete in 23 patients, so that 686 patients 
were included in the final analysis, 385 of whom had osteopenia and 102 normal BMD.
After stratification of patients according to BMD, there were significant differences 
in mean age (64.7 ± 9.9 years vs. 66.0 ± 9.8 years vs. 70.5 ± 10.2 years, p < 0.001), 
gender distribution (34 % vs. 29 % vs. 17 % male patients, p = 0.001) and BMI (28.2 ± 5.1 
vs. 26.7 ± 4.1 vs. 24.3 ± 3.8, p < 0.001) between groups of patients with respectively 
normal BMD, osteopenia and osteoporosis. There was no difference in biochemical 
parameters, number of patients with a previous fracture or with a history of parental 
hip fracture between the three BMD groups; Table 1.
1562 patients presenting to the ER 
of the LUMC with a fracture from 
June 2012 - June 2014  
191 referred to FLS in own region 
43 no follow-up after ER due to nature 
of fracture 
9 lost to follow-up after ER visit 
1319 patients with follow-up visit at 
the outpatient clinic of the 
Departments of Trauma Surgery or 
Orthopaedic Surgery 
Patients not referred to FLS: 
230 failure to refer 
61 under control specialist 
LUMC other than FLS group 
27 screened and treated by GP 
78 decreased cognitive function 
14 unable to visit FLS 
23 significant co-morbidity 
30 died during or close after 
discharge 
856 referred to FLS and invited 
to take part in the study 
147 patients refused 
709 patients included in the study 
Figure 1
Flowchart of inclusion of patients in the study after presenting to the Emergency Room of the Leiden University 
Medical Center with a recent fracture.
ER Emergency Room; FLS Fracture Liaison Service; GP General Practitioner
27
High prevalence of secondary factors in patients with a fracture
2
The majority of patients had a non-hip/non-vertebral (NH/NV) fracture [n = 586 (85 %)], 
60 patients (9 %) had a hip fracture, and 40 patients (6 %) had a clinical vertebral frac-
ture. The most prevalent NH/NV fracture was a wrist fracture [n = 221 (32 %)] followed 
by a fracture of the proximal humerus [n = 91 (13 %)] and of the ankle [n = 79 (12 %)]. Forty 
patients (67 %) with a hip fracture had a secondary factor for bone fragility, 28 patients 
(70 %) with a vertebral fracture and 322 patients (55 %) with a NH/NV fracture; p = 0.049.
A similar distribution of fractures was observed in patients with normal BMD: 6 (6 %) 
hip fracture, 4 (4 %) clinical vertebral fracture and 92 (90 %) NH/NV fracture, osteopenia: 
33 (9 %) hip fracture, 19 (5 %) vertebral fracture and 333 (86 %) NH/NV fracture, and in 
patients with osteoporosis: 21 (11 %) hip fracture, 17 (9 %) vertebral fracture and 161 (81 %) 
NH/NV fracture.
Secondary factors identified by clinical risk factors using FRAX
In patients with normal BMD, 13 patients (13 %) used ≥ 3 units of alcohol a day, 11 (11 %) 
were currently using or had previously used glucocorticoids, 15 (16 %) were active 
smokers and 3 (3 %) had rheumatoid arthritis; Table 2. Eight patients (9 %) had a history 






(n = 199) p-value
Age (years) 64.7 ± 9.9 66.0 ± 9.8 70.5 ± 10.2 < 0.001
Male/female (%) 35/67 113/272 34/165 0.001
(34 %/66 %) (29 %/71 %) (17 %/83 %) 
BMI (kg/m2) 28.2 ± 5.1 26.7 ± 4.1 24.3 ± 3.8 < 0.001
Previous Fracture (%) 41 (40 %) 163 (42 %) 83 (42 %) 0.918
Parental Hip Fracture (%) 10 (10 %) 50 (13 %) 28 (14 %) 0.560
FRAX score major fracture 5.2 ± 0.6 8.9 ± 0.3 17.0 ± 0.7 < 0.001
FRAX score hip fracture 0.5 ± 0.3 2.2 ± 0.2 7.3 ± 0.6 < 0.001
Laboratory data:
Calcium (mmol/L) 2.40 ± 0.12 2.41 ± 0.12 2.41 ± 0.11 0.648
Creatinine (µmol/L) 74.4 ± 15.3 74.7 ± 19.1 72.3 ± 26.4 0.422
PTH (pmol/L) 4.0 ± 2.4 4.4 ± 2.8 4.9 ± 4.2 0.111
25-OH D (nmol/L) 62.7 ± 36.6 57.5 ± 28.2 58.4 ± 30.5 0.677
DXA measurements:
LS BMD (g/cm2) 1.11 ± 0.12 0.95 ± 0.12 0.80 ± 0.14 < 0.001
T-score LS 0.5 ± 1.0 -1.0 ± 1.0 -2.3 ± 1.2 < 0.001
FN BMD (g/cm2) 0.86 ± 0.10 0.70 ± 0.07 0.58 ± 0.08 < 0.001
T-score FN -0.1 ± 0.7 -1.5 ± 0.5 -2.5 ± 0.6 < 0.001




of parental hip fracture and 41 (40 %) had sustained one or more previous fractures. The 
median FRAX 10-year fracture probability was 5.2 % for a major osteoporotic fracture 
and 0.5 % for a hip fracture, and was 7.3 % and 2.2 % respectively without inclusion of 
femoral neck BMD in the calculation.
In patients with osteopenia, 44 patients (11 %) used more than 3 units of alcohol per day, 
42 (11 %) were currently using or had previously used glucocorticoids, 64 (17 %) were 
active smokers, and 11 (3 %) had rheumatoid arthritis; Table 2. 50 patients (13 %) had at 
least one parent with a history of a hip fracture and 163 patients (42 %) had sustained 
a previous fracture.
The median 10-year fracture probability as calculated by FRAX was 8.9 % for a major 
osteoporotic fracture and 2.2 % for a hip fracture. Without inclusion of femoral neck 
BMD in the calculation, the median 10-year fracture probability was 9.4 % for a major 
osteoporotic fracture and 2.8 % for a hip fracture.
In patients with osteoporosis, 22 patients (11 %) used ≥ 3 units of alcohol a day, 27 (14 %) 
were currently using or had previously used glucocorticoids, 43 (22 %) were active smok-
Table 2. Prevalence of secondary factors for bone fragility in patients with a recent fracture grouped 














FRAX clinical risk factors:
Smoking (%) 42 (23 %) 80 (16 %) 15 (16 %) 64 (17 %) 43 (22 %) 122 (18 %)
Use of > 3 IU alcohol (%) 30 (17 %) 49 (10 %) 13 (13 %) 44 (11 %) 22 (11 %) 79 (12 %)
Glucocorticoids (%) 14 (8 %) 66 (13 %) 11 (11 %) 42 (11 %) 27 (14 %) 80 (12 %)
Rheumatoid arthritis (%) 2 (1 %) 20 (4 %) 3 (3 %) 11 (3 %) 8 (4 %) 22 (3 %)
Early menopause (%) - 96 (19 %) 13 (13 %) 45 (12 %) 38 (19 %) 96 (14 %)
Laboratory based factors:
Chronic kidney disease (%) 15 (8 %) 77 (15 %) 10 (10 %) 53 (14 %) 29 (15 %) 92 (13 %)
MGUS (%) 25 (14 %) 65 (13 %) 5 (5 %) 46 (12 %) 39 (20 %) 90 (13 %)
1º hyperparathyroidism (%) - 7 (1 %) 1 (1 %) 4 (1 %) 2 (1 %) 7 (1 %)
2º hyperparathyroidism (%) 7 (4 %) 35 (7 %) 3 (3 %) 25 (7 %) 14 (7 %) 42 (6 %)
Hyperthyroidism (%) 1 (1 %) 12 (2 %) 1 (1 %) 7 (2 %) 5 (3 %) 13 (2 %)
Hypogonadism (%) 8 (4 %) - 1 (1 %) 6 (2 %) 1 (1 %) 8 (1 %)
Patients with > 1 factor (%) 93 (51 %) 297 (59 %) 48 (47 %) 219 (57 %) 123 (62 %) 390 (57 %)
IU International Unit; MGUS Monoclonal Gammopathy of Undetermined Significance
29
High prevalence of secondary factors in patients with a fracture
2
ers and 8 (4 %) had rheumatoid arthritis; Table 2. Twenty-eight patients (14 %) had a history 
of parental hip fracture, and 83 (42 %) had sustained one or more previous fractures.
The median 10-year fracture probability with inclusion of femoral neck BMD was 17 % 
for a major osteoporotic fracture and 7.3 % for a hip fracture, and respectively 16 % and 
6.2 % without inclusion of femoral neck BMD in the calculation.
There was a significant difference in the 10-year FRAX probability for fracture between 
patients with normal BMD, osteopenia or osteoporosis, with or without inclusion of 
femoral neck BMD measurements; Table 1. A similar number of patients with normal 
BMD, osteopenia or osteoporosis had an underlying factor for bone fragility as 
identified by clinical risk factors for fracture using FRAX (41 patients with normal BMD 
(40 %) vs. 164 patients with osteopenia (43 %) vs. 95 patients with osteoporosis (48 %); 
p = 0.381). There was no difference in the prevalence of any individual clinical risk 
factor studied between groups; Fig. 2A.
There was a significant difference in the 10-year FRAX probability for fracture calcu-
lated with BMD values between patients with ≥ 1 secondary factor and patients without 
(12.0 % vs. 8.5 %; p < 0.001), and in the 10-year FRAX probability without BMD values 
(13.0 % vs. 8.3 % ; p < 0.001). Interestingly, there was a significant relationship between 
the cumulative number of factors for bone fragility and the 10-year FRAX probability 







Prevalence of underlying causes for bone fragility





No significant difference in the prevalence of under-
lying secondary factors for bone fragility between 
patients with normal BMD (white bars) osteopenia 
(grey bars) or osteoporosis (black bars) using FRAX.
RA rheumatoid arthritis; EM early menopause.













Prevalence of underlying secondary factors for bone 
fragility by laboratory investigations in patients with 
normal BMD (white bars), osteopenia (grey bars) and 
osteoporosis (black bars). Significantly different prev-
alence of MGUS in patients between the groups.
CKD chronic kidney disease; MGUS Monoclonal 
Gammopathy of Undetermined Significance; 1° HPT 
primary hyperparathyroidism; 2° HPT secondary hy-
perparathyroidism; HG hypogonadism; HT hyperthy-
roidism.
* p = 0.001
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(r = 0.336, p < 0.001), and in the 10-year FRAX probability calculated without BMD val-
ues (r = 0.359, p < 0.001). After stratification for BMD status, this relationship remained 
for normal BMD (r = 0.286, p = 0.004 for FRAX with BMD and r = 0.456, p < 0.001 for 
FRAX without BMD), osteopenia (r = 0.313, p < 0.001 for FRAX with BMD and r = 0.311, 
p < 0.001 for FRAX without BMD) and osteoporosis (r = 0.361, p < 0.001 for FRAX with 
BMD and r = 0.346, p < 0.001 for FRAX without BMD).
Secondary factors identified by laboratory investigations
Laboratory investigations identified an underlying factor for bone fragility in 18 (18 %) of 
patients with normal BMD, in 112 (29 %) of patients with osteopenia and in 69 (35 %) of 
patients with osteoporosis.
In patients with normal BMD, chronic kidney disease was diagnosed in 10 patients (10 %), 
all of whom had CKD stage III. One patient (1 %) had primary hyperparathyroidism and 3 (3 %) 
had secondary hyperparathyroidism (associated with low 25-OH vitamin D levels in 2, and 
combined vitamin D deficiency and renal failure in 1. One patient (1 %) had hyperthyroidism, 
1 male patient had hypogonadism and 5 (5 %) patients were diagnosed with MGUS.
In patients with osteopenia, chronic kidney disease was diagnosed in 53 patients 
(14 %), of whom 49 had stage III CKD and 4 had stage IV CKD. Four patients (1 %) had 
primary hyperparathyroidism and 25 (7 %) had secondary hyperparathyroidism (associ-
ated with low 25-OH vitamin D levels in 15, and combined vitamin D deficiency and 
renal failure in 8). Seven patients (2 %) had hyperthyroidism (5 subclinical), 6 men had 
hypogonadism and 46 (12 %) patients were diagnosed with MGUS.
In patients with osteoporosis, chronic kidney disease was diagnosed in 29 patients 
(15 %), of whom 26 had stage III CKD and 3 had stage IV CKD. Two patients (1 %) had 
primary hyperparathyroidism and 14 had secondary hyperparathyroidism (associated 
with low 25-OH vitamin D levels in 7, and combined vitamin D deficiency and renal 
failure in 7). Five patients (3 %) had hyperthyroidism (2 subclinical), 1 male patient had 
hypogonadism and 39 (20 %) patients were diagnosed with MGUS.
All underlying factors for bone fragility identified by laboratory investigations were 
equally prevalent in patients with normal BMD, osteopenia or osteoporosis, except 
for MGUS (5 % vs. 12 % vs. 20 %; p = 0.001); Fig. 2B. One patient with osteoporosis was 
diagnosed as having multiple myeloma.
The odds of a patient with osteopenia having an MGUS were 2.71 times higher than 
those of a patient with normal BMD, and the odds of a patient with osteoporosis hav-
ing an MGUS were 4.81 times higher than a patient with normal BMD. There was no 
association between BMD and the odds for any other factor for bone fragility; Table 3.
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Relationship between number of secondary factors for bone fragility and 
BMD measurements
390 patients (57 %) had one or more underlying secondary factor for bone fragility. 
The majority of patients (n = 205 [30 %]) had one underlying factor, 122 patients (18 %) 
had two and 63 (9 %) had three or more factors. 38 % of all observed underlying factors 
were identified by laboratory investigations, and 41 % of all factors were reversible. 
There was an inverse relationship between the number of underlying factors for bone 
fragility per patient and mean femoral neck BMD values (r = -0.215, p < 0.001), which 
persisted after adjusting for age, gender and BMI (r = -0.192, p < 0.001).
In patients with normal BMD, 29 patients (28 %) had one underlying factor, 13 patients 
(13 %) had two factors and 6 (6 %) had three or more factors. In patients with osteopenia, 
Table 3. Odds-ratio’s for factors for increased bone fragility in patients with osteoporosis and osteo-
penia, compared with patients with normal BMD















































For every risk factor listed, odds-ratio’s refer to patients with osteoporosis at the top line and to patients with 
osteopenia at the second line. Patients with normal BMD are used as reference.
IU Internal Unit; MGUS Monoclonal Gammopathy of Undetermined Significance
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the majority of patients (n = 122 [32 %]) had one underlying factor, 69 patients (218 %) had 
two and 28 (17 %) had three or more factors. In patients with osteoporosis, 54 patients 
(327 %) had one secondary factor for bone fragility, 40 patients (20 %) had two factors 
and 29 (15 %) had three or more factors.
Vitamin D deficiency
Vitamin D deficiency was prevalent in 292 (43 %) of the 686 patients, of whom 97 
had serum vitamin D levels <  25 nmol/L. Vitamin D deficiency was documented in 
43 patients (42 %) with normal BMD, in 166 patients (43 %) with osteopenia and in 83 
patients (42 %) patients with osteoporosis.
DISCUSSION
Our data from this study demonstrate that 57 % of patients who recently sustained a 
fracture and who were subsequently referred to our Fracture Liaison Service, had one 
or more underlying secondary factor for bone fragility. Interestingly, these secondary 
factors were equally prevalent in our cohort of patients with a recent fracture whether 
they had normal BMD, osteopenia or osteoporosis (47 % vs. 57 % vs. 62 % respectively; 
p = 0.05,) Our data also show a significant inverse relationship between the number of 
underlying factors for bone fragility and femoral neck Bone Mineral Density (BMD). The 
most prevalent underlying factors for bone fragility were smoking (18 %), chronic kid-
ney disease (13 %) and MGUS (13 %). Of clinical relevance is that 41 % of all documented 
secondary factors for bone fragility were reversible (hyperthyroidism, primary and 
secondary hyperparathyroidism, hypogonadism in men, or potentially reversible such 
as excessive alcohol use and smoking). This may hold significant clinical implications 
in the management of these patients as reversal of these factors may be associated 
with an improvement in bone strength, thus contributing in time to a decrease in bone 
fragility. In addition, 43 % had serum levels of 25-OH vitamin D < 50 nmol/L.
The prevalence of secondary factors for bone fragility has been previously reported 
in patients with a recent fracture [13, 15]. Although the majority of previously published 
data studied the prevalence of underlying factors for bone fragility in patients with 
osteoporosis [13–15, 23–27], our findings suggest a similar prevalence of these fac-
tors regardless of BMD measurements after a recent fracture. A novel approach we 
pursued in this analysis was to compare the prevalence of underlying factors for bone 
fragility between groups of patients with normal BMD, osteopenia or with osteoporosis 
in our cohort of 686 patients aged ≥ 50 years who had sustained a recent fracture.
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As expected, the FRAX 10-year probability for a fracture was significantly different 
in patients with normal BMD, osteopenia or osteoporosis. This was also the case 
when femoral neck BMD was not used in the calculation of the FRAX. Our data also 
demonstrate that patients with one or more secondary factor for bone fragility had a 
higher 10-year FRAX fracture probability compared to patients with no documented 
secondary factor(s). Interestingly there was a positive relationship between cumulative 
number of secondary factors for bone fragility and FRAX independently of BMD status, 
which suggests that FRAX may not fully capture the contribution of the cumulative 
effect of these factors on fracture risk.
Our study has strengths as well as limitations. One of its main strengths is that all 
fracture patients were identified at source at the outpatient clinics of the Departments 
of Traumatology or Orthopaedic Surgery by a dedicated fracture nurse from our FLS 
resulting in the successful referral of > 50 % patients to our FLS for screening for os-
teoporosis. Over the last decade, there has been an increasing drive to develop and 
implement FLSs on an international scale for the secondary prevention of fractures 
[28]. These FLSs ensure that future fracture risk is assessed in all patients who have 
sustained a recent fracture, including the risk of falling [29]. These FLSs also secure 
that treatment with bone modifying agents is initiated if and when required. Previous 
studies demonstrated that the implementation of an FLS was cost-effective and ef-
fectively reduced mortality and the incidence of subsequent non-vertebral fractures 
[8, 30].
A further strength of the study is the availability of data on clinical risk factors using 
FRAX, of BMD data and of laboratory data on the most common secondary factors for 
bone fragility. A main limitation of the study is that due to regional hospital policy, the 
majority of patients who presented to our Emergency Room with a hip fracture were 
transferred to other hospitals in the region for primary fracture care, which could have 
influenced patient characteristics, especially age. The limited screening for monoclo-
nal gammopathy of undetermined significance (MGUS) may also be considered as a 
limitation of our study, as data may have been confounded by the bias of the treating 
physician’s decision to screen patients at higher risk for underlying secondary factors 
for bone fragility. However, this would have led to an underestimate rather than an 
overestimate of the prevalence of an MGUS. LS BMD measurements were not ad-
justed for the presence of degenerative changes, which might explain the absence of 
a relationship between the number of underlying factors for bone fragility and LS BMD. 
However, we also found no correlation between the number of underlying factors and 
LS BMD in patients stratified by age groups (data not shown).
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Our data, demonstrating a high prevalence of secondary factors for bone fragility, 
independently of BMD status, in a cohort of patients who had sustained a recent 
fracture, hold significant clinical implications in the management of these patients, 
as nearly half of these factors were potentially reversible. Our findings suggest that 
screening for underlying secondary factors for bone fragility should be considered 
in the setting of Fracture Liaison Services, not only in patients with osteoporosis but 
also in those with osteopenia or normal BMD. Whether reversing secondary factors for 
bone fragility would result in more optimal secondary prevention of fractures remains 
to be established by long-term studies.
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We evaluated the value of VFA in the identification of vertebral fractures using a 
retrospective study and a meta-analysis. Performance of VFA was adequate in the 
meta-analysis although this was not demonstrated in our center. We recommend to 
check the performance of VFA tools before exclusively relying on this tool.
Introduction:
Vertebral fractures are traditionally diagnosed using conventional radiographs of the 
spine. Vertebral Fracture Assessment (VFA) has been advocated as an alternative tool 
in the diagnosis of these fractures.
Methods:
We conducted a retrospective study as well as a systematic review and a meta-analysis 
to evaluate the performance of VFA compared to conventional spinal radiography in 
patients who had sustained a fracture and thus at risk for osteoporosis. A risk of bias 
analysis was also performed.
Results:
The diagnostic study included 542 patients (25 % male) with fractures. The sensitivity 
of low-radiation VFA to detect a patient with a vertebral fracture ≥ Genant grade 2 
was 0.77 and its specificity 0.80. 297(55 %) patients had ≥ 1 and 135(25 %) ≥ 3 unevalu-
able vertebrae. The systematic review identified 16 studies including a total of 3238 
subjects (19 % male) with a mean age range of 45 to 74 years. Seven studies had a low 
risk of bias and 9 had an intermediate risk, mainly due to not consecutively including 
patients. The pooled sensitivity of VFA to detect a patient with a vertebral fracture ≥ 
Genant grade 2 was 0.84 (95 % CI, 0.72–0.92) and specificity 0.90 (95 % CI, 0.84–0.94)
Conclusions:
Our findings from the meta-analysis suggest an adequate performance of VFA for the 
detection of vertebral fractures. However, we could not demonstrate these findings in 
our center, especially the specificity. Our data advocate caution with exclusively rely-
ing on VFA in the assessment of vertebral fractures without identifying performance 
and potential limitations of the technique.
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INTRODUCTION
Vertebral fractures are associated with increased mortality and morbidity, and de-
creased quality of life, and the incidence of these fractures increases with age (1–4). 
The prevalence and grade of severity of vertebral fractures have also been shown to 
be predictive for the risk of new vertebral and non-vertebral fractures, independently of 
Bone Mineral Density (BMD) measurements (5–7). However, vertebral fractures remain 
often underdiagnosed despite their clear value in the assessment of fracture risk (8, 
9). Conventional spine radiography is traditionally used in the evaluation of vertebral 
fractures and is considered to be the “gold standard” for detection of these fractures 
and their grading using the semi-quantitative method of Genant (10). Vertebral Frac-
ture Assessment (VFA) is performed using images obtained by bone densitometers in 
the same session as Bone Mineral Density measurements are performed to screen for 
osteoporosis. The VFA technique enables the acquisition of a patient-friendly alterna-
tive to conventional radiographs for the assessment of vertebral fractures in a one 
stop diagnostic test (11). Other advantages of VFA include lower radiation exposure 
and possibly lower costs. On the basis of available data, VFA has indeed already been 
incorporated in a number of clinical guidelines replacing conventional radiography for 
the assessment of prevalent vertebral fractures and thus for the risk of fracture (12, 13).
However, the advantage of lower radiation doses used in certain bone densitom-
etry scanners are associated with the drawback of poor image quality, and thus of 
potential poor visualization of the contours of the vertebrae and this, which could 
lead to misclassification of fractures or the ascertaining of a vertebra as non-evaluable 
leading to an inaccurate estimation of fracture risk. A standard protocol or technique 
for performing VFA has never actually been developed and the majority of published 
studies compare the performance of VFA to that of conventional spine radiographs 
mostly in diverse patient populations, often consisting of small numbers and mostly 
using different hardware and radiation protocols.
The aims of our study were twofold: first to evaluate the performance of VFA 
compared to conventional spine radiography in our Fracture Liaison Service (FLS) to 
assess whether we could replace conventional radiographs by VFA in the diagnosis 
of vertebral fractures in patients evaluated for osteoporosis after a recent fracture. 
Second, to systematically review all published literature on the performance of VFA 
compared to conventional spine radiography in patients evaluated for suspected 




Vertebral Fracture Assessment: VFA compared to conventional 
radiography
Study design
This was a retrospective study evaluating the performance of low-radiation single 
energy x-ray absorptiometry VFA for the detection of vertebral fractures compared 
to conventional radiography of the spine, in a cohort of consecutive men and women 
aged 50 years or older who had sustained a fracture between June 2012 and June 
2014, and who were assessed for osteoporosis according to screening protocols used 
in the FLS of the Leiden University Medical Center (14). In these protocols, all patients 
attending the FLS are screened, diagnosed and treated for osteoporosis where re-
quired, and data collected at source in a database. Because of the nature of the study, 
the Medical Ethics Committee of the Leiden University Medical Center deemed that no 
written informed consent was required.
For the purpose of this analysis, only patients with available data on both VFA 
and conventional radiography were included in the study. The following data were 
retrieved from the database: age, gender, height, weight, a detailed fracture history, 
family history of osteoporosis, a list of current medication and history of use of bone 
modifying agents were obtained.
Bone Mineral Density measurements
Bone Mineral Density was measured at the lumbar spine (L1–L4) and at the left and 
right femoral neck by dual-energy X-ray absorptiometry (DXA) using Hologic QDR 
4500 (Hologic, Bedford, MA, USA). NHANES III reference values compatible with refer-
ence values for the Dutch population were used to calculate T scores. The diagnosis 
of osteoporosis, osteopenia or normal BMD was established using the World Health 
Organization criteria.
Vertebral Fracture Assessment (VFA)
In addition to the BMD measurements, single energy x-ray lateral VFA images of the 
spine (T4-L4) were obtained by a dedicated technician with the patient lying in supine 
position and a cushion supporting the knees. The effective radiation dose of a VFA 
scan received by the patient is typically 3 microSievert.
Conventional radiography of the spine
Antero-posterior (thoracic spine), postero-anterior (lumbar spine) and lateral conven-
tional radiographs of the thoracic and lumbar spine were performed by a radiology 
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technician using a standardized protocol, with the detector centralized on Th7 for the 
thoracic spine and on L3 for the lumbar spine.
Assessment of vertebral fractures using VFA and conventional radiography of 
the spine
The presence of vertebral fractures was assessed on VFA images using Hologic QDR 
Physician Viewer software. The software generates six points on each vertebral end-
plate which were then manually adjusted by a dedicated technician as required. In the 
majority of vertebrae (more than 90 %), manual adjustment of the automatically placed 
points had to be performed by a trained laboratory technician. Anterior, middle and 
posterior corporal heights were calculated automatically. Following this quantitative 
evaluation, the software further used the criteria for the classification of vertebral frac-
tures as described by Genant (10). Analyses were performed on a per-person basis. 
A vertebral fracture was defined as Genant grade 2 or more. All routinely generated 
reports of conventional radiographs performed as part of the protocol used in the FLS 
were retrieved from the patient’s electronic medical records. In addition, one of the au-
thors (F.M.) further assessed all radiographs for the presence and grading of vertebral 
fractures. Both observers were blinded to the VFA findings. Vertebral fractures were 
classified according to Genant grading system: grade 1 for an anterior, mid or posterior 
reduction of 20 %–25 % in vertebral height; grade 2 for a reduction of 25 %– 40 %; and 
grade 3 for a reduction of more than 40 % in vertebral height. In case of disagree-
ment between radiology reports and evaluation from (F.M.), spine radiographs were 
evaluated by an experienced musculoskeletal radiologist (H.K.), whose evaluation was 
decisive and used in the analysis. In addition, a randomly selected sample of 20 % of 
the remaining patients was also evaluated by (H.K.) in order to validate the classifica-
tion of vertebral fractures based on the combined report of the FLS charts and (F.M.), 
which yielded a kappa of 0.82.
Systematic review of literature
Search strategy
We designed a search strategy in collaboration with a trained librarian for studies that 
primarily focussed on the diagnostic accuracy of Vertebral Fracture Assessment (VFA) 
compared to conventional radiographs of the spine in the diagnosis and grading of 
vertebral fractures in patients at risk for osteoporosis. The search was conducted in 
Pubmed, MEDLINE, EMBASE and Web of Science and included all published articles 
on the topic up to June 10th, 2016. All relevant keywords were used, including free text 
words. The complete search strategy is provided as Supplemental Data.
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Eligibility criteria and data extraction
Only original articles written in English were included. Inclusion criteria were: 1) com-
parison between VFA and spine radiographs performed for the diagnosis of vertebral 
fractures with reported data on sensitivity and specificity, 2) suspicion of osteoporosis 
as indication for the assessment of vertebral fractures, 3) use of the Genant’s or ABQ’s 
method to assess the presence of vertebral fractures in radiography and 4) patients 
aged ≥  18 years. Studies that reported patients with diseases of the spine such as 
ankylosing spondylitis or patients recruited from the general population were not 
eligible.
Articles were assessed by two independent investigators (F.M. and N.M.A-D), first 
by screening for eligibility for inclusion in the analysis by title and abstract. Selected 
articles were further assessed in detail. Disagreements were resolved by consensus.
The following data were extracted from all selected publications: number of patients 
studied, age and gender distribution, hardware used for VFA and DXA, study inclusion 
criteria, method of assessment of vertebral fractures, prevalence of vertebral fractures, 
and sensitivity and specificity of VFA.
Risk of bias assessment
The following characteristics of the study design were evaluated for each published 
study used in the review to assess the risk of bias:
1) Inclusion of patients; were consecutive patients who had conventional spine radio-
graphs included in the study or were only selected patients included? Inclusion of 
consecutive patients was considered a low risk of bias.
2) Definition of vertebral fractures used in the study. Analysis of data using a definition 
of Genant 2 or higher for vertebral fractures was considered a low risk of bias (10).
3) Clear and adequate description of method used to assess vertebral fractures in 
VFA and conventional radiography of the spine. Complete description of method-
ology for the assessment of vertebral fractures was considered a low risk of bias.
4) Blinding of the examiner who examined VFA for the outcome of the spine radio-
graphs. Blinded assessment was considered a low risk of bias.
For each of the 4 elements named above, studies were qualified as adequate, inad-
equate or not reported.
Statistical analysis
The performance of VFA was calculated using conventional radiography as reference, 
sensitivity was estimated by the number of true-positive vertebral fractures divided by 
the number of vertebral fractures identified by conventional radiographs, and specific-
ity was calculated by the number of true-negative vertebral fractures divided by the 
number of intact vertebrae observed on conventional radiographs. The main outcome 
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of the meta-analysis was the pooled sensitivity and specificity of VFA. Conventional 
radiographs of the spine were used as the “gold standard”. The meta-analysis was 
based on a random effects model and a bivariate approach, and sensitivity and speci-
ficity were estimated both per vertebra and per person. Heterogeneity was assumed 
and explored as recommended by Leeflang et al (15).
RESULTS
Vertebral Fracture Assessment: VFA compared to conventional 
radiography
Five hundred and forty-two patients [137 (25 %) men and 405 (75 %) women] were 
included in the study. Mean age of the population was 67.5 ± 10.1 years (range 50.0 – 
92.8), mean BMI was 26.1 ± 4.3 kg/m2 and median time between fracture and FLS visit 
was 2.3 months. Fifty patients (9 %) had sustained a fracture of the hip, 25 (5 %) of the 
vertebrae, 188 (35 %) of the distal radius, 58 (11 %) of the proximal humerus and 61 (11 %) 
of the ankle. The majority of patients had osteopenia (n = 319, 59 %), 163 (30 %) had os-
teoporosis, and 60 (11 %) had a normal Bone Mineral Density; Table 1. On low-radiation 
VFA, 184 (34 %) patients had at least one grade 2 or higher vertebral fracture, of whom 
47 had a Genant grade 3 vertebral fracture. These were 56 men and 128 women with 




Time between fracture and VFA (months) 2.3 ± 0.08
Type of fracture:*
Vertebra 25 (5 %) 
Hip 50 (9 %) 
Proximal humerus 58 (11 %) 
Ankle 61 (11 %) 
Distal radius 188 (35 %) 
DXA-BMD:
Normal 60 (11 %) 
Osteopenia 319 (59 %) 
Osteoporosis 163 (30 %) 
Values are expressed as mean ± SD, except for time between fracture and VFA 
BMI body mass index; kg/m2 kilogram per square meter; VFA vertebral fracture assessment; DXA-BMD bone 
mineral density measurement
* Fracture for which the patient was referred to FLS
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a mean age of 71.4 ± 10.3 years. One hundred and six (58 %) patients had osteopenia, 
64 (35 %) osteoporosis and 14 (8 %) had a normal BMD.
Conventional radiographs of the spine identified 132 (24 %) patients with ≥ one grade 
2 or higher vertebral fracture, of whom 47 had a Genant grade 3 vertebral fracture. 
VFA correctly identified 102 of the 132 patients with a ≥ grade 2 vertebral fracture, 
corresponding to a sensitivity of 0.77 (95 % CI, 0.70–0.84). Of the 30 patients who were 
missed on VFA, 17 had ≥  1 vertebrae that could not be evaluated by VFA. Of these 
patients, 3 had a radiological fracture on their radiographs at a vertebral level that 
could not be evaluated by VFA, and were thus missed. Of the 410 patients without a 
vertebral fracture on spinal radiographs, 328 were also found not to have a vertebral 
fracture on VFA corresponding to a specificity of 0.80 (0.76–0.84); Table 2. Interest-
ingly 297 (55 %) patients had ≥ 1 vertebrae that could not be evaluated by VFA and 135 
(25 %) patients had 3 or more unevaluable vertebrae; Figure 1.
The vertebrae that could not be evaluated by VFA or the patients that were misclas-
sified by VFA were independent of the type of the recently sustained fracture or of the 
time between the recent fracture and the FLS visit.
Search strategy
The search strategy for the systematic review of the literature yielded 694 articles 
(201 from PubMed, 167 from MEDLINE, 203 from Embase and 123 from Web of Sci-
ence). 270 studies were unique and potentially relevant, and were further assessed 
for eligibility. 241 studies were excluded on the basis of title and abstract, 14 were 
review papers and 1 was a Position Paper, 2 studies were performed in a paediatric 
population, 1 study was written in French and 1 study could not be obtained. Twenty-
nine studies were acquired for full assessment. Of these, 4 were excluded because 
there was no comparison between VFA and conventional radiography, 2 studies did 
not report performance parameters, 3 studies included patients with a rheumatologic 
disorder, 1 study included patients from the general population and 1 study was an 
autopsy study; Figure 2.
Table 2. Outcome of VFA compared to conventional spine radiography for the detection of vertebral 
fractures ≥ grade 2
Radiography of the spine
Vertebral fracture No vertebral fracture
VFA Vertebral fracture 102 82
No vertebral fracture 30 328
Total 132 410
VFA vertebral fracture assessment
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TH4 TH5 TH6 TH7 TH8 TH9 TH10 TH11 TH12 L1 L2 L3 L4
278 187 126 85 53 31 21 8 2 2 1 2 11
51% 35% 23% 16% 10% 6% 4% 2% 0.4% 0.4% 0.2% 0.4% 2%
Figure 1
Number (%) of patients with vertebrae that could not be evaluated by VFA.
270 articles identified by the 
search strategy and assessed for 
eligibility 
239 excluded by title and abstract 
2 studies performed in population aged   
< 18 years old 
29 articles acquired for thorough 
assessment of main body of paper 
11 articles not meeting inclusion criteria 
4 no comparison VFA/radiography 
2 no reported sensitivity/specificity 
1 autopsy study 
1 study of healthy subjects 
3 inclusion of patients with 
rheumatologic conditions 
2 articles included related study populations  
16 articles included in the 
final analysis 
Figure 2
Flowchart of selection of articles for systematic review and meta-analysis











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Eighteen articles met all specified inclusion criteria, two of which reported on related 
study populations. A total of 16 studies were thus included in the final analysis. Two of 
these 16 studies included two different populations, namely patients at high and low 
risk for osteoporosis and/or fractures (16, 17). In keeping with our inclusion criteria, 
patients recruited from the general population and thus at low risk for osteoporosis 
were excluded from the analysis (n = 582).
Study characteristics
A total number of 3238 subjects were included in the analysis, the vast majority of 
whom were women (n = 2626). The number of subjects per study ranged from 35 (18) 
to 930 (19) subjects. Mean age of the studied populations ranged from 45 years to 74 
years. The youngest included patient was 23 years old (20) and the oldest 96 years 
old (21). There were seven studies that included both female and male subjects (18, 
20, 22–26). One study included both male and female subjects but did not specify 
the exact gender distribution of subjects who had conventional spinal radiography in 
addition to VFA (25); Table 3.
All studies included subjects recruited from outpatient clinics, and two studies ad-
ditionally included patients admitted with a recent vertebral fracture (27) or hip fracture 
(17). One study solely included patients with radiological evidence of osteoporotic 
vertebral fractures (16). Two studies used data on VFA and conventional radiography 
originally collected for another study (23, 28), one used data from osteoporosis treat-
ment studies, and one from an HIV-related osteoporosis study. Three studies reported 
the inclusion of patients who had recently sustained a fracture (17, 24, 27).
Twelve of the 16 studies used Hologic hardware and five used GE Lunar hardware 
to acquire VFA scans, with one of the 16 studies acquiring VFA images with either 
Hologic or GE Lunar technology (29).
Prevalence of vertebral fractures on conventional spine radiography
The prevalence of vertebral fractures ≥ grade 1 ranged from 1.8 % (22) to 39 % (18), the preva-
lence of patients with a vertebral fracture ≥ grade 1 ranged from 6.9 % (30) to 100 % (16).
Per vertebra analysis
Two studies did not report the VFA sensitivity and specificity per vertebra (25, 26).
The reported sensitivity of VFA to detect a vertebral fracture ≥ grade 1 ranged from 
46.7 % to 98.7 %, and from 52.4 % to 94.4 % to detect a grade 2 or 3 vertebral fracture. 
The reported specificity of VFA to detect a vertebral fracture ≥ grade 1 ranged from 
85.1 % to 99.9 % and the specificity range to detect a vertebral fracture ≥ grade 2 was 
92 % to 99.5 %.
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Per person analysis
Twelve studies reported VFA parameters per patient basis (17, 19, 20–23, 25–27, 
29–31).
The VFA sensitivity range to detect a patient with a ≥ grade 1 vertebral fracture was 
52 % to 97.2 % and with a ≥ grade 2 vertebral fracture was 62 % to 95 %. The specificity 
ranged from 74 % to 98.9 % to detect a patient with a vertebral fracture ≥ grade 1 and 
ranged from 82 % to 99 % to detect a patient with a vertebral fracture ≥ grade 2.
Risk of bias assessment
Seven studies were classified as having a low risk of bias (17, 19, 22, 23, 26, 29, 30). 
The other nine studies were classified as having an intermediate risk of bias.
PV ‡ grade 1
PP ‡ grade 1
PV ‡ grade 2
PP ‡ grade 2
0.82 (0.75 - 0.87)
0.85 (0.74 - 0.92)
0.80 (0.68 - 0.89)
0.84 (0.72 - 0.92)
0.0 0.6 1.0
A
PV ‡ grade 1
PP ‡ grade 1
PV ‡ grade 2
PP ‡ grade 2
0.99 (0.98 - 1.00)
0.93 (0.87 - 0.97)
0.98 (0.93 - 0.99)




(A) Random effects meta-analysis of sensitivity of VFA to detect vertebral fractures.
PV per vertebra; PP per person
(B) Random effects meta-analysis of specificity of VFA to detect vertebral fractures.
PV per vertebra; PP per person
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Twelve studies had no clear consecutive inclusion of patients, 4 studies did not have 
a per vertebra and per person analysis of only ≥ grade 2 vertebral fractures for per ver-
tebra and per person, and 3 and 6 studies did not respectively have a per vertebra and 
per person analysis. One study did not have a clear description of vertebral fractures 
and another study lacked clear information about blinding of observers; Supplemental 
Table 1.
Meta-analysis
In the meta-analysis, sensitivity and specificity were calculated per vertebra and per 
person; Figure 3. In the per vertebra analysis to detect a vertebral fracture ≥ grade 1, 
sensitivity was 0.82 (95 % CI, 0.75–0.87) and specificity was 0.99 (95 % CI, 0.98–1.00). 
In the per person analysis to detect a vertebral fracture ≥ grade 1, sensitivity was 0.85 
(95 % CI, 0.74–0.92) and specificity was 0.93 (95 % CI, 0.87–0.97).
The per-vertebra sensitivity of VFA to detect a vertebral fracture ≥ grade 2 was 0.80 
(95 % CI, 0.68–0.89), and specificity was 0.98 (95 % CI, 0.93–0.99). The per-person 
sensitivity of VFA to detect patients with a vertebral fracture ≥ grade 2 was 0.84 (95 % 
CI, 0.72–0.92) and specificity was 0.90 (95 % CI, 0.84–0.94).
DISCUSSION
We performed a systematic review of the literature and a meta-analysis of published 
data to evaluate the performance of VFA compared to conventional spine radiography 
in the identification of vertebral fractures in patients at high risk for osteoporosis. Find-
ings from these data show a sensitivity of 0.82 (95 % CI, 0.75–0.87) and specificity of 
0.99 (95 % CI, 0.98–1.00) on a per vertebra basis, and a sensitivity of 0.85 (95 % CI, 
0.74–0.92), and specificity of 0.93 (95 % CI, 0.87–0.97) on a per person basis. The 
highly variable sensitivity (47–99 %) and specificity (74–100 %) between reported studies 
is likely to be due to the wide age range, variable gender distribution and difference 
in recruitment of patients (from general practitioners, the outpatient clinics or from an 
admission ward) between studies. These differences, which were also recognized in 
a recent systematic review (32), represent a significant limitation in the interpretation 
and comparison of findings between studies.
Our meta-analysis of available data from published studies show adequate sensitiv-
ity and specificity, also when a vertebral fracture was defined as a vertebral fracture 
≥ grade 2: sensitivity of 0.81 (95 % CI, 0.67–0.91) and specificity of 0.98 (95 % CI, 
0.94–1.00) for per vertebra analysis, and sensitivity of 0.84 (95 % CI, 0.72–0.92) and 
specificity of 0.90 (95 % CI, 0.84–0.94) for per person analysis. It would be expected 
that performance of VFA increased if only vertebral fractures ≥ grade 2 were included. 
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However, intriguingly, the performance of VFA improved when the analysis included 
vertebral fractures ≥ grade 1 rather than only vertebral fractures ≥ grade 2. This may 
be explained by the fact that two of the largest published studies had excellent per-
formance parameters, and provided nearly half of all patients included in the meta-
analysis of performance for identifying vertebral fractures ≥ grade 1 (19, 23). However, 
an analysis for the detection of vertebral fractures ≥ grade 2 was not performed in 
these two studies, which may explain the difference in sensitivity and specificity in 
identifying vertebral fractures ≥ grade 1 and ≥ grade 2. The risk of bias assessment 
showed that 7 out of 16 studies had a low risk of bias, and 9 were at moderate risk of 
bias. It is of note, however, that the majority of these studies did not provide adequate 
information regarding the inclusion process of patients.
Vertebral Fracture Assessment has become a commonly used tool for the detection 
of vertebral fractures in the setting of Fracture Liaison Services, clinical care pathways 
where patients who have recently sustained a fracture are screened for osteoporosis 
and for potential underlying secondary factors for increased fracture risk. Conven-
tional radiographs of the thoracic and lumbar spine are used as the gold standard for 
identification of a vertebral fracture. It has been suggested that VFA may represent an 
attractive alternative to spine radiographs for the detection of vertebral fractures be-
cause of simplicity of the technique (using available DXA device) and lower radiation 
doses than those used in conventional spine radiographs. However, the advantage 
granted by a lower radiation dose is unfortunately counterbalanced by higher noise 
rates and therefore lower image quality, often precluding adequate visualization of 
vertebrae for the presence of a fracture. This may potentially lead to under diagnosis 
of vertebral fractures or the need for confirmatory spine radiography.
In our FLS, a VFA is performed in all patients at the time of BMD measurements 
and conventional spine radiography. We performed a retrospective study comparing 
low-radiation VFA with conventional spine radiography in the detection of patients 
with vertebral fractures ≥ grade 2 in 542 men and women who had recently sustained 
a fracture. VFA correctly detected 77 % of all patients with a vertebral fracture, and 
correctly identified 80 % as having no vertebral fracture. Low-radiation VFA was false 
positive in 82/410 (20 %) patients who had no vertebral fractures on conventional 
radiography, potentially resulting in over diagnosis and thus initiating unnecessary 
osteoporosis treatment. Perhaps more worryingly, low-radiation VFA failed to identify 
a vertebral fracture ≥ grade 2 or more in 30 of 132 patients (23 %) and more than half 
of patients had ≥ 1 vertebrae that could not be evaluated by VFA, the majority of which 
were at the upper thoracic spine region (level Th4 and Th5), potentially resulting in 
under diagnosis and under treatment. Of these, only 3 were missed because the 
fractured vertebrae were deemed unevaluable by VFA, suggesting poor diagnostic 
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performance, the precise cause of which is as yet to be identified, rather than just poor 
visualization due to poor image quality.
Our study has strengths as well as limitations. Its main strength is the large group of 
consecutive patients of both genders all aged ≥ 50 years who had recently sustained a 
fracture, and who were uniformly evaluated using our FLS standard protocols. A possi-
ble limitation of the study is that the inclusion of 144 patients was precluded by the lack 
of data on VFA or radiography. Whereas a further limitation could be the theoretical 
influence of a learning curve to obtain VFA images as this tool was only implemented in 
our FLS care pathway from 2012 onwards, we found no difference in VFA performance 
in the first 100 patients compared to the last 100 patients (data not shown). A matter of 
concern in our study is that the number of patients with ≥ 1 unevaluable vertebrae is 
rather high, particularly in the upper thoracic region. This problem has been reported 
in other VFA studies, which led Deleskog and colleagues to suggest that the method 
was inferior to conventional spinal radiography (18). Notwithstanding, it appears that 
it may be possible to technically enhance the performance of VFA by methods aiming 
at improving image quality (thus reducing the number of vertebrae that could not be 
visualized and improving the measurement of height loss of the vertebrae). A limiting 
factor in the analysis of published data is the general scarcity provided on VFA meth-
odology, particularly radiation dosages, which may have a significant impact on the 
quality of obtained images. In addition, studies included in our systematic review and 
meta-analysis were published over a more than 15-year timeframe, spanning the years 
2000 to 2016 and the improvement in hardware and software of VFA technology may 
have potentially influenced the outcomes. The contribution of different technologies 
to discrepancies in the identification of vertebral fractures has been addressed in a 
study comparing Lunar Prodigy and Lunar iDXA densitometers, which demonstrated 
that iDXA had a better performance record for visualization, and thus evaluation, of 
vertebrae for fractures than the Prodigy densitometer (33). So far, there have been 
no studies comparing VFA performance between single energy and dual energy x-
ray devices. The discrepancy in results of vertebral fracture assessment using VFA 
compared to conventional radiology in our study is in contrast to the concordance of 
results of assessments between radiology and VFA in the majority of studies reported 
in the systematic review and used in the meta-analysis. This difference could have 
been influenced by the different methodology used between studies. Quantitative as-
sessment was thus used to evaluate VFA images in our study compared to the use of 
Genant’s semi-quantitative assessment in the vast majority of studies included in the 
systematic review and meta-analysis.
In conclusion, from our meta-analysis findings of published data demonstrate ad-
equate performance parameters of VFA in studies designed for patients at risk for 
osteoporosis, although a limitation was the very broad range of prevalent vertebral 
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fractures (6.9 %-100 %) and age (23–96 years) which may have influenced study out-
comes. The data of our FLS study were in contrast with the numbers of the meta-
analysis. The precise cause of the underperformance of VFA in our center is currently 
being investigated. Our findings suggest that caution should be advocated with the 
interpretation of VFA data and that centers should check the performance of their VFA 
device against conventional radiography of the spine before exclusively relying on this 
tool in the identification of vertebral fractures.
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Bazzocchi Adequate Adequate for PV
Not adequate for PP
Adequate Adequate
Binkley Not adequate Adequate for PV
Not reported for PP
Adequate N/A
Chapurlat Not adequate Not adequate for PV
Adequate for PP
Adequate Adequate
Damiano Not reported Adequate for PV
Not adequate for PP
Adequate Adequate
Deleskog Not adequate Adequate for PV




Adequate Not adequate Adequate N/A
Diacinti Adequate Not adequate Adequate N/A
Ferrar 2000 Not reported Not adequate Adequate Not reported
Ferrar 2008 Not reported Adequate Adequate Adequate
Fuerst Not reported Adequate Adequate Adequate
Hospers Not reported Adequate for PV
Not adequate for PP
Adequate Adequate
Mazzaferro Not adequate Not adequate Adequate N/A
Rea Not adequate Adequate for PV
Not adequate for PP
Not adequate N/A
Rud Adequate Not adequate for PV
Adequate for PP
Adequate Adequate
Schousboe Not adequate Adequate Adequate Adequate
Vokes Not adequate Not adequate for PV
Adequate for PP
Adequate Adequate
PV per vertebra; PP per person
N/A VFA and radiographs were evaluated by independent observers
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((“vertebral fracture assessment”[all fields] OR “vertebral assessment”[all fields] OR 
“VFA”[all fields] OR ((“assessment”[ti] OR “assessing”[ti] OR assess*[ti]) AND (“Spinal 
Fractures”[Majr] OR “vertebral fracture”[ti] OR “vertebral fractures”[ti] OR “spinal 
fracture”[ti] OR “spinal fractures”[ti] OR “spine fracture”[ti] OR “spine fractures”[ti] OR 
((spine[ti] OR spinal[ti] OR spines[ti] OR vertebral[ti] OR vertebrae[ti] OR vertebr*[ti]) AND 
(fracture[ti] OR fractures[ti] OR fractur*[ti]))))) AND (“Densitometry”[mesh] OR “dual X-ray 
absorptiometry”[all fields] OR “DXA”[all fields] OR “DEXA”[all fields] OR “densitometry”[all 
fields] OR densitometr*[all fields] OR “absorptiometry”[all fields] OR absorptiometr*[all 
fields]) AND (“Radiography”[Mesh:NoExp] OR “radiography”[Subheading] OR 
“radiography”[all fields] OR radiograph*[all fields] OR “Xray”[all fields] OR “Xrays”[all 
fields] OR “X-ray”[all fields] OR “X-rays”[all fields] OR “roentgenography”[all fields] 
OR “rontgenography”[all fields] OR “roentgen”[all fields] OR “rontgen”[all fields] OR 
roentgen*[all fields] OR rontgen*[all fields]) AND (“Comparative Study”[Publication 
Type] OR comparative[all fields] OR compared[all fields] OR comparison[all fields] 
OR compar*[all fields] OR “Reproducibility of Results”[mesh] OR “Sensitivity and 
Specificity”[mesh] OR “Limit of Detection”[all fields] OR “ROC Curve”[all fields] OR 
“Signal-To-Noise Ratio”[all fields] OR “Sensitivity”[all fields] OR “Specificity”[all fields] 
OR “Reproducibility of Results”[all fields] OR “Dimensional Measurement Accuracy”[all 
fields] OR “Reproducibility”[all fields] OR “Reliability”[all fields] OR “Validity”[all 
fields])) OR ((“vertebral fracture assessment”[all fields] OR “vertebral assessment”[all 
fields] OR “VFA”[all fields] OR ((“assessment”[all fields] OR “assessing”[all fields] OR 
assess*[all fields]) AND (“Spinal Fractures”[Mesh] OR “vertebral fracture”[all fields] OR 
“vertebral fractures”[all fields] OR “spinal fracture”[all fields] OR “spinal fractures”[all 
fields] OR “spine fracture”[all fields] OR “spine fractures”[all fields] OR ((spine[ti] 
OR spinal[ti] OR spines[ti] OR vertebral[ti] OR vertebrae[ti] OR vertebr*[ti]) AND 
(fracture[ti] OR fractures[ti] OR fractur*[ti]))))) AND (“Densitometry”[majr] OR “dual X-ray 
absorptiometry”[ti] OR “DXA”[ti] OR “DEXA”[ti] OR “densitometry”[ti] OR densitometr*[ti] 
OR “absorptiometry”[ti] OR absorptiometr*[ti]) AND (“Radiography”[Mesh:NoExp] OR 
“radiography”[Subheading] OR “radiography”[all fields] OR radiograph*[all fields] OR 
“Xray”[all fields] OR “Xrays”[all fields] OR “X-ray”[all fields] OR “X-rays”[all fields] OR 
“roentgenography”[all fields] OR “rontgenography”[all fields] OR “roentgen”[all fields] 
OR “rontgen”[all fields] OR roentgen*[all fields] OR rontgen*[all fields]) AND (“Com-
parative Study”[Publication Type] OR comparative[all fields] OR compared[all fields] 
OR comparison[all fields] OR compar*[all fields] OR “Reproducibility of Results”[mesh] 
OR “Sensitivity and Specificity”[mesh] OR “Limit of Detection”[all fields] OR “ROC 
Curve”[all fields] OR “Signal-To-Noise Ratio”[all fields] OR “Sensitivity”[all fields] OR 
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“Specificity”[all fields] OR “Reproducibility of Results”[all fields] OR “Dimensional Mea-
surement Accuracy”[all fields] OR “Reproducibility”[all fields] OR “Reliability”[all fields] 
OR “Validity”[all fields]))
MEDLINE
((“vertebral fracture assessment”.af OR “vertebral assessment”.af OR “VFA”.af OR 
((“assessment”.ti OR “assessing”.ti OR assess*.ti) AND (exp *”Spinal Fractures”/ OR 
“vertebral fracture”.ti OR “vertebral fractures”.ti OR “spinal fracture”.ti OR “spinal 
fractures”.ti OR “spine fracture”.ti OR “spine fractures”.ti OR ((spine.ti OR spinal.ti OR 
spines.ti OR vertebral.ti OR vertebrae.ti OR vertebr*.ti) AND (fracture.ti OR fractures.
ti OR fractur*.ti))))) AND (exp “Densitometry”/ OR “dual X-ray absorptiometry”.af OR 
“DXA”.af OR “DEXA”.af OR “densitometry”.af OR densitometr*.af OR “absorptiometry”.
af OR absorptiometr*.af) AND (“Radiography”/ OR “radiography”.fs OR “radiography”.
af OR radiograph*.af OR “Xray”.af OR “Xrays”.af OR “X-ray”.af OR “X-rays”.af OR 
“roentgenography”.af OR “rontgenography”.af OR “roentgen”.af OR “rontgen”.af OR 
roentgen*.af OR rontgen*.af) AND (exp “Comparative Study”/ OR comparative.af OR 
compared.af OR comparison.af OR compar*.af OR exp “Reproducibility of Results”/ 
OR exp “Sensitivity and Specificity”/ OR “Limit of Detection”.af OR “ROC Curve”.af OR 
“Signal-To-Noise Ratio”.af OR “Sensitivity”.af OR “Specificity”.af OR “Reproducibility 
of Results”.af OR “Dimensional Measurement Accuracy”.af OR “Reproducibility”.af OR 
“Reliability”.af OR “Validity”.af)) OR ((”vertebral fracture assessment”.af OR ”vertebral 
assessment”.af OR ”VFA”.af OR ((”assessment”.af OR ”assessing”.af OR assess*.af) 
AND (exp ”Spinal Fractures”/ OR ”vertebral fracture”.af OR ”vertebral fractures”.af OR 
”spinal fracture”.af OR ”spinal fractures”.af OR ”spine fracture”.af OR ”spine fractures”.
af OR ((spine.ti OR spinal.ti OR spines.ti OR vertebral.ti OR vertebrae.ti OR vertebr*.ti) 
AND (fracture.ti OR fractures.ti OR fractur*.ti))))) AND (exp *”Densitometry”/ OR ”dual X-
ray absorptiometry”.ti OR ”DXA”.ti OR ”DEXA”.ti OR ”densitometry”.ti OR densitometr*.
ti OR ”absorptiometry”.ti OR absorptiometr*.ti) AND (”Radiography”/ OR ”radiography”.
fs OR ”radiography”.af OR radiograph*.af OR ”Xray”.af OR ”Xrays”.af OR ”X-ray”.af 
OR ”X-rays”.af OR ”roentgenography”.af OR ”rontgenography”.af OR ”roentgen”.af 
OR ”rontgen”.af OR roentgen*.af OR rontgen*.af) AND (exp ”Comparative Study”/ OR 
comparative.af OR compared.af OR comparison.af OR compar*.af OR exp ”Reproduc-
ibility of Results”/ OR exp ”Sensitivity and Specificity”/ OR ”Limit of Detection”.af OR 
”ROC Curve”.af OR ”Signal-To-Noise Ratio”.af OR ”Sensitivity”.af OR ”Specificity”.af 
OR ”Reproducibility of Results”.af OR ”Dimensional Measurement Accuracy”.af OR 
”Reproducibility”.af OR ”Reliability”.af OR ”Validity”.af))
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EMBASE
((“vertebral fracture assessment”.af OR “vertebral assessment”.af OR “VFA”.af OR 
((“assessment”.ti OR “assessing”.ti OR assess*.ti) AND (exp *”Spine Fracture”/ OR “ver-
tebral fracture”.ti OR “vertebral fractures”.ti OR “spinal fracture”.ti OR “spinal fractures”.
ti OR “spine fracture”.ti OR “spine fractures”.ti OR ((spine.ti OR spinal.ti OR spines.
ti OR vertebral.ti OR vertebrae.ti OR vertebr*.ti) AND (fracture.ti OR fractures.ti OR 
fractur*.ti))))) AND (exp “Densitometry”/ OR “dual X-ray absorptiometry”.af OR “DXA”.
af OR “DEXA”.af OR “densitometry”.af OR densitometr*.af OR “absorptiometry”.af OR 
absorptiometr*.af) AND (radiography/ OR bone radiography/ OR “radiography”.af OR 
radiograph*.af OR “Xray”.af OR “Xrays”.af OR “X-ray”.af OR “X-rays”.af OR “roentgen-
ography”.af OR “rontgenography”.af OR “roentgen”.af OR “rontgen”.af OR roentgen*.
af OR rontgen*.af) AND (exp “Comparative Study”/ OR comparative.af OR compared.af 
OR comparison.af OR compar*.af OR exp measurement precision/ OR Reproducibility/ 
OR exp “Sensitivity and Specificity”/ OR “Limit of Detection”.af OR “ROC Curve”.af OR 
“Signal-To-Noise Ratio”.af OR “Sensitivity”.af OR “Specificity”.af OR “Reproducibility 
of Results”.af OR “Dimensional Measurement Accuracy”.af OR “Reproducibility”.af OR 
“Reliability”.af OR “Validity”.af)) OR ((“vertebral fracture assessment”.af OR “vertebral 
assessment”.af OR “VFA”.af OR ((“assessment”.af OR “assessing”.af OR assess*.af) 
AND (exp “Spine Fracture”/ OR “vertebral fracture”.af OR “vertebral fractures”.af OR 
“spinal fracture”.af OR “spinal fractures”.af OR “spine fracture”.af OR “spine fractures”.
af OR ((spine.ti OR spinal.ti OR spines.ti OR vertebral.ti OR vertebrae.ti OR vertebr*.ti) 
AND (fracture.ti OR fractures.ti OR fractur*.ti))))) AND (exp *”Densitometry”/ OR “dual X-
ray absorptiometry”.ti OR “DXA”.ti OR “DEXA”.ti OR “densitometry”.ti OR densitometr*.
ti OR “absorptiometry”.ti OR absorptiometr*.ti) AND (Radiography/ OR bone radiog-
raphy/ OR “radiography”.af OR radiograph*.af OR “Xray”.af OR “Xrays”.af OR “X-ray”.
af OR “X-rays”.af OR “roentgenography”.af OR “rontgenography”.af OR “roentgen”.af 
OR “rontgen”.af OR roentgen*.af OR rontgen*.af) AND (exp “Comparative Study”/ OR 
comparative.af OR compared.af OR comparison.af OR compar*.af OR exp measure-
ment precision/ OR Reproducibility/ OR exp “Sensitivity and Specificity”/ OR “Limit 
of Detection”.af OR “ROC Curve”.af OR “Signal-To-Noise Ratio”.af OR “Sensitivity”.af 
OR “Specificity”.af OR “Reproducibility of Results”.af OR “Dimensional Measurement 
Accuracy”.af OR “Reproducibility”.af OR “Reliability”.af OR “Validity”.af))
web of Science
(TI=((“assessment” OR “assessing” OR assess*) AND (*”Spine Fracture” OR “vertebral 
fracture” OR “vertebral fractures” OR “spinal fracture” OR “spinal fractures” OR “spine 
fracture” OR “spine fractures” OR ((spine OR spinal OR spines OR vertebral OR verte-
brae OR vertebr*) AND (fracture OR fractures OR fractur*)))) AND TS=(“Densitometry” 
OR “dual X-ray absorptiometry” OR “DXA” OR “DEXA” OR “densitometry” OR den-
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sitometr* OR “absorptiometry” OR absorptiometr*) AND TS=(radiography OR bone 
radiography OR “radiography” OR radiograph* OR “Xray” OR “Xrays” OR “X-ray” OR 
“X-rays” OR “roentgenography” OR “rontgenography” OR “roentgen” OR “rontgen” 
OR roentgen* OR rontgen*) AND TS=(“Comparative Study” OR comparative OR com-
pared OR comparison OR compar* OR measurement precision OR Reproducibility 
OR “Sensitivity and Specificity” OR “Limit of Detection” OR “ROC Curve” OR “Signal-
To-Noise Ratio” OR “Sensitivity” OR “Specificity” OR “Reproducibility of Results” 
OR “Dimensional Measurement Accuracy” OR “Reproducibility” OR “Reliability” OR 
“Validity”)) OR (TS=(“vertebral fracture assessment” OR “vertebral assessment” OR 
“VFA”) AND TS=(“Densitometry” OR “dual X-ray absorptiometry” OR “DXA” OR “DEXA” 
OR “densitometry” OR densitometr* OR “absorptiometry” OR absorptiometr*) AND 
TS=(radiography OR bone radiography OR “radiography” OR radiograph* OR “Xray” 
OR “Xrays” OR “X-ray” OR “X-rays” OR “roentgenography” OR “rontgenography” OR 
“roentgen” OR “rontgen” OR roentgen* OR rontgen*) AND TS=(“Comparative Study” 
OR comparative OR compared OR comparison OR compar* OR measurement preci-
sion OR Reproducibility OR “Sensitivity and Specificity” OR “Limit of Detection” OR 
“ROC Curve” OR “Signal-To-Noise Ratio” OR “Sensitivity” OR “Specificity” OR “Repro-
ducibility of Results” OR “Dimensional Measurement Accuracy” OR “Reproducibility” 
OR “Reliability” OR “Validity”))
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This study evaluated the changes in BTMs and their relationship with BMD measure-
ments. We found that changes in BTMS were related with lumbar spine BMD early in 
the treatment with anti-osteoporosis agents.
Introduction:
Bone turnover markers (BTMs) can be easily measured in serum and have the potential 
to be used as a tool to monitor treatment.
Methods:
A prospective study to report the longitudinal pattern of P1NP and Ctx after 3 and 12 
months of antiresorptive treatment and to evaluate their relationship with Bone Min-
eral Density (BMD) values after 12 months of treatment in patients attending a Fracture 
Liaison Service who have recently sustained a fracture.
Results:
127 patients were included in the final analysis. One had a normal BMD, 43 had os-
teopenia and 83 patients had osteoporosis. Changes in P1NP and Ctx after 12 months 
of treatment were significantly inversely related with changes in lumbar spine BMD 
after 12 months (B = 0.043, p = 0.003; B = 0.066, p = 0.020, respectively). Baseline P1NP 
was significantly correlated with the change in BMD at the lumbar spine (B = 0.018, 
p = 0.014).
Conclusion:
Our data suggest that early changes in BTMs or baseline measurements of these 
markers are predictive for the outcome of treatment with anti-osteoporosis drugs. 
Whether these markers could be used to predict the risk for fractures remains to be 
established.
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INTRODUCTION
Osteoporosis is a systemic bone disease characterized by low bone mass and mi-
croarchitectural deterioration of bone tissue leading to increased bone fragility and 
fracture risk (1). Projections for Europe suggest that the number of fractures due to 
osteoporosis will increase by 28 % to an estimated 4.5 million in 2025, resulting in a 
significant increase in personal, societal and economic burdens with consequent in-
crease in Disability Adjusted Life Years (DALY) and general quality of life (2). Based on 
these alarming predictions, recent guidelines have focused on secondary prevention 
of fractures by advocating the establishment of Fracture Liaison Services (FLSs), which 
essentially captures patients at high risk for fractures by implementing a multidisci-
plinary care trajectory for screening of all patients, male or female aged 50 years or 
older who recently sustained a fracture for the presence of osteoporosis using Bone 
Mineral Density (BMD) measurements (3). Treatment using anti-osteoporosis drugs 
shown to be effective in decreasing fracture risk forms an intrinsic part of the care 
trajectory for patients considered at high risk for new fractures (4–6).
Bone turnover markers (BTMs) can be easily measured in serum collected at base-
line and at variable intervals after start of treatment. BTMs recommended for use 
in osteoporosis include the bone formation marker serum procollagen 1 N-terminal 
extension peptide (P1NP), and the bone resorption marker serum C-terminal cross-
linked telopeptide of type I collagen (CTX), both having been found to be the markers 
of choice in osteoporosis (7). In the management of osteoporosis, BTMs have been 
shown to decrease within weeks, whereas changes in BMD are slower, only observed 
after at least a year of treatment with the use of antiresorptive agents. Moreover, it has 
been shown that a decrease in BTMs is correlated with an increase in BMD and with 
anti-fracture efficacy (8, 9). Based on these data, one may suggest that BTMs have 
the potential to be used as a tool to monitor treatment and may predict treatment 
outcome. However, the experience on BTMs outside clinical trials remains scarce. In 
addition, BTMs are elevated for several months in the healing process after a fracture, 
which may complicate the interpretation of these markers.
In this study, we aimed to describe the response of BTMs after 3 and 12 months 
of antiresorptive treatment and their relationship with BMD measurements after 12 




Study design and population
All patients aged 50 years or older who had sustained a fracture from June 2012 to 
June 2014 for which they presented at the Emergency Room of the Leiden University 
Medical Center (LUMC) and were subsequently referred to our Fracture Liaison Service 
(FLS) of the LUMC were considered for inclusion in the study if started on osteoporosis 
treatment using oral bisphosphonates (BPor), intravenous bisphosphonates (BPiv) or 
denosumab (Dmab) as required. Patients with fractures of skull, hands or feet were 
excluded. Details of the methodology of the study are described in a previous publica-
tion from our Center (10).
The following inclusion criteria were additionally used in this particular study: osteo-
porosis treatment had to have been started within 3 months of baseline evaluation, 
and data on P1NP and BMD had to be available at baseline and 12 to 15 months after 
start of treatment. Patients who were already using osteoporosis treatment or those 
with severe liver insufficiency or CKD grade IV-V were excluded from the study.
The treatment regimens used in our FLS protocol are in keeping with Dutch national 
guidelines for the management of osteoporosis (11). Choice of treatment was left at 
the discretion of the treating physician after taking patient preference for treatment 
in consideration. Follow-up visits were planned at 12 months after start of treatment 
for all patients and additionally at 3 months for patients started on oral or intravenous 
bisphosphonates. The study was approved by the Medical Ethical Committee of the 
LUMC.
Study parameters
Data on age, gender, weight and height [from which the body mass index (BMI) was 
calculated], medication history including bone modifying agents and vitamin D supple-
mentation, the date of the most recent fracture and of the first visit to the FLS, and a 
full medical history including detailed fracture history, family history of osteoporosis, 
history of parental hip fractures, age at menopause, dietary calcium intake, alcohol 
use and smoking habits were collected at baseline. Data on the reason and time of 
substitution of one type of osteoporosis drug for another or time and reason for dis-
continuation of treatment were also recorded if applicable.
Biochemical parameters
Serum obtained from blood samples collected at baseline and 3 and 12 months after 
start of treatment was measured for calcium, albumin, inorganic phosphate, alkaline 
phosphatase, creatinine, PTH, 25-OH vitamin D, P1NP and CTX.
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Bone Mineral Density
BMD was measured at the lumbar spine (L1-L4) and at the left and right femoral neck 
at baseline and 12 months after start of treatment using Dual Energy X-ray Absorpti-
ometry (DXA) with a Hologic QDR Discovery A scanner (Holologic, Bedford, MA, USA). 
T-scores were calculated using reference values from the Third National Health and 
Nutrition Survey (NHANES III) compatible with those of the Dutch population. Using 
WHO criteria, osteoporosis was defined as a BMD ≥ 2.5 standard deviation (SD) below 
the average value for young healthy women, expressed as a T-score of ≤ -2.5. Osteo-
penia was defined as a BMD > 1SD but < 2.5 SD below the young adult mean (T-score 
between -2.5 and -1) and normal BMD was defined as a T-score ≥ -1.0.
Statistical analysis
All analyses were performed using SPSS software for Windows (Version 23.0 Chicago, 
IL, USA). Between-group differences in baseline characteristics were assessed us-
ing an ANOVA test for numerical data and a Chi-squared test for categorical data. 
Spearman’s correlation coefficient was used to analyse the correlation between bone 
turnover markers and BMD at baseline and after 12 months of treatment, after perform-
ing Kolmogorov-Smirnoff tests, which showed not normally distributed BTM-values. 
Linear regression analysis was performed using changes in BTMs between baseline 
(T0) and 12 months (T12) and baseline (T0) and 3 months (T3), and the differences 




252 patients, 197 women and 55 men aged 50 years or older, who were referred to the 
FLS after sustaining a recent fracture, were found to be at high fracture risk and were 
eligible for receiving osteoporosis treatment. During the year of follow-up, 7 patients 
had discontinued therapy within 3 months, and 90 had no follow-up BMD at 1 year (4 
had died, 7 had comorbidity that prevented them from attending follow-up visits, 32 
were referred back to their general practitioner, 4 were referred to another specialist, 
19 had follow-up BMD measurements > 15 months after start of treatment and 24 were 
lost to follow-up for unclear reasons), In addition, 23 patients had no available data on 
P1NP at baseline and another 5 no available data at 1-year of follow-up. A full set of 
BMD and P1NP data at baseline and 1-year follow up was thus available in 127 patients 
who were included in the final analysis of data; Figure 1.
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These were 32 men and 95 women with a mean age of 67.0 years (range 50.0 – 89.6 
years) and BMI of 25.3 ± 3.8 kg/m2. The majority of patients had sustained a fracture of 
the distal radius [n = 37 (29 %)], 23 (18 %) of the proximal humerus, 18 (14 %) of the hip and 
14 (11 %) of one or more vertebrae. Mean time between the recently sustained fracture 
and baseline visit to the FLS was 3.0 ± 2.6 months; Table 1.
At baseline, 88 patients started oral BP therapy (BPor), 20 intravenous BP therapy 
(BPiv) and 19 Denosumab (Dmab). During the year of follow-up, 6 patients were 
switched from BPor to BPiv or Dmab at 3 months and 1 was switched at 6 months. 
Of these 7 patients, two switched treatment to BPiv and fi ve to Dmab. Nine patients 
sustained a new fracture after start of anti-osteoporosis treatment.
Baseline values of Bone Mineral Density and bone turnover markers
Eighty-three patients had osteoporosis, forty-three had osteopenia and one had a nor-
mal BMD. Mean BMD was 0.84 ± 0.13 g/cm2 at the lumbar spine and 0.63 ± 0.09 g/cm2 
252 patients evaluated and 
started on treatment  
at baseline visit 
449 not requiring osteoporosis treatment 
7 used osteoporosis treatment before 
study inclusion 
1 serum creatinin > 150 µmol/L  
127 patients with data on 
serum P1NP and BMD at 
baseline and 1-year fu 
88 oral bisphosphonate 
users 
20 iv bisphosphonate 
users 19 Dmab users 
709 patients referred to FLS  
(June 2012 – June 2014) 
7 discontinued treatment < 3months after 
start 
23 had no serum P1NP measured at 
baseline 
90 had no BMD measured at 1-year 
follow up* 
5 had no serum P1NP measured at 1-year 
follow up  
Figure 1
Patient enrolment




32 were referred back to their general practitioner
4 were referred to another specialist
19 had follow-up BMD measurements > 15 months after start of treatment
24 were lost to follow-up for unclear reasons
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at the femoral neck. Mean serum level of P1NP was 75.7 ng/ml (range 23–240 ng/ml) at 
baseline. There was no diff erence in P1NP values between patients with osteoporosis, 
osteopenia or normal BMD (76.1 ± 32.8, 75.3 ± 45.0, 75.0; p = 0.464). Mean P1NP did 
not correlate with mean BMD at the lumbar spine or at the femoral neck (r = -0.066, 
p = 0.461; r = -0.098, p = 0.281, respectively).
Data on Ctx levels at baseline were available in 90 patients and mean serum level was 
0.387 ng/ml (range 0.120–0.940 ng/ml). There was no diff erence in Ctx values between 
patients with osteoporosis, osteopenia or normal BMD (0.400 ± 0.184, 0.349 ± 0.137, 
0.904; p = 0.121). Mean Ctx did not correlate with mean BMD at the lumbar spine or at 
the femoral neck (r = -0.135, p = 0.206; r = -0.043, p = 0.691, respectively).
Follow-up changes in Bone Mineral Density and bone turnover markers 
after 12 months
BMD values increased by 4.4 % from 0.84  ±  0.13 g/cm2 to 0.88  ±  0.13 g/cm2 at the 
lumbar spine, and by 1.6 % from 0.63 ± 0.09 g/cm2 to 0.64 ± 0.09 g/cm2 at the femoral 


















BMI (kg/m2) 25.3 ± 3.8 25.4 ± 4.0 24.8 ± 3.9 24.9 ± 4.3
Previous Fracture (%) 52 (41 %) 86 (49 %) 19 (49 %) 12 (32 %)
FRAX score major 
fracture
13.0 ± 0.7 13.0 ± 0.6 18.0 ± 1.8 15.5 ± 0.9
FRAX score hip fracture 4.0 ± 0.6 5.0 ± 0.5 8.9 ± 1.6 5.8 ± 0.8
Laboratory data:
Creatinine (µmol/L) 72.4 ± 15.3 72.1 ± 20.5 67.2 ± 13.7 80.1 ± 29.5
Calcium (mmol/L) 2.35 ± 0.09 2.36 ± 0.09 2.35 ± 0.13 2.36 ± 0.08
ALP (U/L) 101.2 ± 41.4 103.7 ± 43.7 99.1 ± 32.6 99.8 ± 34.2
PTH (pmol/L) 4.1 ± 2.2 4.2 ± 3.1 4.6 ± 1.9 4.7 ± 2.9
25-OH D (nmol/L) 66.7 ± 28.0 63.4 ± 28.1 72.0 ± 34.2 57.5 ± 22.8
P1NP (ng/mL) 75.8 ± 37.1 83.7 ± 58.4 59.1 ± 26.4 80.7 ± 51.5
CTX (ng/mL) 0.388 ± 0.176 0.406 ± 0.199 0.312 ± 0.145 0.453 ± 0.259
DXA measurements:
LS BMD (g/cm2) 0.84 ± 0.13 0.86 ± 0.14 0.83 ± 0.17 0.87 ± 0.16
FN BMD (g/cm2) 0.63 ± 0.09 0.63 ± 0.10 0.60 ± 0.10 0.61 ± 0.08
BMI Body Mass Index; ALP alkaline phosphatase; PTH parathyroid hormone; DXA Dual




neck. Mean P1NP decreased by 64 % from 75.7 ng/ml to a mean of 23.3 ng/ml (range 
7–105 ng/ml) after one year of treatment. In 82 of the 127 patients, P1NP was also 
measured 3 months after start of treatment. At this time-point, serum levels of P1NP 
decreased by 51 % to 34.5 ± 18.2 ng/ml compared to baseline and by another 23 % to 
23.5 ± 13.3 ng/ml after 12 months of treatment; Figure 2.
Mean Ctx decreased by 58 % from 0.387 ng/ml to a mean of 0.138 ng/ml (range 
0.046–0.416 ng/ml) after one year of treatment.
Predictive value of bone turnover markers for changes in Bone Mineral 
Density
The change in serum levels of P1NP between baseline and 1-year follow-up (∆T0-T12) 
was predictive for (∆T0-T12) BMD at the lumbar spine, with a decrease in P1NP being 
predictive for a significant increase in lumbar spine BMD (B = 0.046, p = 0.001), also 
after adjusting for time after the fracture (B = 0.043, p = 0.003); Figure 3. Changes in 
Figure 2
Change in P1NP levels after 3 and 12 months of treatment









Significant relationship between the difference in P1NP at baseline and 12 months follow-up and the difference 
in lumbar spine BMD at baseline and 12 months follow-up
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serum P1NP levels after 1 year were not, however, predictive for changes in BMD at the 
femoral neck (B = -0.010, p = 0.398).
The change in P1NP concentrations after 3 months of treatment was predictive for 
(∆T0-T12) BMD at the lumbar spine (B = 0.035, p = 0.045) but not for (∆T0-T12) BMD 
at the femoral neck (B = -0.016, p = 0.345). (∆T0-T3) P1NP after 3 months was not 
predictive for (∆T0-T12) BMD at the lumbar spine after adjusting for time after fracture 
(B = 0.028, p = 0.124).
 (∆T0-T12) Ctx was predictive for (∆T0-T12) BMD at the lumbar spine (B = 0.071, 
p = 0.011), also after adjusting for time after the fracture (B = 0.066, p = 0.020), but was 
not predictive for changes in BMD at the femoral neck (B = -0.005, p = 0.840).
We could further evaluate whether individual serum levels of P1NP at baseline were 
predictive for changes in BMD after 1 year of treatment in 132 patients in whom data 
were available for BMD at baseline and follow up and for P1NP at baseline. Higher 
baseline P1NP was found to be predictive for a positive change in BMD at the lumbar 
spine (B = 0.021, p = 0.003), also after adjustment for time after fracture (B = 0.018, 
p = 0.014). Baseline P1NP could not predict the change in BMD at the femoral neck (B 
= -0.10, p = 0.069).
Baseline Ctx levels were not predictive for changes in BMD at the lumbar spine 
(B = 0.039, p = 0.240) or femoral neck (B = -0.022, p = 0.420).
DISCUSSION
Our data from this study demonstrate a relationship between changes in BMD at the 
lumbar spine and changes in P1NP and CTx levels after 12 months of starting osteopo-
rosis treatment after a recent fracture, also after adjustment for time between fracture 
and the initial FLS evaluation. Changes in P1NP levels after 3 months were related with 
(∆T0-T12) BMD at the lumbar spine, but this did not reach significance after adjust-
ment for time between fracture and the first FLS visit. We also observed a positive 
relationship between baseline P1NP before start of treatment and (∆T0-T12) BMD at 
the lumbar spine, also after adjustment of time after fracture.
In the management of osteoporosis, bone turnover markers have been shown to de-
crease within weeks after start of antiresorptive agents, whereas changes in BMD are 
slower, only observed after at least a year of treatment (4, 5, 12, 13). Although these 
observations suggest that bone turnover markers may be an attractive tool for the moni-
toring of treatment of osteoporosis using bone modifying agents, there is to date no 
consensus on the use of these markers in the individual patient in daily clinical practice.
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In a position paper that focuses on the value of using bone turnover markers in moni-
toring osteoporosis treatment, Vasikaran and colleagues have described a number 
of factors that might affect the pattern of response of these markers, such as the 
nature, dose and route of administration of the given agent (7). In order to use BTMs 
in the monitoring of osteoporosis treatment, baseline measurements and follow-up 
measurements after a specified interval are required. The position paper does not 
provide an advice for the time interval that should be used but refers to a number of 
studies that measured BTMs after 3, 6 and 12 months of treatment and found that the 
reduction in BTMs was inversely related with the reduction in the risk of fractures. Our 
study describes data on BTMs measured at baseline and after 3 and 12 months of 
treatment with antiresorptives that were found to be related with BMD outcome.
Interestingly, there was also a relationship between baseline levels of P1NP and the 
change in lumbar spine BMD after 12 months although BTMs measured at baseline are 
heavily affected by the effect of the recently sustained fracture. In keeping with these 
findings is the observation that postmenopausal women with high BTMs at baseline 
have a greater effect on anti-fracture efficacy after start of treatment (14–16). However, 
patients with high P1NP levels at baseline in our study might also have had high P1NP 
levels before they sustained a fracture. We could not test this hypothesis as we lack 
data on pre-fracture P1NP measurements.
Our study has strengths as well as limitations. One of its strengths is that data was 
collected in consecutive patients who have recently sustained a fracture, were aged 
50 year or older and were referred to our FLS. The Leiden University Medical Center 
is a tertiary center but its FLS serves a large regional treatment area. Osteoporosis 
treatment was predominantly given in the form of oral bisphosphonates, which again 
is representative of daily clinical practice. We only included patients with available 
data on BMD and BTMs at 1-year follow-up so that we could evaluate whether these 
markers could reflect a change in bone mass. This may have also limited our study as 
it could have led to a selection bias as only those patients with adequate adherence 
to treatment may have been included.
In conclusion, our study demonstrates that a decrease in P1NP and Ctx levels at 12 
months after starting anti-resorptive agents and higher baseline P1NP levels are 
predictive for a significant increase in BMD at the lumbar spine after 12 months of 
follow-up. These findings suggest that changes in bone turnover markers or measure-
ments of these markers at baseline could be used to predict the effect of treatment 
with anti-osteoporosis drugs. Large follow-up studies are required to establish the 
relationship between the risk of fracture and the change in bone turnover markers or 
baseline measurements.
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Part 2
Impact microindentation 
in the evaluation of bone fragility
 Chapter 5
Reference Point Indentation: a review of in vivo 




Impact microindentation (IMI) is a novel technique, which has been introduced in the 
clinic for the evaluation of tissue-level properties of cortical bone. The number of 
studies addressing the value of this technique in the management of osteoporosis 
has been steadily increasing over the past decade. This chapter focuses on a review 
of published clinical studies using the IMI technique in vivo in humans with special 
emphasis on the four studies which have so far explored the relationship between 
IMI-derived Bone Material Strength index (BMSi) and fracture.
Available data from these studies provide evidence for the value of IMI in differen-
tiating between patients with increased fracture risk and control patients. However, a 
main limitation identified in the interpretation of IMI data is the high variability in BMSi 
in patients as well as control populations between studies. This observed variability is 
likely to be due to the absence of a standard protocol for performing the procedure, 
leading to variable study protocols being used by different centers. Notwithstanding, 
data gathered so far from our studies and that of others suggest that IMI represents a 
valuable additive tool in the evaluation of elements of bone fragility which are not fully 
captured by currently used methods such as DXA.
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INTRODUCTION
Bone fragility is a complex concept and its evaluation remains a challenge in clini-
cal practice. The assessment of bone fragility has to date mainly focussed on the 
evaluation of clinical risk factors for increased bone fragility together with quantita-
tive evaluation of bone mass by Dual Energy X-ray Absorptiometry (DXA) (1–5). Bone 
Mineral Density (BMD) measurements have been performed in the clinic for over three 
decades and experience with their use is substantial. However, evidence has been 
accumulating for limitations of this technique as it has now been demonstrated that 
only one third of an individuals’ fracture risk can be explained by BMD values (1). Other 
available tools to assess bone fragility include High Resolution peripheral Quantitative 
Computed Tomography (HRpQCT) to assess bone structure, bone biopsies to assess 
bone histomorphometry and nano-indentation to assess material properties of bone 
(6, 7). However, these methods are associated with either high radiation exposure or 
with the use of invasive and time-consuming procedures so that their use has so far 
been largely restricted to research settings. Material properties of bone significantly 
contribute to bone fragility but the study of these parameters is difficult. Traditional 
mechanical tests such as bending or compression techniques, considered as the 
golden standard for evaluating material properties of bone, cannot be performed in 
vivo.
Reference Point Indentation (RPI) has been introduced just over a decade ago for 
the evaluation of in vivo tissue-level properties of cortical bone (4, 5). In contrast to 
other indentation techniques, RPI is designed to be used without surgically exposing 
the bone surface and does not require the use of an optic microscope to register the 
deformation of the indentations (8).
The principle of RPI is based on the hypothesis that a fracture is precipitated by 
the separation of mineralized collagen microfibers, leading to microcracks (9). These 
microcracks are similar to those observed in fractured bone, so that is has been hy-
pothesized that RPI measurements may be of value in assessing bone’s ability to resist 
fracture or in other words in reflecting bone fragility. Since the introduction of the RPI 
technique in 2006, experience has been accumulating with the use of this technique 
with increasing numbers of patients being tested. An adaption of the original device 
has been developed and applied and a standard operating procedure has been re-
cently published (10, 11).
This Review Chapter primarily focuses on published clinical studies using the Refer-
ence Point Indentation technique in vivo in humans, and summarizes reported data 
and clinical implications regarding the use of this technique in the evaluation of tissue 
level properties of cortical bone and possibly beyond overall bone fragility.
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THE REFERENCE POINT INDENTATION TECHNIQUE
Two Reference Point Indentation devices are currently available, namely the Osteo-
probe for in vivo use in humans and large animals, and the Biodent, which is mainly 
used for basic research studies although the first two human studies were performed 
using this device. To avoid confusion with the interpretation of data, a unified nomen-
clature has been proposed in a recent publication: cyclic reference point microinden-
tation (CMI) is performed using the Biodent device and impact microindentation (IMI) is 
performed using the Osteoprobe RUO device (11).
Although the main principle of indenting the bone surface holds for both devices, 
there are significant differences between the two tools. Firstly, the Biodent makes use 
of a cyclic loading system and the Osteoprobe of single impact loading. Secondly, 
Biodent drives the test probe into the bone with a load from 2 to 10 Newton with 
an adjustable number of cycles (up to 20), whereas the Osteoprobe drives the test 
probe into the bone with a 30 Newton load, after a pre-load of 10 Newton to stabilize 
the test probe. Thirdly, several parameters are acquired with the Biodent using the 
force-distance curves, including the total Indentation Distance Increase, Indentation 
Distance Increase (IDI), creep Indentation Distance, loading and unloading slope and 
the average Energy Dissipation. In contrast, the Osteoprobe has only one outcome 
parameter: Bone Material Strength index (BMSi), which is calculated using the indenta-
tion distance increase (IDI) from the test probe during the load application. After the 
measurements on the bone tissue, five measurements are performed on a calibration 
phantom consisting of polymethylmetacrylate (PMMA). BMSi is defined as 100 times 
the harmonic mean of IDI from impact into the PMMA divided by the average IDI from 
impact into bone tissue (10, 11). Fourthly, the Osteoprobe differs from the Biodent in 
that it lacks a reference probe but uses an inertial reference point located at the point 
from the test probe just before the impact is activated, thereby eliminating the need 
to scrape the periosteum.
A further practical difference between the two devices is that measurements using 
the Biodent need to be performed using a fixed device mounted over the patient 
whereas the Osteoprobe is a handheld device, which facilitates its use in clinical 
practice, particularly in an outpatient setting.
Clinical studies using the Biodent
Diez-Perez and colleagues were the first to report CMI data in 27 postmenopausal 
women who had sustained osteoporotic fractures (25 hip, 2 vertebra) and 8 controls 
(9). Their data showed significantly greater indentation distances in fracture patients 
compared to controls, with the caveat that total hip BMD was significantly higher in the 
latter group. CMI measurements were also performed on cadaveric bone samples of 
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the tibia of 5 human donors (age range 17 – 74 years; 2 male, 3 female). Mechanical 
tests performed to measure crack growth toughness, showed a significant inverse 
relationship between IDI and crack growth toughness. Based on these data, the re-
searchers raised the hypothesis that microindentation may induce microcracks on the 
bone surface and may in turn reflect bone fragility.
This publication was followed by another study using the Biodent in 6 patients with 
atypical femoral fractures, 38 patients with hip fractures, 6 patients without incident 
fractures but using long-term bisphosphonates, and 20 non-fracture controls (12). In 
keeping with the initial CMI study, patients with hip fractures had significantly greater 
IDI compared to controls without fractures. In addition, IDI was greater in AFF patients 
than in controls, but was comparable to that of hip fracture patients suggesting that 
AFF patients and conventional hip fracture patients have similar tissue-level properties 
of bone. IDI of long-term bisphosphonate users with no incident fracture during treat-
ment was comparable with IDI of controls, suggesting similar tissue-level properties of 
bone between these two groups.
These two studies were the first to provide information on bone material properties 
in patients with osteoporotic fractures and AFF, as well as experience with the use of 
the technique of microindentation. Several adaptions and improvements were subse-
quently applied to the Osteoprobe instrument, which has been further solely used for 
in vivo clinical studies in humans (Table 1).
Clinical studies using the Osteoprobe
Fifteen studies have been so far published on the in vivo use of the IMI technique 
in humans. Most of these studies included patient groups with an increased risk for 
fracture not fully explained by BMD values. An interesting study from Sweden evalu-
ated the association between BMSi, micro architectural parameters of bone and sub-
cutaneous fat at the tibia in 202 elderly women with no specific underlying pathology 
(13). The investigators found an inverse relationship between BMSi and the amount of 
subcutaneous fat, whole body fat mass and BMI. In addition, BMSi was associated with 
cortical porosity and cortical volumetric BMD at the distal tibia. These findings suggest 
a negative influence of adipose tissue on bone strength.
Effect of type 2 diabetes mellitus on BMSi measurements
The first published IMI study was from the United States and evaluated Bone Material 
Strength index in 30 postmenopausal women with type 2 diabetes mellitus (T2DM) 
compared to 30 healthy controls (14). In this study, the authors observed that BMSi was 
significantly lower in patients with T2DM compared to controls, also after adjustment 
for multiple variables potentially confounding according to the authors (e.g. BMI, hy-
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Table 1. Clinical studies using impact microindentation
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US United States; NL The Netherlands; ES Spain; NO Norway; SE Sweden.
FN BMD femoral neck Bone Mineral Density; BMSi Bone Material Strength index; T2DM type 2 diabetes mel-
litus; Ca/D3 calcium/ 25-OH vitamin D supplementation; RSN Risedronate; Dmab Denosumab; TPTD Teripara-
tide; CAG chronic atrophic gastritis; HIV human immunodeficiency virus; Renal Tx renal transplantation
* Sundh and Rudang reported the same patient group
** BMSi was measured in 38 renal Tx patients and 93 controls
*** Total hip BMD was reported
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pertension, retinopathy). There was a relationship between BMSi and mean glycated 
haemoglobin level over the 10 years prior to the study, but not with current HbA1c as 
measured at the screening visit, or with other variables such as age, BMI or BMD.
Two further studies confirmed the association between BMSi and T2DM. The first, 
also from a research group in the United States, was conducted in 16 postmenopausal 
women with T2DM and in 19 age-matched non-diabetic controls. Significantly lower 
BMSi values were demonstrated in T2DM patients compared to controls, and there 
was a significant relationship between BMSi and the duration of T2DM (15). In addition, 
AGE accumulation in the skin as measured by skin autofluoresence, which has been 
previously shown to be a surrogate marker of AGE levels in bone, was significantly 
inversely correlated with BMSi in T2DM patients. This suggests that the accumulation 
of AGEs may also lead to impaired tissue-level properties of bone.
The second study was a population-based study conducted in 1053 elderly Swed-
ish women aged 75–80 years with or without T2DM, of whom respectively 36 % and 
38 % had sustained a fracture. Fifty-one women with T2DM and 438 without T2DM 
consented to have IMI measurements. BMSi was significantly lower in T2DM patients 
compared to controls (16).
Effect of glucocorticoid use on BMSi measurements
The only study that evaluated sequential changes in BMSi measurements was 
conducted in 52 Spanish subjects commencing treatment with glucocorticoids, a 
drug shown to rapidly lead to deterioration of bone tissue (17). Patients were allo-
cated to treatment with different anti-osteoporosis agents based on Spanish national 
guidelines. 19 patients received only calcium/vitamin D supplementation (CA/D), 14 
risedronate (RSN), 14 denosumab (Dmab) and 5 teriparatide (TPTD). Measurements 
were performed at baseline, and at 7 and 20 weeks after start of treatment. After 7 
weeks of treatment, there was a significant decrease in BMSi in the Ca/D3 group, 
no change in the RSN group, and an increase in BMSi in the Dmab and TPTD group, 
with no parallel change in BMD. However, the significant differences in demographic 
characteristics, glucocorticoid dose and different osteoporosis agents used, represent 
a significant limitation of this study. Patients were also pragmatically switched from the 
Ca/D group to an active treatment group if a 10 % decrease in BMSi was observed in 
the first follow-up visit.
Geographical differences in BMSi
Duarte Sosa studied whether BMSi could differentiate between Norwegian and Span-
ish women, the former known to have increased risk for fracture not explained by 
BMD values (18). BMSi was shown to be significantly lower in 42 Norwegian women 
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compared to 46 Spanish women with the caveat that femoral neck BMD was signifi-
cantly higher in Norwegian women. There was no relationship between BMSi and any 
other studied patient characteristic.
BMSi in patients with Human Immunodeficiency Virus
In a study that aimed at elucidating the mechanism of increased fracture risk associ-
ated with Human Immunodeficiency Virus (HIV), IMI was performed in 50 HIV patients 
[15 (30 %) female] and 35 healthy controls [11 (31 %) female] living in Spain (19). HIV 
patients had significantly lower BMSi values than controls. In these patients, BMSi 
was also significantly lower in women than in men [80 (IQR 77–83) vs. 85 (IQR 83–87); 
p = 0.0004]. In healthy control, there was no difference in BMSi values between sexes 
in healthy controls.
BMSi in kidney transplant recipients
In a further study from the same Spanish research group, 40 long-term kidney transplant 
recipients (58 % female) and 94 controls (79 % female) selected from a reference 
database of healthy controls subjects were evaluated using Trabecular Bone Score 
(TBS) and IMI (20). There was no relationship between BMD, TBS and BMSi values. 
Although BMSi values were significantly lower in renal transplant recipients compared 
to controls in the unadjusted analysis, this difference was no longer observed after 
adjusting for age, sex and BMI. The authors based their conclusion on their finding 
of similar tissue-level properties of bone in long-term kidney transplant recipients 
compared to control patients by conducting the final analyses using only adjusted 
BMSi values.
BMSi in chronic atrophic gastritis
Aasarod and colleagues evaluated Norwegian patients with chronic atrophic gastritis 
(CAG) compared to healthy controls to address the question whether CAG is associ-
ated with impaired material properties of bone (21). No difference in BMSi values was 
observed between CAG and control patients. The study was heavily underpowered, 
with BMSi values available in only 14 CAG patients and in 18 controls. The rationale 
for investigating bone material properties in this patient group was also not clear as 
the only mentioned potential contributory risk for altered material properties was the 
chronic gastric hypoacidity with this condition.
BMSi in acromegaly
Acromegaly is a rare endocrine disorder caused by overproduction of growth hor-
mone associated with increased vertebral fracture risk in the presence of relatively 
normal BMD values. Our group demonstrated the presence of significantly lower mean 
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BMSi values in 48 acromegaly patients compared to 44 controls (22). There was no 
significant difference in BMSi between acromegaly patients with or without vertebral 
fractures.
BMSi in type 1 Gaucher disease
In the most recent study from the Spanish group, BMSi values were found to be sig-
nificantly lower in 16 type 1 Gaucher disease (GD1) patients compared to 29 healthy 
volunteers (23). An inverse relationship was also observed between BMSi and chitot-
riosidase levels, a marker of GD activity, in keeping with the previously demonstrated 
relationship between BMSi and AGE accumulation in patients with T2DM.
BMSi and fracture risk
To date, four studies have evaluated the association between BMSi and prevalent frac-
tures. Our group demonstrated that there was a strong negative relationship between 
BMSi and age, but not between BMSi and any other variable studied, including BMD, 
amongst 90 patients with low bone mass, 63 of whom had sustained a fragility fracture 
and 27 had not (24). BMSi was lower in patients who had sustained a fragility fracture 
than in patients who did not, in the presence of comparable BMD values (79.9 ± 0.6 
vs. 82.4 ± 1.0; p = 0.032). However, after stratification for BMD, BMSi values were found 
to be lower in patients with osteopenia and fragility fractures than in patients with no 
fractures. There was no difference in BMSi values observed in patients with osteopo-
rosis with or without fractures.
The study from Rudang and colleagues reported BMSi results of a population-based 
cohort of 75 to 80 year old Swedish postmenopausal women with (n = 117) or without 
fractures (n = 63) (25). They authors found a significant correlation between BMSi 
and areal BMD values at the lumbar spine, hip and distal radius. After adjustment for 
multiple covariates including, age, weight and height, use of bone-modifying agents 
and different operators, the only significant relationship which remained was between 
BMSi and BMD at the distal radius. BMSi was comparable in patients with or without 
fractures, also in the analysis that included only patients with osteopenia and osteo-
porosis (76.1 ± 6.9 vs. 75.1 ± 7.0; p = 0.43, respectively).
A further study from Norway specifically included women with stress fractures of the 
tibia but excluded patients with osteoporosis or previous low-energy fractures (26). 
Results from this study demonstrated significantly lower BMSi in patients with stress 
fractures than in controls without fractures (70.5 ± 8.7 vs. 77.1 ± 7.2; p = 0.01).
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Finally, a study published by Duarte Sosa et al demonstrated that in 132 post-meno-
pausal women, of whom 66 had sustained a fragility fracture at age ≥  45 years or 
had osteoporosis at either the lumbar spine or femoral neck, and 66 had no fractures 
and normal BMD values, fracture patients had significantly lower BMSi values than 
no fracture controls (71.5 ± 7.3 vs. 76.4 ± 6.2; p = 0.008) (27). In the 24 patients with 
vertebral fractures, BMSi was inversely related with severity of vertebral fractures, also 
after adjustment for age and total hip BMD.
FUTURE PERSPECTIVES
Evidence has been accumulating on the value of IMI in the in vivo evaluation of tissue-
level material properties of bone in humans. Current data highlight the ability of this 
technique in discriminating specific patient groups at risk for fractures from controls. 
Data on the value of IMI in the follow-up of patients with increased fracture risk remain 
inconclusive as available data are too scarce to provide adequate interpretation of 
results.
The technique is however not without limitations and so far available data suggest that 
some matters should be taken in consideration before recommending the use of IMI in 
the management of patients with increased bone fragility.
The Osteoprobe is a handheld device specifically designed for in vivo use in hu-
mans. The tool is relatively easy to use, but is also prone to variability in its results, in 
part because of the lack of a standard operating procedure. Data thus suggest that IMI 
is subject to inter-operator variability as shown in one study in which four different op-
erators performed BMSi and reported variable results (25). This finding suggests that 
BMSi values may have to be operator-adjusted before allowing reliable comparison of 
data between different centers. Although it has been shown that IMI measurements 
can identify patients at increased risk for fractures, it remains unclear which specific 
mechanical properties of bone are captured by IMI. To our knowledge, only one study 
directly compared IMI with parameters obtained by the three-point bending technique 
and demonstrated no correlation between data obtained by the two techniques (28). 
Data from studies addressing the relationship between CMI and traditionally used 
mechanical tests provide contrasting results for instance regarding the relationship 
between CMI parameters and toughness (29–31). These data suggest that both IMI 
and CMI measure aspects of bone strength other than those measured by mechanical 
tests, and it is currently not known which aspects are precisely measured by RPI. The 
modest or non-existent correlation between CMI and IMI parameters suggests that the 
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two techniques measure different parameters and study results cannot therefore be 
extrapolated from one to the other (32).
One of the important limitations in the interpretation of IMI data is that study proto-
cols vary in a number of key issues between centers. Study protocols differ in the 
number of measurements obtained per patient to calculate BMSi, and, even more 
significantly, different strategies are used to identify false measurements. This has 
led to the recent publication of a standard operating procedure for performing RPI 
including a recommended number of measurements and a protocol to be used to 
determine which measurements should be excluded from the calculation of BMSi (11). 
It is of utmost importance for the interpretation of BMSi results that all research groups 
using IMI adopt an identical study protocol so that results could be compared between 
centers. IMI is a simple, minimally invasive technique that is not time-consuming. Only 
two minor adverse events have been so far reported, one patient experienced a local 
allergic reaction to local anaesthetic (Lidocaine), and another patient developed a mild 
localized skin infection, which resolved after a short course of antibiotics.
A further complicating matter in the interpretation of BMSi results is the intriguing 
wide variability of BMSi values of control patients between studies. Some studies 
thus reported BMSi values of 80 or higher in control patients, whilst others reported 
lower BMSi values in the range of 70–78, corresponding to the range of BMSi values 
observed in patient groups in a number of studies identified to have increased fracture 
risk; Table 1. There are several potential causes for this discrepancy in findings. There 
might be a geographical difference in BMSi values as suggested by a study compar-
ing BMSi values between Norwegian and Spanish women, which demonstrated sig-
nificantly lower BMSi values in Norwegian women (18). Our group further consistently 
reported a highly significant relationship between BMSi and age, with a significant 
decrease in BMSi observed with increasing age (24, 33). The influence of age on BMSi 
may be particularly important in the interpretation of results from the study conducted 
by Rudang et al, where no relationship was found between BMSi and fracture in a 
population-based study in women aged 75–80 years (25). It can thus be hypothesized 
that BMSi values already significantly influenced by age may not be further significantly 
negatively influenced by the presence of prevalent fractures. These data suggest that 
reference values established for different ages and background are needed for the 
better interpretation of BMSi values, similar to the case with BMD and FRAX reference 
values.
A further matter of interest is whether IMI performed at the midshaft of the tibia may 
reflect tissue-level properties of bone at other skeletal sites than the tibia, thus reflect-
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ing overall bone fragility rather than just cortical bone fragility. Interestingly, there are 
contrasting data on the relationship between BMSi and vertebral fractures. Whereas 
there was no relationship between BMSi and vertebral fractures in a population-based 
study of 211 older women, including 58 with vertebral fractures (25), a study of 132 
postmenopausal women demonstrated significantly lower BMSi values in fracture 
patients (24 with vertebral fractures) compared to controls, also showing a significant 
relationship between BMSi and severity of vertebral fractures (27). Our group further 
demonstrated low BMSi values in patients with acromegaly, with or without vertebral 
fractures (22), and low BMSi values in fracture patients, independently of whether this 
was a vertebral fracture or a non-vertebral fracture (33), suggesting that BMSi may 
reflect overall bone fragility rather than just cortical bone fragility.
Based on currently published data, we can conclude that IMI captures elements of 
bone strength not captured by BMD in specific patient groups known to have in-
creased fracture risk. IMI is not a measure of bone mass, and there is no clear relation-
ship demonstrated between these two, suggesting that IMI should be considered as 
an additional tool in the assessment of bone health and not a replacement for BMD 
measurements. Large prospective clinical trials are required to determine whether 
BMSi values are of added value to currently used diagnostic tools such as DXA in 
the identification of patients with high fracture risk, and whether it is suitable for the 
prediction of treatment outcome in the management of osteoporosis. Results from 
these studies will determine whether IMI could be used in clinical practice or whether 
its use should be restricted for the time being to research settings until more evidence 
is gathered about its optimal use in the clinic.
Further experimental studies are also required to establish the relationship between 
IMI and traditional mechanical properties of bone.
In conclusion, IMI is an exciting technique which enables researchers to evaluate 
tissue-level material properties of bone in a minimally invasive manner in vivo, adding 
to available tools such as DXA by capturing aspects of bone fragility not reflected by 
these currently used tools.
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Bone Mineral Density (BMD) does not fully capture fracture risk as the majority of 
fractures occur in patients with osteopenia, suggesting that altered bone material 
properties and changes in microarchitecture may contribute to fracture risk.
Objective:
To evaluate the relationship between Bone Material Strength (BMS), measured by 
microindentation in vivo, and fracture in patients with low bone mass.
Methods:
BMS was measured in 90 patients (mean age 61.0 years (range 40.4–85.5 years)) with 
low bone mass with or without a fragility fracture. Sixty-three patients had sustained 
one or more fragility fractures.
Results:
There was a significant negative correlation between age and BMS (r = -0.539, 
p < 0.001) and with the 10-year fracture probability with and without inclusion of femo-
ral neck BMD as calculated by FRAX (r = -0.383, p < 0.001 and r = -0.426, p < 0.001, 
respectively). BMS values were lower in patients with a fragility fracture compared to 
non-fracture patients (79.9 ± 0.6 vs. 82.4 ± 1.0, p = 0.032) despite similar BMD. BMS 
was comparable in patients with a fragility fracture whether they had osteopenia or 
osteoporosis (79.8  ±  0.8 vs. 78.7  ±  1.1, p = 0.456). In patients with osteopenia, BMS 
was significantly lower in fracture patients than in non-fracture patients (80.3 ± 0.7 vs. 
83.9 ± 1.2; p = 0.015).
Conclusion:
These data suggest that patients with fractures have altered material properties of 
bone which are not captured by BMD. Further studies are required to establish the 
value of BMS in the prediction of fracture risk, especially in patients with osteopenia.
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INTRODUCTION
Osteoporotic fractures are common and their incidence rises with age, regardless of 
gender(1–3). All fractures represent a significant cause of morbidity and decreased 
quality of life, but fractures have also been shown to be associated with increased 
mortality(4, 5). There is mounting evidence that Bone Mineral Density (BMD) measure-
ments using DXA only partially capture fracture risk, as a majority of fragility fractures 
have been shown to occur in patients with osteopenia(6, 7). This strongly suggests 
that determinants of bone strength other than bone mass may contribute to bone fra-
gility in these patients. Such determinants would include changes in microarchitecture 
and of material properties of bone. Up until recently this hypothesis was, however, 
difficult to test in humans due to lack of appropriate techniques for evaluation of these 
determinants of bone strength.
Recent studies examining structural changes of bone in patients with fractures dem-
onstrated a deterioration in bone microarchitecture(8, 9), as well as an association 
between increased cortical porosity and distal forearm fractures in patients with osteo-
penia(10). Reference point indentation is a new tool that permits in vivo measurements 
of bone material properties in humans. This technique has been extensively validated 
in animal models(11–13). Diez-Perez et al were the first to report data on microindenta-
tion in vivo in humans, showing a significantly higher indentation distance increase 
(IDI) in patients with osteoporotic fractures compared to non-fracture controls(14). 
Further development of the technique has led to the introduction of a handheld device 
to measure Bone Material Strength (BMS), a parameter derived from the ratio of the 
mean IDI between the calibration phantom and bone, as a quantifiable parameter of 
the ability of bone to resist microindentation(15). This device is inserted in the skin of 
the tibia until it reaches the bone surface and indents it. Using this technique, Farr et 
al recently reported that postmenopausal women with type 2 diabetes mellitus had 
lower BMS compared with age-matched non-diabetic controls, and suggested that this 
may contribute to the increased bone fragility observed in these patients(16).
The main objective of our study was to evaluate the relationship between BMS, as 






Cross-sectional study evaluating Bone Material Strength (BMS) using the microindenta-
tion in vivo technique in men and women attending the outpatient clinic of the Center 
for Bone Quality or the regional Fracture Liaison Service (FLS) of the Leiden University 
Medical Center between July 2013 and August 2014.
Patients
Patients were sequentially invited to take part in the study. Details of the recruitment 
process are shown in Supplemental Figure 1. Inclusion criteria included age between 
40 and 85 years, low bone mass (osteopenia or osteoporosis as diagnosed by DXA) 
and willingness to be investigated using the microindentation in vivo technique. Exclu-
sion criteria were a metabolic bone disorder other than osteoporosis, serum 25-OH 
vitamin D concentrations < 25 nmol/L, pathological fractures, severe liver or kidney 
impairment (CKD stage IV or V), current use of glucocorticoids, aromatase inhibitors, 
androgen deprivation therapy or chemotherapy and previous or current use of bone-
acting agents (bisphosphonates, denosumab, selective estrogen receptor modulators 
(SERMs), strontium ranelate, recombinant PTH), immobilization, local infection of the 
tibia at the site of examination, bilateral hip replacement, participation in other re-
search studies and inability to provide informed consent. Past use of glucocorticoids 
(longer than 3 months ago) was not an exclusion criterion as fracture risk has been 
shown to reverse quickly after discontinuation of treatment(17, 18). The Medical Ethics 
Committee of the LUMC approved the study and informed consent was obtained from 
all patients.
Methods
A full medical history including data on menopausal status, clinical risk factors for frac-
tures for the calculation of the 10-year fracture probability (FRAX), a detailed fracture 
history with documentation of site and date of occurrence of the fracture, and informa-
tion about use of medication were obtained from all patients. A fragility fracture was 
defined as any low energy fracture, excluding those of the hands, feet and skull. The 
FRAX probability for a major osteoporotic fracture and for a hip fracture was calculated 
using reference values for the Dutch population(19). Both fracture probabilities were 
computed with and without the inclusion of femoral neck BMD in the calculation. Frac-
tures sustained < 12 months before the investigation were not included as a previous 
fracture in the calculation of the FRAX(20–22).
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Serum Biochemistry
Blood samples were collected for the measurement of serum calcium, phosphate, 
albumin, creatinine, and liver enzymes using semi-automated techniques; serum 
25-hydroxyvitamin D was measured using the 25-OH-vitamin D TOTAL assay (DiaSorin 
D.A./N.V., Brussels, Belgium) and plasma Intact PTH was measured by the immulite 
2500 (Siemens Diagnostics, Breda, Holland).
Bone Mineral Density
Areal Bone Mineral Density (BMD) was measured at the lumbar spine (L1-L4) and at 
both femoral necks using Dual-energy X-ray absorptiometry (DXA) with the Hologic 
QDR 4500 (Hologic Inc., Waltham, MA, USA). Average values of the left and right femo-
ral neck (FN) were used for analysis. T-scores were calculated using reference values 
of the National Health and Nutrition Examination Survey NHANES III and osteopenia 
and osteoporosis were diagnosed according to WHO criteria.
Radiographs of the spine
Lateral radiographs of the thoracic and lumbar spine were performed for the detection 
of vertebral deformities. All radiographs were independently evaluated by two of the 
authors using the semi-quantitative method of Genant(23).
Bone Material Strength
Bone Material Strength (BMS) was evaluated by microindentation in vivo using the 
Osteoprobe®, a Reference Point Indenter (kindly provided by Active Life Scientific 
Inc., Santa Barbara, CA, USA)(11, 14, 15). After local anaesthesia using a solution of 1 % 
Lidocaïne, the hand-held Osteoprobe® is inserted in the skin of the midshaft of the right 
tibia (mean distance between distal apex of the patella and medial malleolus) until it 
reaches the bone surface which is indented upon activation of the instrument. During 
measurements, the Osteoprobe® is maintained perpendicular to the surface of bone at 
the site of investigation. A minimum of five and up to twenty-five measurements were 
performed at the same site. During the procedure, the operator classified the sequential 
measurements as poorly, adequately or well performed, before checking the obtained 
data, to avoid reporter bias in the interpretation of results. After at least five adequate 
measurements in each subject, five additional measurements are performed on a poly-
methylmethacrylate (PMMA) plastic calibration phantom. BMS is calculated as 100 times 
the ratio of the mean indentation distance increase from impact into the PMMA calibra-
tion phantom divided by the indentation distance increase from impact into bone. The 
probe induces a microfracture as it indents the surface of the cortical bone of the tibia. 
The more easily this occurs, the deeper the probe indents the bone, and thus the lower 




All analyses were performed using the SPSS software for Windows (Version 20.0; SPSS 
Inc., Chicago, IL, USA). All data are expressed as mean ± SD unless otherwise stated. 
Normality assumptions were checked by normality plots and by inspection of histo-
grams of residuals from the various regression models. Between-group differences in 
baseline characteristics were assessed using a Student’s t-test, a Chi-square test or 
a Mann-Whitney U test for non-normally distributed variables. Pearson’s correlations 
were used to assess correlations between patients’ parameters and BMS. Spearman’s 
correlations were used to assess correlations between parameters that were not nor-
mally distributed and BMS values. Analysis of variance models with BMS as outcome 
variable, adjusted for covariates, were used to compare BMS values between groups. 
Binary logistic regression analysis was used to assess the separate contributions of 
BMS and femoral neck BMD (variables) to fracture (outcome). A probability level of 
random difference of 0.05 was considered significant.
RESULTS
Ninety of 125 eligible patients with low bone mass agreed to take part and were in-
cluded in the study (Supplemental Figure 1). Forty-nine of them, all with fractures, were 
recruited from the FLS while 41, with or without fractures, were attending the outpatient 
clinic. Patients’ characteristics and laboratory values are shown in Table 1. These were 
53 women and 37 men, mean age 61.0 years (range 40.4 and 85.5 years), 61 % of whom 
had osteopenia. Sixty-three patients (24 men) had sustained a low energy fracture 
(vertebral n = 8; hip n = 10; non-hip/non-vertebral n = 45), in 43 of whom the fracture 
was recent. Microindentation was performed at a median time of 4.0 months after a 
fracture. Patients without history of a clinical fracture had also no radiological evidence 
for vertebral deformities on spinal radiographs.
Bone Material Strength (BMS) was significantly inversely related with age (r = -0.539, 
p < 0.001; Figure 1) and with the 10-year fracture probability with and without inclusion 
of femoral neck BMD in the calculation of FRAX (r = -0.383, p < 0.001 and r = -0.426, 
p < 0.001, respectively). BMS values were inversely and significantly related with age 
and with the 10-year fracture probability in both genders (age: women r = -0.422, 
p = 0.001, men r = -0.570, p < 0.001; FRAX: women r = -0.286, p = 0.038, men r = -0.393, 
p = 0.016). Because of the relationship between BMS and age all further reported 
values of BMS were adjusted for age. Unadjusted values are shown in Supplemental 
Table 1.
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Table 1. Characteristics of 90 patients with low bone mass
Fracture (n = 63) No fracture (n = 27) p-value
Age (years) 62.6 ± 9.6 57.1 ± 9.5 0.015
Male/female 24/39 13/14 0.374
BMI (kg/m2) 24.3 ± 3.5 25.3 ± 4.7 0.725
Parental Hip Fracture (%) 9 (14 %) 4 (15 %) 0.948
Smoking (%) 14 (22 %) 2 (7 %) 0.092
Alcohol use > 3 IU/day (%) 14 (22 %) 1 (4 %) 0.031
Glucocorticoids (%) 4 (6 %) 6 (22 %) 0.028
FRAX probability
 Major fracture (%) 6.9 ± 1.0 4.0 ± 0.8 0.001 
 Hip fracture (%) 2.0 ± 0.8 1.0 ± 0.3 0.003 
PTH (pmol/L) 3.8 ± 1.9 3.5 ± 1.5 0.570
Calcium (mmol/L) 2.41 ± 0.08 2.41 ± 0.10 0.826
25-OH D (nmol/L) 67.4 ± 28.6 79.6 ± 26.5 0.062
Creatinine (µmol/L) 73.5 ± 13.1 78.4 ± 15.0 0.163
LS BMD (g/cm2) 0.87 ± 0.13 0.86 ± 0.12 0.402
T-score LS -1.7 ± 1.2 -1.9 ± 1.1 0.431
FN BMD (g/cm2) 0.67 ± 0.09 0.69 ± 0.08 0.303
T-score FN -1.8 ± 0.7 -1.6 ± 0.6 0.329
Values are expressed as mean ± SD. FRAX is expressed as median ± SEM.
BMI Body Mass Index; PTH parathyroid hormone; LS lumbar spine; FN femoral neck;
BMD Bone Mineral Density.
Reference range PTH (0.7–8.0 pmol/L)
Reference range Calcium (2.15–2.55 mmol/L)
Reference range Creatinine (64–104 µmol/L for males, 49–90 µmol/L for females)











Relationship between age and Bone Material Strength (BMS) in 90 patients with osteoporosis or osteopenia. 
Closed circles represent patients with fragility fractures, open circles represent patients without fragility fractures.
r = -0.539, p < 0.001.
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BMS values did not differ between women and men (80.0 ± 0.7 vs. 81.6 ± 0.8; p = 0.147). 
There was no significant relationship between BMS and BMD (lumbar spine: r = 0.129, 
p = 0.157; femoral neck: r = 0.134, p = 0.143), BMI (r = 0.075, p = 0.413) or any of the bio-
chemical parameters measured.
BMS in patients with low bone mass
BMS was comparable in patients with osteoporosis and those with osteopenia 
(79.9 ± 0.8 vs. 81.2 ± 0.7, p = 0.230). Patients with osteoporosis were predominantly 
women, had significantly lower BMI and significantly lower lumbar spine and femoral 
neck BMD than patients with osteopenia.
Patients with osteoporosis and a history of fragility fracture (n = 21) were significantly 
older than those without a fragility fracture (n = 14) (65.8 years ±  10.5 vs. 53.7 years 
± 10.0; p = 0.002) and were more likely to be active smokers and/or to consume > 3 
units of alcohol/day (29 % vs. 0 %; p = 0.028 for either). All other measured parameters, 
including BMS (79.3  ±  1.3 vs. 80.7  ±  1.6, p = 0.540) did not differ between the two 
groups; Figure 2.
In patients with osteopenia, there was no significant difference in clinical character-
istics, serum biochemistry or BMD between fracture (n = 42) and non-fracture (n = 13) 
patients. However, BMS values were significantly lower in patients with fragility frac-
tures compared to those without a fragility fracture (80.3 ± 0.7 vs. 83.9 ± 1.2; p = 0.015); 











Bone Material Strength (BMS) in patients with osteoporosis (open bars) and osteopenia (closed bars), with and 
without fragility fractures. Mean ± SEM are shown.
*p = 0.015
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Figure 2. This difference remained significant also after exclusion of patients with a hip 
fracture (80.4 ± 0.8 vs. 83.8 ± 1.2; p = 0.027).
BMS in patients with fragility fractures
BMS values were significantly lower in patients with fragility fractures compared to 
those who had never sustained a fracture (79.9 ± 0.6 vs. 82.4 ± 1.0, p = 0.032), despite 
similar lumbar spine and femoral neck BMD values between the two groups; Figure 3. 
A lower BMS was associated with a higher odds for fractures [OR 1.15 (1.05–1.27), 
p = 0.004] whereas this was not the case for femoral neck BMD [OR 6.17 (0.02–2124.51), 
p = 0.542].
Among patients with a fragility fracture (n = 63), 42 had osteopenia and 21 osteoporosis; 
details shown in Table 2. BMS values were comparable in all patients with fragility frac-
tures whether they had osteopenia or osteoporosis (79.8 ± 0.8 vs. 78.7 ± 1.1, p = 0.456); 
Figure  2. There was no significant difference in BMS between patients who had 
sustained a leg fracture of the ipsilateral side of the measurement (n = 8) compared to 
those with a fracture of the contralateral side (n = 10) (77.6 ± 1.8 vs. 78.3 ± 1.6, p = 0.777). 
Compared to patients with osteoporosis, patients with osteopenia comprised rela-
tively more men and had higher BMI and BMD and lower 10-year fracture probability. 






























































(A) Femoral neck Bone Mineral Density (FN BMD) and (B) Bone Material Strength (BMS) in patients with and 
without fragility fractures.
Data are shown in box-whisker plots and statistical differences are displayed for BMS. Boxes indicate median 





We show here that patients who had sustained a fragility fracture demonstrate a 
significantly lower Bone Material Strength, as measured by the microindentation in 
vivo technique, compared to patients who did not fracture. More importantly, our data 
also demonstrate that there was no difference in Bone Material Strength in patients 
with fragility fractures whether they had osteopenia or osteoporosis. Our findings thus 
suggest that bone material properties are altered in patients with a fragility fracture 
and that the microindentation in vivo-derived BMS measurement captures elements of 
bone fragility independently of BMD. Analysis of data on bone turnover markers, which 
may also be associated with an increase in fracture risk independently of BMD(24), 
were not undertaken in this study because reliable interpretation of the data was 
precluded by the large number of patients with a recent fracture and the influence of 
this on serum levels of these markers.
Table 2. Characteristics of 63 patients with fragility fractures
Osteopenia (n = 42) Osteoporosis (n = 21) p-value
Age (years) 61.0 ± 8.8 65.8 ± 10.5 0.058
Male/female 20/22 4/17 0.028
BMI (kg/m2) 25.0 ± 3.2 22.8 ± 3.8 0.046
Parental Hip Fracture (%) 6 (14 %) 3 (14 %) 1.000
Smoking (%) 8 (19 %) 6 (29 %) 0.391
Alcohol use > 3 IU/day (%) 8 (19 %) 6 (29 %) 0.391
Glucocorticoids (%) 3 (7 %) 1 (5 %) 0.715
FRAX probability
 Major fracture (%) 6.5 ± 0.6 9.8 ± 2.6 0.004 
 Hip fracture (%) 1.4 ± 0.4 4.0 ± 2.2 0.001 
PTH (pmol/L) 3.8 ± 1.8 3.9 ± 2.2 0.913
Calcium (mmol/L) 2.41 ± 0.08 2.41 ± 0.09 0.975
25-OH D (nmol/L) 69.2 ± 29.3 63.7 ± 27.5 0.474
Creatinine (µmol/L) 74.6 ± 12.1 71.5 ± 14.9 0.159
LS BMD (g/cm2) 0.92 ± 0.12 0.77 ± 0.09 < 0.001
T-score LS -1.3 ± 1.1 -2.6 ± 0.9 < 0.001
FN BMD (g/cm2) 0.71 ± 0.07 0.60 ± 0.09 < 0.001
T-score FN -1.5 ± 0.5 -2.3 ± 0.8 < 0.001
Values are expressed as mean ± SD. FRAX is expressed as median ± SEM.
BMI Body Mass Index; PTH parathyroid hormone; LS lumbar spine; FN femoral neck;
BMD Bone Mineral Density.
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Microindentation in vivo is a new technique, designed to measure the resistance 
of bone to fracture by separating mineralized collagen microfibers and thus, locally 
inducing microcracks. In the first human studies, the material properties of bone were 
quantified by Total Indentation Distance, Indentation Distance Increase (IDI), and creep 
Indentation Distance(14, 25). Of these parameters, IDI differentiated best between 
bone which was easily susceptible to fracture, and bone that did not easily fracture 
and the parameter was found to correlate best with toughness of bone(11, 13). This has 
led to the development of the derived parameter of Bone Material Strength (BMS), 
which is calculated by the ratio of the IDI of the calibration material PMMA to the IDI 
of bone(15).
 In our study, we found a strong relationship between BMS and age, which may play 
an important role in the increased fracture risk observed in elderly patients, in whom 
deteriorated bone microarchitecture has also been demonstrated(8). Several ex vivo 
studies have shown an inverse relationship between age and toughness of bone(26, 
27). Bone toughness is best predicted by the Indentation Distance Increase and thus 
by BMS(13). As bone strength is inversely correlated with the density of microcracks in 
bone tissue, the observed alteration in bone material properties in the elderly might 
well be explained by the previously demonstrated age-related accumulation of micro-
cracks(26, 27).
Having established that BMS reflected bone fragility independently of BMD, we went 
on to test the association between BMS and the clinical risk factors used in the FRAX 
algorithm without inclusion of BMD measurements in the calculation. We found a sig-
nificant relationship between BMS and the 10-year fracture probability calculated by 
FRAX without BMD, probably reflecting the lack of correlation between BMS and BMD 
values. These observations suggest that microindentation in vivo is able to capture an 
element of the contribution of clinical risk factors used in the FRAX algorithm to altered 
material properties of bone, and thus to increased fracture risk.
Our data complement and extend those of Diez-Perez et al, who, using the microin-
dentation technique, showed that bone material properties, as measured by IDI, were 
poorer in 27 postmenopausal women who had sustained mainly a hip fracture (n = 25) 
or vertebral fracture (n = 2), compared to age-matched controls who had not sustained 
a fracture, with the caveat that women in the control group had a higher BMD than the 
fracture patients(14).
Postmenopausal women have altered bone microarchitecture, and more recent data 
showed that osteopenic women who sustained a fracture had worse bone microar-
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chitecture than non-fracture controls(8, 9). Increased cortical porosity has also been 
suggested to contribute to the risk of distal forearm fractures in postmenopausal 
women with osteopenia(10). Our data provide evidence that bone material properties 
are altered in patients with osteopenia who have sustained a fracture, the majority of 
whom are currently not being offered treatment with bone-modifying agents.
Our study has strengths as well as limitations. We sequentially investigated patients of 
both genders with a wide age range and low bone mass reflecting everyday clinical 
practice. The frequency of osteopenia and osteoporosis within the group of patients 
with a fragility fracture is further consistent with previous reports in fracture patients(6, 
7) and all measurements were performed by two dedicated operators. Furthermore, 
age and gender of patients enrolled in the study did not differ from those who were 
not investigated. A limitation of our study is that, whereas the main source of the fragil-
ity fracture patients included in the study was our regional Fracture Liaison Service, 
the non- fragility fracture controls were recruited from patients routinely attending our 
outpatient clinic, in whom bone mineral density measurements were requested at the 
discretion of the treating physician, possibly creating a selection bias.
In conclusion we demonstrate in this study that Bone Material Strength, as measured 
by the microindentation in vivo technique, captures elements of bone fragility such 
as the effect of aging and that of the cumulative effect of clinical risk factors as cal-
culated by the FRAX algorithm, independently of BMD. Furthermore, we demonstrate 
that Bone Material Strength is comparable in patients with a fragility fracture, whether 
they have osteoporosis or osteopenia. These data suggest an aspect of altered bone 
quality contributing to bone fragility which is not captured by BMD. Further studies 
are required to establish the value of BMS as a predictor of fracture risk, especially in 
patients with osteopenia.
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Patients with low bone mass  








Excluded n= 264 
 
25-OH vitamin D <25 n=23 
Treatment with bone modifying agents n=98 
Bilateral hip replacement n=4 
Participation other study n=11 
Unable to provide consent n=21 




Did not attend investigators’ outpatient clinic 
 n=131 
Supplemental Figure 1
Supplemental Table 1. Unadjusted and adjusted BMS values
Osteoporosis Fx+ Osteoporosis Fx- Osteopenia Fx+ Osteopenia Fx- Fracture No fracture
Unadjusted BMS 77.6 ± 1.4 83.2 ± 1.7 80.3 ± 0.7 83.9 ± 1.3 79.4 ± 0.7 83.6 ± 1.1
Adjusted BMS 79.3 ± 1.3 80.7 ± 1.6 80.3 ± 0.7 83.9 ± 1.2 79.9 ± 0.6 82.4 ± 1.0
Values are expressed as mean ± SEM.
Fx+ fracture patients; Fx- non-fracture patients; BMS Bone Material Strength.
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We evaluated the relationship between BMSi and fragility fractures, including vertebral 
fractures. Our data showed that BMSi is low in all fracture patients with low bone mass, 
independently of whether patients sustained a vertebral or a non-vertebral fracture.
Introduction:
Impact microindentation (IMI) is a new technique for the measurement of tissue-level 
properties of cortical bone in vivo. Previous studies showed an association between 
Bone Material Strength index (BMSi) and non-vertebral fractures but an association 
with vertebral fractures is still being debated.
Objective:
To evaluate the relationship between BMSi and different types of fragility fractures, 
including vertebral fractures.
Methods:
In this cross-sectional study, we measured BMSi in patients of both sexes with different 
types of fragility fractures and low bone mass with the IMI method using the Osteo-
probe®. Vertebral fractures were diagnosed and graded on lateral spine radiographs.
Results:
132 patients were included in the study, of whom 101 patients (65 women) had sus-
tained a low energy fracture and 31 (mean age 57.7  ±  9.9 years) had no history or 
radiological evidence for a fracture. Of the fracture patients, 53 (mean age 62.8 ± 8.3 
years) had only non-vertebral fractures (VF-/Fx+), 34 (mean age 62.8 ± 9.9 years) had 
vertebral and non-vertebral fractures (VF+/Fx+) and 14 (mean age 64.7  ±  9.3 years) 
had only vertebral fractures (VF+/ Fx-). BMSi values, adjusted for age and BMD, were 
similar for all 3 groups of fracture patients (78.9 ± 0.7, 78.3 ± 0.9 and 78.4 ± 1.4, respec-
tively; p = 0.866). BMSi values were not associated with number or severity of vertebral 
fractures.
Conclusion:
Our data demonstrate that BMSi is low in fracture patients with low bone mass, ir-
respective of whether they sustained a vertebral fracture or a non-vertebral fracture.
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INTRODUCTION
Reference Point Indentation (RPI) is a technique to measure cortical bone indentation 
properties in vivo and to potentially assess bone mechanical properties. Currently 
available RPI devices use two different methods to assess cortical bone resistance 
to indentation namely cyclic microindentation (CMI, Biodent) and impact microinden-
tation with an easier to use hand-held indenter (IMI, OsteoProbe), the latter being 
specifically designed for in vivo use in humans and large animals [1–3]. The principles, 
similarities and differences as well as results of clinical application of the two devices 
were recently reviewed [4–6]. In a direct comparison of the two methods in cadaveric 
human tibiae, Karim and colleagues reported that results of measurements are weakly 
related indicating that each device reflects different aspects of cortical bone indenta-
tion properties [7]. Although the exact properties of bone measured in vivo by micro-
indentation need to be determined, clinical studies with both devices demonstrated 
that the method could differentiate patient groups with increased fracture risk from 
control groups independently of Bone Mineral Density (BMD) values suggesting that 
the method measures aspects of bone fragility not captured by BMD.
Initial application of CMI in humans showed that postmenopausal women with osteo-
porotic fractures (hip or vertebra) or those with atypical femoral fractures had greater 
indentation distances compared with controls, that were poorly related with hip BMD 
[2, 8]. Clinical studies with IMI demonstrated that the measured parameter Bone Mate-
rial Strength index (BMSi) was significantly lower in postmenopausal women with type 
2 diabetes mellitus compared with healthy controls in the presence of similar BMD 
values[9], and patients treated with glucocorticoids showed significant deterioration of 
BMSi within 7 weeks of starting treatment, before any changes in BMD [10]. Our group 
also showed that despite similar BMD values, BMSi values were lower in patients with 
fragility fractures compared with those without fractures [11].
The impact microindentation technique has recently been used to examine the 
association between BMSi and vertebral fractures, but results are conflicting. In a 
population-based cohort of 211 older women with or without fractures, including 58 
women with vertebral fractures, there was no association between BMSi values and 
prevalent vertebral fractures [12]. In contrast, a preliminary communication of a study in 
101 postmenopausal women (30 with vertebral fractures) reported lower BMSi values 
in patients with fractures than in healthy controls and a significant inverse relationship 
between BMSi and severity of vertebral fractures [13].
The question raised by these studies is whether BMSi as measured by IMI provides 
information on just cortical bone fragility or on overall bone fragility. To address this ques-
tion, we expanded our previously reported cohort to specifically examine the association 




This was a cross-sectional study that evaluated Bone Material Strength index (BMSi) in 
men and women attending the outpatient clinic of the Center for Bone Quality of the 
Leiden University Medical Center. The patients described in the current study include 
those of our previous report of the comparison of BMSi between patients with fragility 
fractures and those without fractures [11]. The study design, inclusion and exclusion 
criteria and methodology used were previously described [11] and are summarized 
below. The Medical Ethics Committee of the LUMC approved the study and informed 
consent was obtained from all patients.
Sequentially invited patients aged between 40 and 85 years with low bone mass 
(osteopenia or osteoporosis), and no secondary osteoporosis or other metabolic bone 
disease were invited to participate in the study. Other exclusion criteria included serum 
25-OH vitamin D concentrations ≤ 25 nmol/l, current use of glucocorticoids, aromatase 
inhibitors, androgen deprivation therapy or chemotherapy or ever use of bone-acting 
agents such as bisphosphonates or denosumab. Fragility fractures were defined as 
any low-energy fracture, excluding those of hands, feet and skull. FRAX 10-year prob-
abilities for a major osteoporotic fracture and a hip fracture, with and without femoral 
neck BMD, were calculated using the FRAX algorithm [14]. Blood was collected for 
standard laboratory investigations including calcium, creatinine, parathyroid hormone 
and 25-OH vitamin D. BMD was measured by DXA (Hologic QDR 4500) and conven-
tional lateral radiographs of the thoracic and lumbar spine were obtained. Vertebral 
fractures were identified and graded according to the semi-quantitative method of 
Genant by two of the authors (F.M. and N.A.-D.) [15]. Kappa was 0.85.
BMSi was measured in all patients by impact microindentation (IMI) [3, 5] on the 
midshaft of the right tibia using a hand-held microindenter (OsteoProbe® RUO, Active 
Life Scientific, CA, USA) by a single operator [11]. The patient is placed in a decubitus 
supine position with the tibia in external rotation to orient the flat surface of the medial 
tibia diaphysis in a horizontal position. The measurement site is defined as the mean 
distance between the distal apex of the patella and medial malleolus. Following dis-
infection of the area and local anaesthesia of the skin and periosteum with Lidocaine 
1 %, the test probe is gently inserted in the skin until the bone surface is reached. The 
operator ensures that the test probe is placed perpendicularly to the bone surface and 
classifies the measurements as “well performed”, “adequate” or “poorly performed” 
after the indentation and before checking the computer display of the result. “Poorly 
performed” measurements are usually due either to slipping of the test probe or to 
moving of the subject’s leg and are discarded. After five adequate measurements, as 
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recommended [5], five additional measurements are performed on a polymethylmeth-
acrylate (PMMA) calibration phantom. BMSi is calculated as 100 times the harmonic 
mean of the indentation distance increase from impact into the PMMA material divided 
by the average indentation distance increase from impact into bone. As the probe 
indents the surface of the cortical bone of the tibia, it induces a microfracture. The 
more easily this occurs, the deeper the probe indents the bone, and thus the lower 
the BMSi is [3].
In 10 subjects the measurement was repeated in the same leg at sites 2 cm apart; 
mean (SD) of the two measurements was 75.9 ± 5.7 and 76.6 ± 4.9, respectively. The 
intra-observer coefficient of variation (CV) was 2.2 %.
Statistical analysis
All data are expressed as mean ± SD unless otherwise stated. Between-group dif-
ferences in baseline characteristics were assessed by Student’s t-test, ANOVA and 
Chi-square test or a Mann-Whitney U test or Kruskall-Wallis test for non-normally 
distributed variables. Post-hoc analyses using Bonferroni were performed to adjust for 
multiple comparisons if required and non-parametric post-hoc analyses using Kruskall-
Wallis were performed to compare BMSi values between the three fracture groups 
and non-fracture controls. Pearson’s or Spearman’s correlations were used to assess 
correlations between patients’ parameters and BMSi. ANOVA with BMSi as outcome 
variable, adjusted for age was used to compare BMSi values between patients with 
fractures and those without fractures. The relationship between BMSi and the severity 
of vertebral fractures was assessed by a linear multiple regression model adjusted for 
age and femoral neck BMD. A probability level of random difference of 0.05 was con-
sidered significant. The SPSS software for Windows (Version 23; SPSS Inc., Chicago, 
IL, USA) was used for statistical analysis of results.
RESULTS
One hundred and thirty-two patients (64 % women), 101 of whom had sustained at least 
one fragility fracture, consented to take part in the study and underwent impact micro-
indentation, a median of 3.3 months after their most recent fracture; Table 1. Mean age 
of the whole group was 61.8 ± 9.4 years, 76 patients (58 %) had osteopenia and 56 (42 %) 
osteoporosis. Consistent with our previous findings, in this larger cohort, we found that 
BMSi was inversely and significantly related with age (r = -0.485, p < 0.001) and with 
FRAX 10-year probability calculated with and without femoral neck BMD (Spearman’s 
r = -0.313, p < 0.001 and Spearman’s r = -0.356, p < 0.001, respectively). There was 
no correlation between BMSi with any other patient characteristic, laboratory or BMD 
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value. There was no difference in BMSi values between women and men (79.7 ± 0.6 
vs. 80.0 0.8; p = 0.789). In the whole cohort of subjects with low bone mass, patients 
with fractures had significantly lower age-adjusted BMSi values than those without 
fractures (79.0 ± 0.5 vs. 82.5 ± 0.9; p = 0.001).
53 patients had only non-vertebral fractures (VF-/Fx+), 34 had non-vertebral and 
vertebral fractures (VF+/Fx+), and 14 had only vertebral fractures (VF+/Fx-); Table 2. 
Clinical characteristics and biochemical findings were similar among the three groups 
Table 1. Demographic characteristics of 132 patients with low bone mass
Fracture
(n = 101)
No fracture  
(n = 31) p-value
Age (years) 63.1 ± 8.9 57.5 ± 9.9 0.004
Male/female 36/65 11/20 0.987
BMI (kg/m2) 24.6 ± 3.5 25.1 ± 4.7 0.475
PTH (pmol/L) 3.6 ± 1.8 3.4 ± 1.4 0.618
Calcium (mmol/L) 2.41 ± 0.09 2.40 ± 0.10 0.784
25-OH D (nmol/L) 66.2 ± 27.1 78.1 ± 30.0 0.080
Creatinine (µmol/L) 73.4 ± 12.3 76.7 ± 15.2 0.228
LS BMD (g/cm2) 0.87 ± 0.12 0.83 ± 0.08 0.090
FN BMD (g/cm2) 0.67 ± 0.08 0.68 ± 0.07 0.672
BMI Body Mass index; PTH parathyroid hormone; LS lumbar spine; FN femoral neck; BMD bone mineral den-
sity.






(n = 53) p-value
Age (years) 64.7 ± 9.3 62.8 ± 9.9 62.8 ± 8.3 0.761
Male/female 8/6 14/20 14/39 0.073
BMI (kg/m2) 25.4 ± 3.1 24.7 ± 3.6 24.3 ± 3.6 0.574
PTH (pmol/L) 4.3 ± 2.0 4.0 ± 1.8 3.2 ± 1.6 0.021
Calcium (mmol/L) 2.39 ± 0.10 2.41 ± 0.11 2.42 ± 0.08 0.657
25-OH D (nmol/L) 64.8 ± 24.6 67.1 ± 28.0 66.0 ± 27.6 0.932
Creatinine (µmol/L) 79.4 ± 10.3 74.3 ± 11.7 71.2 ± 12.8 0.078
LS BMD (g/cm2) 0.86 ± 0.11 0.88 ± 0.16 0.87 ± 0.10 0.833
FN BMD (g/cm2) 0.70 ± 0.09 0.69 ± 0.09 0.65 ± 0.07 0.010a
VF+/Fx- only vertebral fractures; VF+/Fx+ vertebral fractures and non-vertebral fractures; VF-/Fx+ only non-
vertebral fractures; BMI Body Mass index; PTH parathyroid hormone; LS lumbar spine; FN femoral neck; BMD 
bone mineral density.
apost-hoc notations FN BMD: VF+/Fx+ vs. VF-/Fx+; p = 0.05
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with the exception of PTH values and femoral neck BMD which were lower in the (VF-/
Fx+) group.
To evaluate possible differences in fracture risk due to different fracture history we 
analysed the number and type of prevalent non-vertebral fractures in the two groups. 
Twenty-four (71 %) patients in the (VF+/Fx+) group and 31 (59 %) patients in the (VF-/
Fx+) group had only one prevalent non-vertebral fracture; (p = 0.254). The number of 
patients with hip fractures did not differ between groups (6 vs. 7 respectively). Simi-
larly, there was no difference between the two groups in the total number of prevalent 
non-vertebral fractures, [48/34 (1.4 per patient) vs. 76/53 (1.4 per patient)] or major 
non-vertebral fractures [34/34 (1.0 per patient) vs. 45/53 (0.8 per patient)].
BMSi and vertebral fractures
BMSi values were similar in the three fracture groups, and significantly lower than 
those of the non-fracture control group; Figure 1. Results remained unchanged after 
exclusion of patients with mild (grade 1) vertebral fractures from the analysis.
We further examined the relationship between BMSi and the number and severity 
of vertebral fractures as classified using Genant’s grading of vertebral fractures. There 
were 28 patients with 1 vertebral fracture, 9 with two vertebral fractures, and 11 had 3 
or more vertebral fractures. There was no difference in BMSi in patients with 1, 2, or ≥ 3 
vertebral fractures (78.6 ± 0.9, 76.8 ± 1.6, 79.0 ± 1.4; p = 0.555).
Figure 1
Bone Material Strength index (BMSi) in patients with only vertebral fractures (VF+/Fx-), vertebral fractures and 
non-vertebral fractures (VF+/Fx+), only non-vertebral fractures (VF-/Fx+) and in control patients (VF-/Fx-). Data 
are shown as box-whisker plots. Boxes indicate median and interquantile range. Bars indicate minimum and 
maximum values.
Main effect difference: F = 3.74; p = 0.013. Post-hoc notations: VF+/Fx- vs. VF-/Fx-; p = 0.004, VF+/Fx+ vs. VF-/Fx-; 
p = 0.001, VF-/Fx+ vs. VF-/Fx-; p < 0.001
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Eighteen patients had a grade 1 vertebral fracture as their highest graded fracture, 
20 had grade 2 and 10 had grade 3. There was no relationship between BMSi values 
and the severity of vertebral fractures, (β = 0.826; p = 0.375).
DISCUSSION
The present study confirms our previous results demonstrating that BMSi is lower in 
patients who had sustained one or more fragility fractures compared to patients who 
never sustained a fracture, independently of BMD measurements. It also demonstrates 
that vertebral fractures are associated with low BMSi values, which are not further 
negatively affected by the additional presence of non-vertebral fractures, including hip 
fractures. Taken together, these findings suggest that BMSi as measured by IMI on the 
tibia is associated with increased bone fragility at all relevant skeletal sites.
Our results are in keeping with those of Duarte Sosa et al who reported in a pre-
liminary communication that postmenopausal women with fractures, including those 
of the spine, had significantly lower BMSi values than controls [13]. Our data are at 
odds, however, with those of Rudang et al who reported no difference in BMSi values 
between women with and without fractures, and no association between BMSi and 
vertebral fractures [12]. Various reasons may be responsible for the discrepancy in 
results between the latter study and ours, all related to major differences in design and 
methodology. Firstly, Rudang and colleagues studied elderly women, aged between 
75 and 80 years, who were recruited from a population cohort while we included a 
clinically-based cohort of men and women aged between 40 and 85 years in whom 
we demonstrated a significant relationship between age and BMSi values. Secondly, 
broad inclusion criteria were used in this study compared to the strict selection criteria 
for inclusion in our study, an important prerequisite for studies using new methodolo-
gies. Thirdly, in our study the presence of fractures was radiologically confirmed in all 
patients compared to information about non-vertebral fractures obtained by question-
naire and not confirmed by review of medical records or radiographs. Finally, subjects 
with traumatic fractures who were specifically excluded in our study were included 
although it is not yet clear whether such fractures are associated with altered bone 
composition. Moreover, in our study BMSi measurements were performed by a single 
operator compared to 4 different operators in the study of Rudang and colleagues 
leading to the need to adjust their data because of the significant differences in the 
results obtained.
It should be also noted that differences in BMSi values were observed in a study of 
42 Norwegian and 46 Spanish women suggesting possible geographical variations in 
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BMSi [16]. These differences in BMSi between countries suggest that, similar to FRAX, 
normative values for BMSi should perhaps be developed for different countries to 
minimize the implications of these differences in the interpretation of BMSi results.
Our study has strengths as well as limitations. Of the strengths of the study is the 
consecutive inclusion of men and women aged between 40 and 85 years with low 
bone mass attending our outpatient clinic. Although this is a main strength in our 
group of patients with fractures, it may be also perceived as a limitation of our patient 
control group because BMD measurements were performed at the discretion of the 
patients’ physician. A further strength of our study is that patients who were currently 
using or had used bone-modifying agents were excluded, although this might also 
have resulted in the exclusion of patient known to have a high fracture risk. Of the 
limitations of our study are its cross-sectional design and the limited sample size after 
stratification for fracture type.
In conclusion, we show that Bone Material Strength index measured by IMI is low in pa-
tients with fragility fractures regardless of whether this is a vertebral or a non-vertebral 
fracture. These data suggest that BMSi may reflect general bone fragility although this 
remains to be established in prospective studies.
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Acromegaly is a rare disease caused by excess growth hormone (GH) production 
by a pituitary adenoma. The skeletal complications of GH and IGF-1 excess include 
increased bone turnover, increased cortical bone mass and deteriorated microarchi-
tecture of trabecular bone, associated with a high risk of vertebral fractures in the 
presence of relatively normal Bone Mineral Density (BMD). We aimed to evaluate 
tissue-level properties of bone using impact microindentation (IMI) in well-controlled 
patients with acromegaly aged ≥ 18 years compared to 44 controls from the outpatient 
clinic of the Center for Bone Quality.
Design and methods:
In this cross-sectional study, Bone Material Strength index (BMSi) was measured in 48 
acromegaly patients and 44 controls with impact microindentation using the Osteo-
probe®.
Results:
Mean age of acromegaly patients (54 % male) was 60.2 years (range 37.9–76.5), and 
60.5 years (range 39.8–78.6) in controls (50 % male). Patients with acromegaly and 
control patients had comparable BMI (28.2kg/m2 ± 4.7 vs. 26.6kg/m2 ± 4.3, p = 0.087), 
and comparable BMD at the lumbar spine (1.04g/cm2  ±  0.21 vs. 1.03g/cm2  ±  0.13, 
p = 0.850) and at the femoral neck (0.84g/cm2 ± 0.16 vs. 0.80g/cm2 ± 0.09, p = 0.246). 
BMSi was significantly lower in acromegaly patients than in controls (79.4 ± 0.7 vs. 
83.2 ± 0.7; p < 0.001).
Conclusion:
Our data indicate that tissue-level properties of cortical bone are significantly altered 
in patients with controlled acromegaly after reversal of long-term exposure to patho-
logically high GH and IGF-1 levels. Our findings also suggest that methods other than 
DXA should be considered to evaluate bone fragility in patients with acromegaly.
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INTRODUCTION
Acromegaly is a rare endocrine disease characterized by excess circulating growth 
hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) levels, usually caused by an 
adenoma of the anterior pituitary gland. GH excess results in morbidity of multiple 
organ systems, including generalised tissue hypertrophy, cardio-metabolic disorders 
(diabetes mellitus, hypertension and cardiomyopathy) and arthropathy. Acromegaly 
has been shown to be associated with an increased risk of vertebral fractures in the 
presence of a relatively normal Bone Mineral Density (BMD), and it has also been 
shown that these fractures may progress despite adequate control of disease activ-
ity(1–5). Patients with active acromegaly demonstrate high bone turnover associated 
with increased cortical BMD in the presence of stable trabecular bone mass. Iliac 
crest biopsies indeed show an increase in bone remodelling compared to healthy 
controls(6). Trabecular connections are lost, due to the high bone turnover, resulting 
in altered bone microarchitecture, which persists also after successful induction of 
remission and restoration of bone remodelling rates(7, 8). In a study with HRpQCT, 
structural measurements confirmed this altered bone microarchitecture in patients 
with active as well as controlled acromegaly. This included deteriorated trabecular 
microarchitectural parameters in the distal radius and distal tibia, and increased corti-
cal volumetric BMD in the distal tibia in patients with active disease(9). Areal BMD is 
often reported to be normal in these patients, although some studies do suggest an 
association with low bone mass(2, 10). Overall, current methods do not provide an 
adequate explanation for the increased fracture risk in these patients. However, in 
a recently published study evaluating the association between bone microstructure, 
as measured by high-resolution cone beam computed tomography, and vertebral 
fractures, the authors found deteriorated microstructure in both the trabecular and the 
cortical bone compartment of acromegaly patients with vertebral fractures compared 
to those without vertebral fractures(11).
There are no published data available on the assessment of material properties 
of cortical bone in patients with acromegaly, however, there are published data on 
material properties of trabecular bone in patients with acromegaly(12). The technique 
of impact microindentation (IMI) was introduced as a Reference Point Indentation 
method to acquire Bone Material Strength index measurements in vivo, and is used as 
a surrogate to assess tissue-level properties of bone. Previous studies have shown de-
teriorated material properties in postmenopausal women with osteoporotic fractures, 
atypical femoral fractures, with type 2 diabetes mellitus, and in patients with fragility 
fractures. (13–16). Although IMI reflects cortical bone properties rather than trabecular 
bone properties there is evidence that the elevated GH levels seen in acromegaly 
affect both compartments(6, 11). As current diagnostic tools do not adequately identify 
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acromegaly patients, which are at high risk for vertebral fractures, new methods are 
needed.
In this study, we aimed to evaluate previously reported findings of poor bone mate-
rial properties in patients with acromegaly by evaluating whether BMSi is different 
between patients with acromegaly in remission and controls without acromegaly. 
In addition, we also aimed to evaluate whether BMSi was different in patients with 
acromegaly, with or without vertebral fractures.
PATIENTS AND METHODS
Study design
We performed a cross-sectional study to compare Bone Material Strength index (BMSi) 
between patients with well-controlled acromegaly and non-acromegaly control pa-
tients with osteopenia or normal Bone Mineral Density (BMD), with or without fractures. 
Patients were studied at the outpatient clinics of the Leiden University Medical Center. 
The Medical Ethics Committee of the Leiden University Medical Center reviewed and 
approved the study, and all patients gave written informed consent to participate in 
the study.
Patients with acromegaly
All patients aged 18 years or older with well-controlled acromegaly attending the 
outpatient clinic of the Department of Endocrinology of the Leiden University Medical 
Center were identified from hospital records. 170 patients with acromegaly, 73 of whom 
fulfilled the inclusion criteria and were invited to participate in the study. Forty-eight 
patients responded positively and were included in the study; Fig. 1. Of these patients, 
26 (54 %) had been evaluated in previously reported studies from our center(2, 4).
In this study, well-controlled acromegaly was defined as serum IGF-1 levels within 
the normal age range after surgery, radiotherapy, medical treatment or a combination 
thereof, and when required additional confirmation of remission from glucose-sup-
pression tests. Oral glucose tolerance tests were performed yearly to assess disease 
activity, except in patients receiving medical treatment(17).
Controls
Controls were recruited from the outpatient clinic of the Center for Bone Quality or 
from the regional Fracture Liaison Service of the Leiden University Medical Center and 
were matched on age and BMD. A number of these control patients have been also 
reported in an earlier study (n = 12) (16). Control patients who reported fragility fractures 
or who had grade 2 or 3 morphometric vertebral fractures were excluded from the 
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study. A fragility fracture was defined as any low-energy fracture, excluding those of 
the hands, feet, and skull. Control patients with fractures after a high-energy trauma or 
grade 1 morphometric vertebral fractures were included in the study.
Both acromegaly and non-acromegaly control patients were excluded if they had a 
metabolic bone disease other than osteoporosis, any untreated endocrine disorder, 
severe liver insufficiency or chronic kidney disease stage IV or V, have had bilateral 
hip replacement, were currently using aromatase inhibitors or androgen deprivation 
therapy and were currently using or had used bisphosphonates, denosumab, selec-
tive estrogen receptor modulators (SERMs), strontium ranelate or recombinant PTH. 
Furthermore, patients were excluded if they had a localized infection of the tibia or 
were unable to provide informed consent. Current or past use of glucocorticoids was 
also an exclusion criterion with the exception of hydrocortisone supplementation for 
secondary adrenal insufficiency.
170 patients identified from 
medical records with diagnosis 
of acromegaly 
144 eligible patients  
9 referred to other center 
4 not able to obtain consent 
13 recorded wish not to be involved in studies 
36 acromegaly not in complete remission 
13 using bone modifying drugs 
7 inability to measure femoral neck BMD  
14 comorbidity 
1 metabolic bone disease (fibrous dysplasia) 
73 patients invited to 
participate in study 
BMSi measured  
in 48 patients 
25 refused to participate 
Figure 1




Medical history data including date of start of treatment, type of treatment (surgery, ra-
diotherapy, medication use or combined), date of normalization of IGF-1, data on other 
pituitary function tests, menopausal status, previous or current medication use and 
fracture history were collected at time of inclusion in the study. Daily calcium intake 
was calculated and clinical risk factors for fracture as used in the FRAX algorithm were 
obtained from each patient.
Laboratory investigations
Serum calcium, phosphate, albumin and creatinine were measured using semi-auto-
mated techniques. Plasma intact PTH was measured by the immulite 2500 (Siemens 
Diagnostics) and serum 25-hydroxyvitamin D was measured using the 25-OH-vitamin 
D TOTAL assay (DiaSorin D.A./N.V.). Procollagen type 1 amino-terminal propeptide 
(P1NP) and β-Crosslaps were measured by an electrochemoluminescent immunoassay 
with a Modular Analytics E-170 system (Roche Diagnostics).
Serum IGF-1 levels (nmol/L) were measured using an immunometric technique on an 
Immulite 2500 system (Diagnostic Products Corporation). The intra-assay variations at 
mean plasma levels of 8 and 75 nmol/L were 5.0 % and 7.5 %, respectively. IGF-1 levels 
were expressed as SDS, using λ-μ-σ smoothed reference curves based on measure-
ments in 906 healthy individuals(18, 19).
Serum GH levels were measured with a immunofluorometric assay (Siemens Di-
agnostics) calibrated against World Health Organization (WHO) National Institute for 
Biological Standards and Control (NIBSC) 2nd International Standard 98/574. Values 
were multiplied by 1.02.
Bone Mineral Density
BMD was measured at the lumbar vertebrae (L1-L4) and at the left and right femoral 
neck using Dual-energy X-ray Absorptiometry (DXA) (Hologic QDR Discovery A (Ho-
logic, Bedford, MA, USA)) at time of indentation. NHANES III reference values compat-
ible with reference values of the Dutch population were used to calculate T-scores. 
Normal bone mineral density, osteopenia or osteoporosis were diagnosed using WHO 
criteria.
Spinal radiographs
Conventional antero-posterior and lateral radiographs of the thoracic and lumbar 
spine were performed following standard protocols, at a focus-detector distance of 
115 cm, with the detector centralized on Th7 for the thoracic spine and on L3 for the 
lumbar spine at time of inclusion. The semi-quantitative method of Genant was used 
to assess the presence and grading of vertebral fractures. Vertebral fractures were 
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scored as grade 1 (reduction in anterior, middle and/or posterior height between 20 % 
and 25 %), grade 2 (reduction in anterior, middle and/or posterior height between 25 % 
and 40 %) or grade 3 (reduction > 40 % in anterior, middle and/or posterior height) (20), 
without a history of high energy trauma.
Radiographs were independently assessed by two of the authors (NA-D, HK). Con-
sensus was reached in case of difference in assessment.
Impact microindentation
A Reference Point Indentation tool, the Osteoprobe®, specifically designed for in 
vivo measurements of Bone Material Strength index (BMSi) in humans and large 
animals(21), was used as a surrogate to evaluate bone material properties(16). Impact 
microindentation is performed on the midshaft of the tibia by inserting a test probe in 
the skin until the bone surface is reached. By indenting the bone surface, the resis-
tance of the bone tissue to fracture is evaluated; Fig 2. The first studies performed in 
humans with a previous version of the technique, have shown that postmenopausal 
women with osteoporotic fracture and with atypical femoral fracture have significantly 
higher indentation distance increase (IDI) than controls without fractures. Further 
studies using the impact microindentation technique demonstrated that patients with 
suspected deteriorated material properties such as patients with fragility fractures 
or patients with Type 2 Diabetes Mellitus had significantly lower BMSi values(13–16). 
The measurement site was defined as the mean distance between the distal apex of 
Figure 2




the patella and medial malleolus. Local anaesthesia (Lidocaine 1 %) was applied at the 
measurement site. The test probe was inserted at the site of interest after successful 
anaesthesia of the skin and periosteum and was pushed gently until it reached the 
bone surface. It was ensured that the test probe was always perpendicular to the bone 
surface during measurements. The operator was not allowed to check the measure-
ments on the computer screen before these were classified as “well performed”, “ad-
equate” or “poorly performed”. Measurements were classified as “poorly performed” 
if the measurement probe slipped or if the subject moved his/her leg. At least five 
adequate measurements were obtained from each patient, followed by five additional 
measurements performed on a polymethylmethacrylate (PMMA) calibration phantom. 
The number of measurements ranged from 10 to 24. The resultant outcome BMSi was 
defined as 100 times the ratio of the harmonic mean indentation distance increase 
from impact into the PMMA calibration phantom divided by the indentation distance 
increase from impact into bone(21).
The intra-observer coefficient of variation (CV) was 2.2 %. Ten subjects were mea-
sured twice on the same leg. The distance between the two measurement sites was 
2 centimetres.
Statistical analysis
Analyses were performed using SPSS software for Windows (version 23.0; SPSS Inc., 
Chicago, IL, USA). Data are expressed as mean ± SD unless otherwise stated. Normal-
ity assumptions were checked by evaluation of normality plots and by inspection of 
histograms of residuals from miscellaneous regression models. Differences between 
groups were assessed using a two-sample t tests or Chi-square tests. Pearson/Spear-
man correlation coefficients were used to express correlations between IGF-1 levels, 
duration of disease remission and BMSi values. Analysis of variance models with BMSi 
as outcome variable adjusted for age, were used to compare BMSi values between 
patients and controls. Differences were considered to be significant at p < 0.05.
RESULTS
We included 48 patients with acromegaly and 44 controls who were comparable in 
gender, age, BMI and BMD at the lumbar spine and at the femoral neck; Table 1. The 
two groups were also comparable regarding the number of patients who had sustained 
a non-vertebral fracture, 11 (23 %) in acromegaly patients and 11 (25 %) in controls. There 
were more acromegaly patients with a vertebral deformity than controls [28(58 %) vs. 
7(16 %); p < 0.001].
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In the acromegaly group, 27 patients (56 %) were in remission after surgery, 7 of 
whom received additional radiotherapy. 21 (44 %) patients were controlled with ongo-
ing medical treatment with somatostatin analogs only (n = 14), Pegvisomant, a GH 
receptor antagonist, only (n = 3) or combination therapy (n = 4), 1 of whom had received 
radiotherapy, 16 of whom had surgery and 4 of whom had both. The mean duration 
of acromegaly remission was 16.1 years (range 0.5–37.8 years). There were 8 patients 
with type 2 diabetes mellitus, 3 of whom were conservatively treated and 5 received 
drug therapy (4 oral anti-diabetic agents, 1 insulin therapy), 11 with treated hypothyroid-
ism, 10 with treated adrenal insufficiency and 9 with treated hypogonadism.
Table 1. Characteristics of patients with acromegaly and non-acromegaly controls
Acromegaly (n = 48) Control (n = 44) p-value
Age (years) 60.2 ± 11.0 60.5 ± 8.5 0.849
Male/female 26/22 22/22 0.689
BMI (kg/m2) 28.2 ± 4.7 26.6 ± 4.3 0.087
Fracture 11 (23 %) 11 (25 %) 0.815
Vertebral Fracture 28 (58 %) 7 (16 %) < 0.001
- Grade 1 28 (58 %) 7 (16 %) < 0.001 
- Grade 2/3 11 (23 %) 0 0.001 
Smoking (%) 6 (13 %) 8 (18 %) 0.449
Alcohol use > 3IU/d (%) 5 (10 %) 8 (18 %) 0.304
Glucocorticoids (%) 8 (17 %) 5 (11 %) 0.466
PTH (pmol/L) 4.6 ± 2.8 3.3 ± 1.5 0.014
Calcium (mmol/L) 2.38 ± 0.11 2.39 ± 0.10 0.473
25-OH D (nmol/L) 67.3 ± 28.5 67.3 ± 27.6 0.944
Creatinine (µmol/L) 78.8 ± 14.3 76.1 ± 18.4 0.471
GH (mU/L) 4.0 ± 5.5 -
IGF-1 (nmol/L) 19.5 ± 7.6 -
IGF-1 SD 1.0 ± 1.3 -
LS BMD (g/cm2) 1.04 ± 0.21 1.03 ± 0.13 0.850
T-score LS -0.3 ± 1.8 -0.3 ± 1.2 0.963
FN BMD (g/cm2) 0.84 ± 0.16 0.80 ± 0.09 0.246
T-score FN -0.6 ± 1.2 -0.8 ± 0.8 0.358
Values are expressed as mean ± SD.
BMI Body Mass Index; PTH parathyroid hormone; GH growth hormone; IGF-1 Insulin-like Growth Factor 1; SD 
standard deviation; LS lumbar spine; FN femoral neck; BMD Bone Mineral Density.
Reference range PTH (0.7–8.0 pmol/L); Calcium (2.15–2.55 mmol/L); 25-OH D (50–250 nmol/L); Creatinine 
(64–104 µmol/L for male, 49–90 µmol/L for female); GH (0.00–7.25 mU/L); IGF-1 (6.8–26.5 nmol/L).
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Bone Material Strength index
Patients with acromegaly had significantly lower BMSi values compared to controls 
(79.4  ±  0.7 vs. 83.2  ±  0.7; p  <  0.001), also after adjustment for age (79.4  ±  0.7 vs. 
83.2 ± 0.7; p < 0.001); Fig. 3. This finding remained if patients with type 2 diabetes mel-
litus were excluded (79.2 ± 0.8 vs. 83.2 ± 0.7; p < 0.001). Although numbers are small, 
there was no statistically significant difference in BMSi in patients with acromegaly 
regardless of the therapeutic intervention used to normalize IGF-1 levels (surgery: 
81.1 ± 1.0, surgery and radiotherapy: 77.9 ± 1.7, medical treatment: 78.4 ± 1.0; p = 0.114).
In the group of patients with acromegaly, there was a significant relationship between 
BMSi and age (r = 0.291, p = 0.045). BMSi was not correlated with other clinical char-
acteristics including BMI and duration of remission. There was also no relationship 
between BMSi and any biochemical parameter measured including parameters of cal-
cium metabolism, serum levels of GH and IGF-1, gonadal hormone status or with BMD. 
There was no difference in BMSi values between male or female patients (79.5 ± 0.9 
vs. 79.2  ±  1.0; p = 0.804), or between patients with or without a non-vertebral frac-
ture (80.2  ±  1.4 vs. 79.1  ±  0.8; p = 0.511). There was no statistically significant differ-
ence in BMSi between patients with (n = 28) or without a vertebral fracture (n = 20); 
Supplemental Figure, also in the comparison between patients with Genant ≥ grade 2 
vertebral fractures (n = 11) and patients with Genant ≤ grade 1 vertebral fractures (n = 37) 
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Figure 3
(A) Mean femoral neck Bone Mineral Density (FN BMD) and (B) Bone Material Strength index (BMSi) in patients 
with acromegaly and non-acromegaly controls.
Data are shown in box-whisker plots and statistical differences are displayed for BMSi. Boxes indicate median 
and inter-quantile range. Bars indicate minimum and maximum values.
*p < 0.001
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In the control group, there was a significant inverse relationship between BMSi and 
age (r = -0.457, p = 0.002), but no relationship between BMSi and any other parameter 
measured, including BMD.
DISCUSSION
To our knowledge, this is the first study examining tissue-level properties of cortical 
bone in patients with well-controlled acromegaly, previously shown to be at high risk 
for vertebral fractures independently of BMD. Our data show significantly lower bone 
material strength index (BMSi) values in patients with well-controlled acromegaly than 
in controls with comparable age and BMD. There was no difference in BMSi within the 
group of patients with acromegaly, in the presence or absence of vertebral fractures, 
or in the presence or absence of treated hypogonadism.
The reported prevalence of vertebral fractures in patients with acromegaly is high, 
ranging from 53 to 59 %(1, 2, 10). Longitudinal data also show that vertebral fractures 
continue to progress in controlled disease in patients both with and without previous 
vertebral fractures(4, 5). This increased vertebral fracture risk in the presence of normal 
or high-normal BMD in patients with well-controlled acromegaly suggests that compo-
nents other than bone mass may influence bone strength in these patients, such as 
bone microarchitecture or bone material properties. Indeed, histological findings from 
bone biopsies of the iliac crest performed in patients with active acromegaly confirm 
this suggestion by showing altered histomorphometric parameters of bone, particu-
larly at cortical sites(6). During active acromegaly, bone turnover is increased and this 
is associated with an increase in cortical bone mass. Trabecular bone mass remains 
stable although trabecular connections are lost due to the high bone turnover(6–8). 
Further reported data have also shown an increase in the diameter of trabeculae, sug-
gesting microarchitectural changes in the trabecular compartment of bone(22). These 
findings were further confirmed in a study using HRpQCT, which demonstrated altered 
microarchitecture of trabecular bone in eugonadal acromegalic patients compared 
to healthy controls(9). The observations from the same study regarding the cortical 
compartment appear to contrast with the findings from our study, as cortical volu-
metric BMD was increased in active acromegalic patients. However, these patients 
were compared with patients with controlled acromegaly and our cohort consists of 
well-controlled acromegaly patients only.
A recent study in transgenic bGH mice demonstrated poor microarchitecture of both 
cortical and trabecular compartments of the tibia. This is an animal model with patho-
logical elevated GH levels occurring in utero and in adult life. Although this mouse 
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model develops increased GH levels during skeletal development and is therefore 
not fully comparable with the manifestation of GH excess after epiphyseal closure 
in acromegaly, it may provide interesting observations on the effect of GH on the 
skeleton. The bGH mice were shown to have a significantly lower trabecular number 
and lower trabecular thickness than control mice, in the presence of overall larger 
bones and increased tibia length. bGH mice were also found to have increased corti-
cal bone perimeter and cross-sectional area in the tibia, compared with control mice, 
despite lower cortical bone thickness(23). Cortical BMD was also significantly lower in 
the vertebrae of bGH mice compared to control mice. Vertebral trabecular BMD was 
comparable but trabecular thickness was decreased. Mechanical tests performed on 
the femora showed significantly lower mechanical properties, including ultimate stress 
and Young’s modulus, in bGH mice compared to littermate controls. These results 
suggest that the cortical compartment in vertebrae is perhaps more affected than its 
trabecular compartment as a result of exposure to excess growth hormone. These 
data may provide some further understanding of our finding of a lower Bone Mate-
rial Strength index, which mainly measures cortical bone properties, in patients with 
acromegaly with and without fractures.
The observation that BMSi of acromegaly patients with vertebral fractures was not 
statistically different from BMSi of acromegaly patients without vertebral fractures 
might be in keeping with previous suggestions that acromegaly affects not only the 
trabecular compartment but the cortical compartment as well. For instance, Vallassi 
et al reported that both cortical and trabecular volumetric BMD were reduced at the 
proximal femur in 35 acromegaly patients, regardless of gender, gonadal status, and 
disease activity(24). Recently, Maffezzoni and colleagues reported in 40 patients with 
acromegaly that those with vertebral fractures (n = 15) had lower bone volume/tra-
becular volume ratio, greater mean trabecular separation, and higher cortical porosity 
compared to those without vertebral fractures (n = 25)(11). However, as is also seen 
in our study, group sizes are small due to the rarity of the disease and preclude firm 
conclusions.
Impact microindentation is an emerging Reference Point Indentation technique that 
measures tissue-level properties of cortical bone in vivo at the mid-shaft of the tibia, 
thus reflecting tissue-level properties of cortical rather than trabecular bone. Although 
this technique appears as a promising alternative to assess bone fragility, data on 
fractures (including vertebral fractures) and Bone Material Strength index are relatively 
limited. A preliminary report of postmenopausal women with (49 % vertebral fracture, 
51 % non-vertebral fracture) or without fractures found lower BMSi values in fracture 
patients and a significant inverse relationship between BMSi and grade of vertebral 
fracture(25), whereas a recent study in elderly community-dwelling women showed 
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no relationship between prevalent vertebral fractures and BMSi(26). Within our own 
cohort of patients with low bone mass and fragility fractures, we demonstrated that 
BMSi was low irrespective of the type of fracture: vertebral, non-vertebral or a combi-
nation of the two fracture types(27). The difference in BMSi between patient groups 
(including fracture patients) and controls in reported literature is variable from 4.5 % 
up to 9.2 %(15, 16, 25, 28). Although our findings are in keeping with those from other 
groups, the predictive value remains to be determined.
This study has strengths as well as limitations. A major strength of the study is hav-
ing had access to a large cohort of well-characterized patients with acromegaly, all 
hormonally and metabolically well controlled. A limitation of the study is the cross-
sectional design. It remains to be established whether BMSi is a predictor for vertebral 
fractures in acromegaly patients in prospective studies. Also, we were only able to 
obtain areal BMD data from all patients but not volumetric BMD in any. GH significantly 
increases the size of the skeleton in patients with acromegaly and areal BMD does 
not adjust for the size of bone. Although acromegaly is associated with comorbidities 
such as type 2 diabetes mellitus and hypogonadism, which in itself may contribute to 
bone fragility, all endocrine deficiencies were adequately supplemented and diabetes 
well controlled by their treating physician as required. Lastly, patients with a very high 
fracture risk could not be included in this study, because these patients were currently 
or had been previously treated with bone modifying agents.
Findings from our study add to the accumulating evidence for the association of 
acromegaly with structural changes of bone, also after adequate control of growth 
hormone production. This is in keeping with findings from two recent studies that 
reported a decrease in trabecular bone score (TBS) in the presence of an increase 
in lumbar spine BMD after successful treatment of acromegaly(29), and a decrease 
in cortical and trabecular volumetric BMD measured at the femur, independently of 
acromegaly disease status(24).
In keeping with our previous observation, we found a strong inverse relationship 
between BMSi and age in our control group. In contrast, we found a positive relation-
ship between BMSi and age in patients with acromegaly. A possible explanation of 
this contrasting finding is that older patients had longer remission periods and the 
skeleton may have had more time to recover from the effects of high GH levels. This 
may suggest that acromegaly patients with more recent exposure of high GH levels 
(the young patients with acromegaly) have lower BMSi values than patients with ac-
romegaly with longer duration of remission. However, we did not find a relationship 
between BMSi and the duration of remission in our series (r = 0.220, p = 0.133). There 
was no difference in BMSi values between men and women in the group of acromegaly 
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patients and in the control group. Although skeletal health has been shown to differ 
between the sexes, this observation is in keeping with other data on BMSi previously 
reported by our group(16) and another group(30), and partly in keeping with a study 
that investigated male and female HIV patients and controls and observed lower BMSi 
values in female HIV patients compared to male patients but comparable BMSi values 
between male and female controls(31).
In conclusion, we demonstrate that BMSi is significantly lower in patients with well-
controlled acromegaly compared to controls. These data indicate that tissue-level 
properties of cortical bone remain significantly altered after cessation of long-term 
exposure to pathologically high GH and IGF-1 levels, probably contributing to the previ-
ously demonstrated ongoing increased risk for vertebral fractures. Future prospective 
studies addressing the skeletal complications of acromegaly should incorporate the 
study of microarchitecture and material properties of bone in addition to bone mass 
measurements.
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Supplemental Figure
Bone Material Strength index (BMSi) in patients with acromegaly, with (VF+) and without (VF-) vertebral fractures. 
Data are shown in box-whisker plots and statistical differences are displayed for BMSi. Boxes indicate median 
and interquantile range. Bars indicate minimum and maximum values.
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Impact microindentation is a new technique for the in vivo measurement of tissue-
level properties of cortical bone in humans. To address issues related to the proper 
application of IMI in clinical practice and to directly examine cortical bone properties 
in patients with tibia pathology, we studied 11 subjects without tibia pathology and 
9 patients with Paget’s disease of the tibia in biochemical remission after bisphos-
phonate treatment. Serial indentations in the tibiae of both legs were performed in 
all subjects by a single operator until 10 adequate measurements were obtained in 
each tibia. In patients without Paget’s disease [7 men and 4 women; mean age 61.9 
years (range 51–72 years)], there was no difference in mean Bone Material Strength 
index (BMSi) between the dominant and non-dominant leg (82.1 ± 1.3 and 81.4 ± 1.3, 
respectively; p = 0.606). In each individual subject studied, sequential indentations in 
both legs showed no trends for higher or lower values with time. The standard devia-
tion of unnormalized Bone Material Strength (BMSu) was also comparable between 
the dominant and non-dominant tibia (5.3 and 4.5, respectively; p = 0.657). In patients 
with Paget’s disease [4 men and 5 women; mean age 69.5 years (range 55–87 years)], 
mean BMSi of the Pagetic tibia was lower, albeit non-significantly, than that of the 
contralateral non-affected tibia (74.7  ±  1.7 and 78.7  ±  1.3, respectively; p = 0.120). In 
contrast to subjects without Paget’s disease, the SD of adequate BMSu values was 
significantly larger in the Pagetic tibia compared to that of the non-Pagetic tibia (7.6 
vs. 5.0, respectively, p = 0.008). These results highlight the consistency of serial IMI 
measurements as performed by a single operator in the presence as well as absence 
of tibia pathology and illustrate that the method is able to capture alterations of tissue-
level cortical bone properties in patients with Paget’s disease of the tibia.
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INTRODUCTION
Impact microindentation (IMI) is a new Reference Point Indentation technique that 
measures tissue-level properties of cortical bone in humans in vivo at the mid-shaft of 
the tibia. The tool used to perform IMI is a hand-held device (OsteoProbe) that imparts 
a single impact load to the bone surface. The methodology and clinical value of the 
method have been recently reviewed (1–3). In the course of the investigation, repeated 
indentations are performed on the tibia until a minimum number of adequate measure-
ments is obtained. The manufacturer of the device does not provide an algorithm to 
automatically flag inadequate measurements, the evaluation of which is left to the 
judgement of the operator during the procedure. To our knowledge, the variance of 
measurements obtained in an individual subject by sequential adequate indentations 
has not been previously reported. Moreover, whereas the non-dominant leg is recom-
mended as the preferred investigation site (3), data supporting this recommendation 
are not available. An important, clinically relevant question is whether the application 
of IMI is informative and reliable in patients with tibia pathology, particularly as pathol-
ogy at this site has so far been considered as an exclusion criterion. IMI measurements 
may indeed provide valuable information not only on the tissue-level properties of the 
diseased tibia, but also on the performance of the technique in general.
Figure 1




To address these questions and to obtain more insight into the value of IMI in clinical 
practice, we examined tissue-level properties of cortical bone of both legs in individuals 
without tibia pathology and in patients with Paget’s disease of the tibia. Localizations 
of Pagetic lesions in the tibia can be found in the original description of the disease 
by Sir James Paget in 1887, (4) and we have previously reported that lesions of the tibia 
comprised 7 % of all Pagetic lesions in 180 consecutive patients from our cohort of 
patients with Paget’s disease of bone (5). Paget’s disease of the tibia has characteristic 
radiologic features such as cortical thickening and abnormal bone texture (Figure 1) 
and may be associated with significant deformity, pain and increased risk of stress and 
complete fractures (6).
PATIENTS AND METHODS
Impact microindentation was performed in all subjects by a single operator (FM) in 
the Out-Patient Clinic of the Center for Bone Quality of the Leiden University Medical 
Center (LUMC). The group of patients without tibia pathology included in this study 
consisted of consecutive patients attending our Out-Patient Clinic who participated 
in our studies of tissue-level properties of cortical bone in patients with and without 
fractures and with well-controlled acromegaly and who consented to having further 
IMI measurements undertaken in both legs. Details of the characteristics and selec-
tion of these patients have been previously published (7,8). Exclusion criteria included 
localized infection of the tibia, metabolic bone disease other than osteoporosis, any 
untreated endocrine disorder, bilateral hip replacement, severe liver insufficiency, 
chronic kidney disease stage IV or V, and current or past use of glucocorticoids with 
the exception of hydrocortisone supplementation for secondary adrenal insufficiency 
in patients with acromegaly and inability to provide informed consent. All patients 
with radiologically confirmed Paget’s disease of the tibia who were followed regularly 
in our Center and were in remission after treatment with bisphosphonates were also 
studied. The study was approved by the Medical Ethics Committee of the LUMC and 
all participants provided written informed consent.
Data on age, gender, height and weight, history of fractures and use of medications 
(current and previous) were documented in all patients included in the study. In sub-
jects without Paget’s disease, the presence of morphometric vertebral fractures was 
examined by spine radiographs and Bone Mineral Density was measured by DXA. In 
patients with Paget’s disease the date of diagnosis of the disease and dates, type and 
number of bisphosphonate treatments were recorded and radiographs of the tibiae 
were reviewed to confirm the presence of a Pagetic lesion of the tibia.
143
Impact microindentation: serial measurements
9
Laboratory investigations
Blood was collected and serum measured for calcium, phosphate, albumin and 
creatinine using semi-automated techniques, for alkaline phosphatase (ALP) using a 
fully-automated P800 modulator system (Roche Diagnostics), for procollagen type 1 
amino-terminal propeptide (P1NP) using an electrochemoluminescent immunoassay 
with a Modular Analytics E-170 system (Roche Diagnostics) and for 25-hydroxyvitamin 
D using the 25-OH-vitamin D TOTAL assay (DiaSorin D.A./N.V.). Plasma was measured 
for intact PTH using the Immulite 2500 assay (Siemens Diagnostics).
Impact microindentation
Bone Material Strength index (BMSi) was measured in all subjects by IMI applied to 
the mid-shaft of the tibia by a single operator (FM) using a hand-held microindenter 
(OsteoProbe® RUO, Active Life Scientific, CA, USA), as previously described and rec-
ommended by a group of experts (3).The patient was placed in a decubitus supine 
position with the tibia in external rotation to orient the flat surface of the medial tibia 
diaphysis in a horizontal position. Indentations of both tibiae were performed in a 
single session without repositioning of the patient. The measurement site was defined 
as the midpoint of the distance between the distal apex of the patella and medial 
malleolus. The operator ensured that the test probe was placed perpendicularly to 
the bone surface and classified the measurements as “well performed”, “adequate” 
or “poorly performed” after the indentation and before checking the computer display 
according to the following criteria : “well performed” when the operator judged that the 
test probe was exactly perpendicular to the bone surface; “adequate” when the test 
probe was within acceptable deviation from the bone surface (9); “poorly performed” 
when the operator judged that the test probe was not appropriately placed. “Poorly 
performed” measurements are usually due to slipping of the test probe, moving of the 
subject’s leg or failure to place the device perpendicularly to the bone surface and are 
excluded from the analysis. In the present study the operator continued the protocol 
until 10 adequate measurements were obtained. Five additional measurements were 
subsequently performed on a calibration phantom, a cube of polymethylmethacrylate 
(PMMA), firmly secured in a holder and placed on a stable surface. BMSi is calculated 
as 100 times the harmonic mean of the indentation distance increase from impact 
into the PMMA material divided by the indentation distance increase from impact into 
the bone (3). Another parameter, unnormalized BMS, has been used in the original 
description of the method to describe the effects of instrument variables on measure-
ments (9). The authors of this publication concluded that unnormalized BMS directly 
obtained by measurement of individual sequential indentations, is more suitable for 
the analysis of variability of the procedure than BMSi, which is the final result of all 
sequential measurements in a single patient after correction with the PMMA calibra-
Chapter 9
144
tion phantom. Normalization of the measured values to the calibration phantom, as 
done in the standard calculation of BMSi, would remain relatively consistent when a 
variable, such as probe sharpness or indentation angle, is changed. Unnormalized 
BMS is defined as 100 times the ratio of the ideal indentation distance increase from 
the impact into PMMA (150 μm) divided by the indentation distance increase from the 
impact into the bone sample. We used this parameter for the calculation of variability 
of sequential measurements in the same subject and we arbitrarily defined it BMSu as 
opposed to BMSi.
The intra-observer coefficient of variation (CV) of the technique was calculated to 
be 2.2 % in a previous study of patients with low bone mass with or without fractures 
by measuring BMSi twice in the right leg according to the above mentioned protocol 
with the second investigation performed 2 centimetres below the first measurement 
site in 10 subjects (10). Mean ± SD BMSi of the two measurements was 75.9 ± 5.7 and 
76.6 ± 4.9, respectively.
Statistical analysis
Indentations judged “poorly performed” by the operator were not included in the cal-
culation of the final BMSi or in the variation analyses. Results are reported as mean±SE 
unless otherwise stated. Between-group differences in baseline characteristics were 
assessed using a Student t test, a chi-square test, or a Mann-Whitney U test for non-
normally distributed variables. Pearson’s and Spearman’s correlations were used to 
assess correlations between BMSi and patients’ parameters that were normally and 
not normally distributed. A paired t-test was used to compare BMSi values between 
both tibiae. A Wilcoxon Signed Ranks Test was used to compare the standard deviation 
of the ten adequate BMSu values between both tibiae. Differences were considered 
to be significant at p  < 0.05. All analyses were performed using SPSS software for 
Windows (version 23.0; SPSS Inc., Chicago, IL, USA). Scatterplots were constructed 
with Graphpad Prism (version 7.0; Graphpad Software Inc., La Jolla, CA, USA); BMSu 
values were plotted in the sequence they were obtained from the first to the last.
RESULTS
We studied 11 consecutively presenting individuals (7 men) aged 61.9 years (range 51 
to 72 years) and BMI 27.3 ± 1.7, without pathology of the lower extremities and who 
consented to bilateral IMI measurements. Four had osteoporosis, 5 had osteopenia 
and 2 had normal Bone Mineral Density. Two patients with osteoporosis had a his-
tory of a clinical vertebral fracture and one with osteopenia of a distal radius fracture. 
Five patients from the acromegaly cohort had morphometric vertebral fractures. In 
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all subjects studied biochemical parameters of bone and mineral metabolism were 
within the normal laboratory reference ranges (not shown). Nine patients (4 men) with 
Paget’s disease of the tibia with a mean age of 69.5 years (range 55 to 87 years), and 
BMI 27.5 ± 1.1, who were in biochemical remission for at least one year after treatment 
with bisphosphonates (median 5.5 years, range 1–30 years) were also studied. At the 
time of the investigation mean serum alkaline phosphatase activity was 76.7 ± 5.7 IU/l 
(reference range 40–120 IU/l) and serum P1NP was 41.8 ± 4.6ng/ml (reference range 
< 65 ng/ml).
Impact microindentation in subjects without tibia pathology
In subjects without Paget’s disease a mean of 12 indentations (range 11–15) were per-
formed in the dominant leg and 12 indentations (range 10–14) in the non-dominant leg 
in order to obtain 10 adequate measurements in each tibia of all tested individuals. In-
adequate measurements were evenly spread during the procedure with the exception 
of the fi rst indentation that was classifi ed as “poorly performed” by the operator in 10 
of the 22 measurements (7/14 and 3/8 measurements in acromegaly and remaining pa-
tients, respectively). Mean BMSi of the dominant leg was not diff erent from that of the 
non-dominant leg (82.1 ± 1.3 and 81.4 ± 1.3, respectively; p = 0.606). Individual adequate 
measurements of the same tibia generally showed minimal variations (Figure 2A), but 
larger variations were also observed (Figure 2B), which did not in any case aff ect the 
Figure 2
Scatterplot of 10 sequential adequate indentations of both legs in 2 subjects (A and B) without tibia pathology.
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mean BMSi value. These larger variations were not operator-dependent and bore no 
relation to the sequence timing of the indentation. This is illustrated in Figure 3 by the 
lack of a trend towards lower or higher values or alterations in the magnitude of SDs 
of the mean BMSu of sequential adequate indentations. Mean SDs of BMSu of the 
dominant and non-dominant legs were overall not diff erent (5.3 and 4.5, respectively; 
p = 0.657). Similarly, there was no diff erence in mean SD of BMSu of the right and left 
leg (5.1 and 4.7, respectively; p = 0.657). There was no diff erence in BMSi values after 
5 or 10 adequate measurements in either investigated leg (82.7 ± 1.2 vs. 82.1 ± 1.3 and 
81.1 ± 1.3 vs. 81.4 ± 1.3 for the dominant and non-dominant leg, respectively).
Impact microindentation in patients with Paget’s disease of the tibia
In patients with Paget’s disease a mean of 11 indentations (range 10–12) were per-
formed in the aff ected tibiae and 12 indentations (range 10–16) were performed in the 
non-Pagetic tibia in order to obtain 10 adequate measurements of each tibia. Mean 
BMSi of Pagetic bone was lower, albeit non-signifi cantly, than that of the contralateral 
non-aff ected bone (74.7 ± 1.7 and 78.7 ± 1.3, respectively; p = 0.120). In contrast to the 
observations in subjects without Paget’s disease, the variability of measured BMSu 
values of the Pagetic tibia was greater than that of the contralateral tibia (Figures 4 and 
5). This was confi rmed by the signifi cant diff erence in mean SDs of BMSu measure-
ments between Pagetic and non-Pagetic bones (7.6 vs. 5.0, respectively, p = 0.008). In 
none of the patients with Paget’s disease was the SD of BMSu larger in the unaff ected 
bone compared to the aff ected one.
Figure 3
Scatterplot of standard deviations of mean unnormalized Bone Material Strength (BMSu) of sequential ad-
equate indentations.
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Figure 4
Scatterplot of 10 sequential adequate indentations of the healthy and of the aff ected tibia in 2 patients (A and 
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Box-plots of unnormalized Bone Material Strength (BMSu) values of healthy and aff ected tibiae of all patients 




The in vivo measurement of IMI in the tibia of humans using the OsteoProbe is a 
new technique that provides information about tissue-level material properties of 
cortical bone. Although the relationship between measured properties of bone and 
its traditional mechanical properties still needs to be determined, clinical studies have 
demonstrated that the method could differentiate patient groups at increased risk 
for fracture from control groups independently of BMD values, suggesting that the 
method measures aspects of bone fragility not captured by BMD (7,11–13). In the present 
study we report for the first time serial indentations of both legs in all tested subjects 
to address issues related to the proper application of this technique in clinical practice 
and to directly examine properties of cortical bone in patients with Paget’s disease of 
the tibia compared to cortical bone of non-pathologic tibiae.
Results obtained by in vivo, non-automated methods of investigation are subject to 
variations that depend on the operator, on the performance of the procedure and on 
underlying individual biological variance. Results obtained using the OsteoProbe may 
be affected by all these factors and adequate evaluation of these factors may help 
in explaining some discrepancies in reported results between different groups that 
raised questions regarding the value of this method in the Clinic (2).
The IMI method used in the present study does not automatically exclude inadequate 
measurements, a task which is left to the judgement of the operator. This has been 
an issue of critique, particularly as there has been no specific reference to flagged 
results in most reported studies so far. Our data from this study demonstrate that in the 
hands of an experienced operator, who applied exclusion of inadequate indentations 
without knowledge of the result, up to 16 indentations was needed in order to obtain 
10 adequate measurements. Although we have no data to compare the performance 
of different operators, our previous results with a single operator showing minimal 
intra-observer variation are clearly at odds with studies reporting results obtained by 
different operators, which showed large and significant variations in measured BMSi 
values requiring statistical adjustment of the results (14). This confirms the notion that 
an experienced operator is a sine qua non for the successful clinical application of 
the technique. If this is not feasible, additional operators should undergo a period of 
training with continuous comparison of their performance with that of an experienced 
operator. Relevant to this issue is the variable number of indentations required for 
the final results in different studies that ranged from 5 adequate to 15 in total (7,11,14–16). 
In the recent technical report of the application of OsteoProbe in human studies, 5 
adequate indentations are recommended to be performed in each tested subject (3). 
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We found no difference in final BMSi values between 5 and 10 adequate indenta-
tions, a result that is in agreement with the recommendation. However, more than 5 
indentations may be required when an intrinsic, operator-independent, variability in 
values is expected. The exclusion of the result of the first indentation routinely and 
independently of the operator’s evaluation, as used by some investigators, has also 
been recommended (3). In our study flagged measurements were evenly distributed 
among sequential indentations for up to 16 indentations with the exception of the first 
indentation that had to be flagged by the operator in 10 of the 22 measurements in 
subjects without Paget’s disease. This high number of inadequate first indentations 
justifies the recommendation of routinely excluding the first indentation value from the 
measurements. On the other hand, a remarkable consistency of sequential results and 
minimal variability in mean values was observed indicating a robust method. Although 
variability may be greater in individual subjects this did not seem to affect the final 
outcome. These findings, together with the overlap of values between tested control 
and patient groups in reported studies, suggest that whereas the method can cur-
rently provide valid information in groups of individuals, it cannot be recommended 
as yet for drawing firm conclusions about tissue material properties of cortical bone in 
individual patients. Finally, we show here that in the absence of tibia pathology, there 
is no difference in measured BMSi between the two legs. Although the harmonized 
use of the non-dominant leg is recommended for consistency of data acquisition and 
for comparison of outcomes obtained with the use of the OsteoProbe between differ-
ent centers (3), our bilaterally obtained data do suggest that the investigator’s choice 
of the most suitable leg for testing may be allowed as this does not compromise the 
outcome of the procedure.
Taken at face value, our first ever reported results of impact microidentation in patients 
with Paget’s disease of the tibia unexpectedly showing no significant decrease in 
BMSi in the affected compared to the normal tibia may seem surprising and perhaps 
disappointing about the value of IMI in discerning abnormal tissue level properties 
of cortical bone in Pagetic tibiae (17). However, a caveat in the interpretation of these 
results as well as of the absence of complications of the procedure in pathological 
tibiae, may be due to the small number of patients studied, limiting the power of the 
study to detect significant differences between healthy and pathological bone or to 
capture complications. It is also of note that all nine patients with Paget’s disease 
were in biochemical remission for longer than one year following treatment with 
bisphosphonates and none had sustained a stress or complete fracture of the tibia 
or had been subjected to a corrective surgical procedure. Whereas the finding of no 
significant BMSi difference between pathological and healthy tibiae in patients with 
Paget’s disease in our study may well have been related to bisphosphonate treatment 
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and long-term remission of the disease, our data cannot address this assumption, 
as we did not investigate treatment-naïve patients. Interestingly, Mellibovsky et al 
recently reported that risedronate treatment given for 20 weeks to patients treated 
with glucocorticoids significantly improved BMSi before any measurable change in 
BMD could be observed (15).
The most important novel finding in our study was the wide variability of adequate 
measurements of BMSu of the affected Pagetic tibia indicating a heterogeneity of 
tissue properties associated with the bone pathology of the disease. In this disorder, 
the localized accelerated bone remodeling results in the deposition of a disorganized 
mosaic of woven and lamellar bone leading to heterogeneous structural changes at 
affected skeletal sites. The BMSu values we recorded were very variable: within or 
higher than the range of values of the contralateral non-Pagetic tibia, interspersed 
with very low measured values. The variability of these measurements reveals a new, 
previously unreported, heterogeneous pattern of tissue level properties of pathologi-
cal bone which is not due to methodological inadequacies and cannot be readily ex-
plained. This finding raises, in addition, the question whether variability of adequately 
performed indentations in individual subjects may enable the identification of aspects 
of biological variance of bone properties which are not captured by mean BMSi values. 
This issue warrants further investigation in appropriately selected patients or groups 
of patients.
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Fragility fractures are common and their incidence increases with age. These fractures 
are associated with increased morbidity and mortality and with a significant increase 
in social and economical burden. The presence of a fragility fracture is also a strong 
predictor for future fractures. Osteoporosis represents the main cause for fragility 
fractures and there has been a significant worldwide trend to establish fracture liaison 
services (FLS) in order to screen patients who have recently sustained a fracture 
for the presence of low bone mass using DXA. An FLS offers a multidisciplinary ap-
proach to identify patients at high risk for future fractures and to start treatment with 
anti-osteoporosis agents when required. A number of initiatives such as the global 
campaign “Capture the Fracture” of the International Osteoporosis Foundation and 
recommendations issued by various national and international guidelines have driven 
the initiation and implementation of these services worldwide, including in the Neth-
erlands, aiming at the secondary prevention of fragility fractures in patients who have 
recently sustained a fracture. It has been shown that the use of these services has 
already led to a reduction in mortality and in the incidence of new fractures, and that 
their use has been proven to be cost-effective. The results of our experience with our 
own FLS in the Leiden University Medical Center (LUMC) are discussed in Chapters 2 
to 4. The LUMC is a teaching hospital with its FLS serving the emergency and trauma 
center for primary fracture care for patients who have sustained an acute fracture. 
All fracture patients are identified by a dedicated FLS coördinator at the outpatient 
clinic of the Departments of Traumatology and Orthopaedic Surgery. Patients aged 
50 years or older are invited to be screened for the presence of osteoporosis and for 
the risk of future fractures. Upon consent, the FLS coördinator immediately initiates 
the screening programme which consists of collection of data on clinical risk factors 
for fracture, performing laboratory investigations and of a Bone Mineral Density (BMD) 
measurement including a Vertebral Fracture Assessment (VFA) in the same sitting 
(Figure  1). Using this approach has succeeded in initially capturing more than 50 % 
of all patients referred with a recent fracture for screening for increased fracture risk 
and when necessary start of treatment at the start of the FLS in 2012. After several 
improvements such as combining the appointments for both BMD measurements and 
laboratory investigations on the same day as that of the patients’ regular follow-up visit 
to the outpatient clinic of Traumatology or Orthopaedic Surgery, the rate of patients’ 
referrals to the FLS had risen to 95 % in 2016.
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PART 1: THE FRACTURE LIAISON SERVICE
In this thesis, Chapter 2 , Chapter 3 and Chapter 4 discuss the results of data col-
lected from all patients who were referred to our FLS from June 2012 to June 2014 for 
screening for osteoporosis and for increased fracture risk.
Chapter 2 reports on the prevalence of underlying secondary factors for increased 
bone fragility in 686 patients who had recently sustained a fragility fracture. Data from 
this study demonstrate a high prevalence of underlying secondary factors in patients 
who had recently sustained a fracture, independently of whether they had a normal 
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BMD, osteopenia or osteoporosis (47, 57 and 62 %, respectively). A significant negative 
relationship was identified between the cumulative number of underlying factors and 
BMD measurements. Previous studies had already reported a high number of underly-
ing factors in patients with recent fractures, although mainly focusing on patients with 
osteoporosis. Our data complements data obtained from these studies in providing 
evidence for the importance of these underlying factors, independently of BMD status. 
A clinically relevant observation is that almost half of all underlying factors were poten-
tially reversible by adopting specific lifestyle changes or by initiating medical treatment 
suggesting that the increase in bone fragility may be decreased upon reversal of these 
factors. As underlying factors for osteoporosis are equally prevalent in patients with 
recent fractures independently of BMD, this study further emphasizes that screening 
for these factors should be performed in all patients with fragility fractures and not just 
in those with osteoporosis.
Chapter 3 describes a retrospective study assessing the value of low-radiation VFA 
compared to conventional radiography of the thoracic and lumbar spine in identifying 
vertebral fractures in the FLS cohort of patients described in Chapter 2. Only patients 
with data available for both VFA and conventional spine radiography were included 
in this study. VFA is an additional tool available for use on DXA machines for the 
acquisition of lateral images of the thoracic and lumbar vertebrae in the same session 
at which BMD is measured. In our study, the sensitivity of low-radiation VFA to detect 
a patient with a vertebral fracture grade 2 or greater was 0.77 and the specificity was 
0.80. This means that using VFA a vertebral fracture ≥ grade 2 was missed in 23 % of 
patients. As these numbers were not in keeping with data from current literature on 
VFA, we went on to perform a systematic review and a meta-analysis of all published 
data on the value of Vertebral Fracture Assessment compared to conventional radi-
ography in patients at risk for osteoporosis. Our systematic review covered 16 studies 
on the value of VFA including a total of 3238 patients. Our review shows that these 
studies were heterogeneous, with variable patient inclusion criteria, which have led 
to considerable variability in sensitivity (47–99 %) and specificity (74–100 %) between 
studies. Data from our meta-analysis demonstrated a sensitivity of 0.82 (95 % CI, 
0.75–0.87) and a specificity of 0.99 (95 % CI, 0.98–1.00) for the ability of VFA to detect 
vertebral fractures grade 1 or more. Findings from our retrospective study were thus 
not in keeping with those obtained from our systematic review and meta-analysis. A 
possible explanation for this discrepancy in findings may be not only the different in-
clusion criteria, but also the use of different software and hardware to obtain VFA data. 
Based on this, we recommend that individual centers intending to use VFA should not 
replace conventional spinal radiography with VFA before the ability of their centers’ 
VFA to detect patients with vertebral fractures has been investigated and established.
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Bone turnover markers (BTMs) are not commonly used outside research settings in 
the follow-up of patients treated for osteoporosis although these markers can be 
easily measured in blood samples. However, data obtained from clinical trials have 
shown that BTMs may be potentially used to monitor response to treatment with 
anti-osteoporosis drugs as serum levels of these markers have been shown to be 
inversely related with changes in BMD and with anti-fracture efficacy. In Chapter 4, 
we assessed the longitudinal pattern of change in the bone turnover markers P1NP 
and Ctx after 3 and 12 months of treatment with antiresorptive drugs, and the relation-
ship between these markers and BMD after 12 months of treatment in FLS patients 
who have recently sustained a fracture. Our results show that changes in P1NP levels 
after 3 and 12 months of treatment were significantly inversely related with changes 
in BMD at the lumbar spine after 12 months of treatment, although only the relation-
ship between P1NP and lumbar spine BMD after 12 months persisted after adjustment 
for time after fracture. Changes in Ctx levels after 12 months of treatment were also 
significantly inversely related with BMD changes after 12 months of treatment after 
adjustment for time after fracture. We also observed a relationship between baseline 
P1NP values and the change in lumbar spine BMD at 12 months of treatment. Data 
from this study suggest that changes in bone turnover markers may be used early in 
follow-up of treatment to predict the effect of antiresorptive treatment on BMD in the 
long term. Whether early changes in BTMs are related to a decrease of future fracture 
risk remains to be established in large clinical follow-up studies.
PART 2: IMPACT MICROINDENTATION IN THE EVALUATION 
OF BONE FRAGILITy
Chapters 6 to 9 describe the results of our clinical studies performed using the impact 
microindentation technique (IMI), a new technique that measures tissue-level proper-
ties of cortical bone in humans in vivo. Chapter 5 provides a general introduction and 
an up-to-date review of all published studies using the IMI technique.
In Chapter 6, we evaluated the relationship between Bone Material Strength index 
(BMSi) and fracture in 90 patients with low bone mass who were attending our FLS or 
the outpatient clinic of the Center for Bone Quality. We observed that patients who had 
sustained a fragility fracture had significantly lower BMSi values compared with pa-
tients with no fractures, despite similar BMD values between fracture and non-fracture 
patients. We also demonstrated a strong and significant inverse relationship between 
BMSi and age. These data suggest that tissue-level properties of cortical bone are 
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altered in patients who have sustained a fragility fracture, and that IMI captures certain 
elements contributing to bone fragility independently of BMD.
After publication of the results from our study described in Chapter 6, Duarte Sosa and 
colleagues published data from a further study showing significantly lower BMSi val-
ues in 66 postmenopausal women compared to 66 controls in addition to a significant 
relationship between BMSi and the severity of vertebral fractures. In contrast, a study 
from Rudang and colleagues found no relationship between BMSi and the presence of 
fractures, including vertebral fractures. To further investigate this discrepancy in data 
between studies, we evaluated the relationship between BMSi and different types of 
fragility fractures in our own cohort of patients with fragility fractures, the results of 
which are described in Chapter 7. In this study, we demonstrate that BMSi values were 
low in the presence of a fracture, irrespective of whether this was a vertebral or a non-
vertebral fracture. We also found that BMSi values of patients with vertebral fractures 
were comparable with those of patients with non-vertebral fractures in addition to a 
vertebral fracture, suggesting that BMSi may reflect general bone fragility rather than 
just cortical bone fragility.
As a proof of concept, we evaluated tissue-level properties of bone in a cohort of 
acromegaly patients who have been previously demonstrated to have increased 
vertebral fracture risk, and compared this cohort to control patients with osteopenia 
or normal BMD. The results of this study are described in Chapter 8. All patients 
with well-controlled acromegaly attended the outpatient clinic of the Department 
of Endocrinology of the LUMC and are part of a well-characterized, hormonally and 
metabolically well-controlled cohort of patients. We found significantly lower BMSi 
values in patients with well-controlled acromegaly compared to control patients with 
similar BMD values. BMSi values were similarly low in patients with acromegaly, with 
or without vertebral fractures. These data suggest that tissue-level properties of bone 
are altered in patients with acromegaly and may contribute to the increased bone 
fragility observed in these patients.
Over the last few years, data from our group and that of other research groups have 
been accumulating on the value of impact microindentation in the assessment of 
bone fragility. Although experience with the use of this technique has significantly 
increased, a number of clinically relevant questions remain as yet to be answered, 
such as the identification of inadequately performed measurements, the approach 
of the sometimes large variance of consecutive measurements, the choice of the 
preferred site of investigation (currently the non-dominant leg although there are no 
data to support this recommendation) and whether IMI could be used in patients with 
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localized pathology of the tibia, which is currently an exclusion criterion. A number of 
these relevant questions are addressed in the study described in Chapter 9, that used 
IMI to investigate tissue-level properties of cortical bone in both legs in patients with 
Paget’s disease of bone at one tibia compared to bilateral measurements in patients 
without tibia pathology. In patients without tibia pathology, we observed a minimal 
variance of sequentially obtained adequate measurements. There was also no differ-
ence in mean BMSi values between the dominant and non-dominant leg. Interestingly, 
in patients with Paget’s, mean BMSi of the affected tibia was lower compared to that 
of the healthy tibia, albeit not reaching significance (74.7 ± 1.7 and 78.7 ± 1.3; p = 0.120). 
This finding was rather unexpected since Paget’s disease is associated with significant 
alterations in the microarchicture of bone and with an increased risk of fracture at the 
site of the lesion. However, these intriguing results might be due to the limited sample 
size of our study. There was a significantly greater variability in sequentially obtained 
measurements in the Pagetic tibia compared to measurements obtained in the non-
Pagetic tibia. These data suggest that the variability of measurements may provide 
additional relevant information on tissue-level properties of cortical bone in addition 
to that provided strictly by BMSi values.
FUTURE PERSPECTIVES
There is mounting evidence that impact microindentation is a promising technique 
which enables the measurement of aspects of bone fragility not solely captured by 
BMD values. It has been shown that IMI can be used to differentiate patient groups with 
conditions known to negatively affect bone health such as type 2 diabetes mellitus, use 
of glucocorticoids and presence of fragility fractures from control patients. Although 
knowledge and experience with the use of IMI is steadily increasing, a number of 
aspects of the interpretation of data generated by this technique such as the relation-
ship between BMSi and age and its relationship with BMD values, or the relationship of 
BMSi with traditional measurements of material properties of bone such as toughness 
remain unclear. Large clinical studies are required to unravel these issues. In addition, 
the observation of variable BMSi values in controls groups from different studies which 
range between 70 to 85 is very intriguing. This is clearly reflected in a study that 
demonstrated significantly lower BMSi values in Norwegian compared with Spanish 
women. These observations suggest that reference values should be established for 
different geographical groups, in addition to different age groups, before BMSi could 







Een groot deel van de bevolking loop tenminste eenmaal in hun leven een fractuur 
op. Patiënten met een hogere leeftijd hebben een grotere kans op het ontwikkelen 
van fracturen. Het krijgen van een fractuur zonder adequaat trauma is een teken 
dat er mogelijk sprake is van onderliggende osteoporose. Fracturen behoren tot de 
klinisch meest relevante uitkomsten van osteoporose en zijn gerelateerd met een toe-
genomen morbiditeit en mortaliteit en met hogere kosten voor de gezondheidszorg. 
Verder is de aanwezigheid van een fractuur positief voorspellend voor het krijgen van 
eventuele toekomstige fracturen.
Zogenaamde “fractuurklinieken’ zijn multidisciplinaire samenwerkingsverbanden 
met het doel om patiënten te identificeren die recent een fractuur hebben gehad en 
om deze patiënten vervolgens, indien nodig, te behandelen met anti-osteoporose 
therapie. De Wereldgezondheidsorganisatie (WHO) heeft in 2013 wereldwijd de cam-
pagne “Capture the Fracture” gelanceerd om de ontwikkeling en toepassing van deze 
klinieken te stimuleren met als einddoel adequate secundaire preventie van fracturen 
bij patiënten die recent een fractuur hebben doorgemaakt. Fractuurklinieken leiden 
op een kosteneffectieve wijze tot een reductie in mortaliteit en in het aantal toekom-
stige fracturen.
Dit proefschrift is voor een groot deel gebaseerd op gegevens van patiënten vanuit 
de fractuurkliniek van het Leids Universitair Medisch Centrum (LUMC). Hoewel het 
LUMC een tertiair doorverwijzingscentrum is, verzorgt de fractuurkliniek van het LUMC 
de acute opvang voor alle fractuurpatiënten in de regio Leiden. De fractuurpatiënten 
die geschikt zijn voor doorverwijzing naar de fractuurkliniek worden uit de spreekuren 
van de polikliniek traumatologie en orthopedische chirurgie geïdentificeerd door een 
doktersassistente osteoporose. Deze aanpak is zeer succesvol gebleken en leidde tot 
een percentage doorverwijzingen van meer dan 50 % gedurende de eerste twee jaar 
en steeg naar 95 % in 2016.
DEEL 1: DE FRACTUURkLINIEk
Hoofdstuk 2, 3 en 4 beschrijven een grote groep patiënten van 50 jaar en ouder 
die tussen juni 2012 en juni 2014 vanwege een recente fractuur zijn doorverwezen 
naar de fractuurkliniek van het LUMC. Het screeningsprogramma dat wordt ge-
bruikt in de fractuurkliniek bestaat uit een aantal onderdelen, ten eerste worden 
patiënten geanalyseerd op de aanwezigheid van osteoporose door middel van een 
botdichtheidsmeting met een DXA-scanner. Ten tweede wordt de aanwezigheid van 
onderliggende secundaire oorzaken voor osteoporose geëvalueerd door middel van 
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het verzamelen van klinische gegevens zoals leeftijd, geslacht, lengte en gewicht, 
fractuurvoorgeschiedenis en de aanwezigheid van risicofactoren voor osteoporose 
zoals gebruikt in het FRAX algoritme en door middel van laboratoriumonderzoek. Als 
laatste wordt er gezocht naar de aanwezigheid van wervelinzakkingen door middel 
van de VFA-functie op het DXA-apparaat en door middel van röntgenfoto’s van de 
thoracale en de lumbale wervelkolom.
In hoofdstuk 2 wordt de prevalentie van onderliggende secundaire oorzaken voor 
osteoporose beschreven in bovenstaand beschreven groep van 686 patiënten uit de 
fractuurkliniek van het LUMC. Wij zagen een groot aantal onderliggende oorzaken 
voor osteoporose bij patiënten met een recente fractuur ongeacht de botdichtheid; 
47 % van de patiënten met een normale botdichtheid, 57 % van de patiënten met 
osteopenie en 62 % van de patiënten met osteoporose hadden een of meer onderlig-
gende oorzaken voor osteoporose. Verder zagen wij een relatie tussen het aantal 
onderliggende oorzaken per patiënt en de botdichtheid. Klinisch relevant is dat meer 
dan de helft van het aantal onderliggende oorzaken reversibel is, mogelijk leidt het 
wegnemen of het opheffen hiervan tot een vermindering van het risico op nieuwe 
fracturen. Vanwege de hoge prevalentie onderliggende oorzaken voor osteoporose 
bij patiënten met een recente fractuur onafhankelijk van de botdichtheid, adviseren 
wij dat er niet alleen bij de patiënten met osteoporose naar de aanwezigheid van deze 
oorzaken moet worden gezocht, maar bij alle fractuurpatiënten.
De resultaten van onze studie naar de waarde van VFA-onderzoek voor het identifi-
ceren van wervelinzakkingen bij patiënten boven de 50 jaar met een recente fractuur 
worden beschreven in hoofdstuk 3. Vertebral Fracture Assessment (VFA) is een 
onderzoek dat in dezelfde meetsessie als de botdichtheidsmeting kan worden uitge-
voerd met het DXA-apparaat. Met een zeer lage hoeveelheid straling wordt laterale 
beeldvorming van de thoracale en laterale wervelkolom gemaakt, waarop vervolgens 
kan worden beoordeeld of er sprake is van wervelinzakkingen. De sensitiviteit van 
VFA voor het identificeren van een patiënten met een wervelinzakking graad 2 of 
hoger was 0.77 en de specificiteit was 0.80. Dit houdt in dat het VFA-onderzoek 23 % 
van alle patiënten met een wervelinzakking graad 2 of hoger heeft gemist. Deze uit-
komsten wijken sterk af van onderzoeksuitkomsten uit de literatuur en om deze reden 
is er naast bovenstaande analyse ook een systematische review en een meta-analyse 
uitgevoerd naar de waarde van VFA-onderzoek, deze staan eveneens beschreven in 
hoofdstuk 3. Onze systematische review leidde tot 16 verschillende studies waarin 
totaal 3238 patiënten waren geïncludeerd. De gerapporteerde sensitiviteit en spe-
cificiteit van de studies waren echter zeer verschillend (respectievelijk 47–99 % en 




inclusie criteria van patiënten. De meta-analyse toonde een sensitiviteit van 0.82 (95 % 
BI, 0.75–0.87) en een specificiteit van 0.99 (95 % BI, 0.98–1.00) voor het identificeren 
van wervelinzakkingen graad 1 of hoger door VFA-onderzoek. Samenvattend waren 
de resultaten van zowel de systematische review als de meta-analyse discrepant hoog 
in vergelijking met de resultaten van onze eigen studie. De verschillen kunnen worden 
verklaard door verschillen in studie opzet en in het gebruik van variabele software 
en hardware. Vanwege deze bevindingen adviseren wij om de uitkomsten van de 
VFA-methode in ieder ziekenhuis te controleren voordat deze methode in plaats van 
röntgenfoto’s van de laterale wervelkolom wordt gebruikt om de aanwezigheid van 
wervelinzakkingen te evalueren.
De mate van formatie en resorptie van botweefsel kan worden gemeten met behulp 
van botturnovermarkers. Botturnovermarkers kunnen gemakkelijk worden gemeten in 
serum van de patiënt en zijn potentieel geschikt voor het vervolgen van het therapie-
effect van anti-osteoporose medicatie. In hoofdstuk 4 wordt het effect van anti-osteo-
porose medicatie op de botturnovermarkers P1NP en Ctx beschreven bij patiënten 
met een recente fractuur, daarnaast wordt de relatie tussen deze botturnovermarkers 
en de botdichtheid beschreven. Er is een omgekeerde relatie tussen het verschil 
in P1NP gemeten na 3 en 12 maanden therapie en het verschil in botdichtheid van 
de lumbale wervelkolom na 12 maanden therapie. Na correctie voor tijd tussen het 
oplopen van de fractuur en starten van therapie was alleen de relatie tussen de bot-
turnovermarkers en de botdichtheid van de lumbale wervelkolom 12 maanden na het 
starten van therapie statistisch significant. Er is ook een omgekeerde relatie tussen 
het verschil in Ctx gemeten na 12 maanden therapie en het verschil in botdichtheid 
van de lumbale wervelkolom na 12 maanden therapie nadat er is gecorrigeerd voor 
tijd tussen het oplopen van de fractuur en starten van therapie. Verder wordt er een 
relatie gezien tussen de P1NP waarde voor het starten van anti-osteoporose medicatie 
en het verschil in botdichtheid van de lumbale wervelkolom gemeten na 12 maanden. 
Deze studie toont aan dat het vroege effect op botturnovermarkers na het starten van 
antiresorptieve therapie voorspellend is voor het effect op de botdichtheid door deze 
therapie. Of botturnovermarkers voorspellend zijn voor het risico op fracturen moet 
worden aangetoond in grote longitudinale studies.
DEEL 2: IMPACT MICROINDENTATIE
In hoofdstuk 6 tot en met 9 worden de resultaten van de studies naar impact microin-
dentatie (IMI) beschreven. IMI is een nieuwe methode voor het onderzoeken van ma-
teriaal eigenschappen van bot bij de mens en wordt uitgevoerd met de Osteoprobe®. 
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De methode is gebaseerd op de hypothese dat een fractuur het gevolg is van de 
scheiding van gemineraliseerde collageenvezels, waardoor microscheurtjes in het bot 
ontstaan. De metingen worden bij mensen met slechts plaatselijke anesthesie op de 
anterieure zijde van de tibia uitgevoerd. Voor de meting wordt er een meetnaaldje in 
de Osteoprobe geplaatst en de naald wordt met een kracht van 40 Newton tegen het 
botoppervlakte gedreven. Deze handeling heeft microscheurtjes en micro-indentaties 
tot gevolg en wordt een aantal keer herhaald. De grootte van de micro-indentatie 
wordt de “Indentation Distance Increase” (IDI) genoemd. Hierna wordt dezelfde han-
deling herhaald op fantoommateriaal gemaakt van polymethylmethacrylate. Met de 
metingen op het bot en op de fantoom kan de “Bone Material Strength index” (BMSi) 
worden berekend met de formule 100 x (harmonisch gemiddelde van de IDI op de 
fantoom / gemiddelde van de IDI op het bot). Dat wil zeggen dat de BMSi waarde 100 
zal zijn als het bot precies zo sterk is als de fantoom. Indien het bot minder weerstand 
heeft tegen de indentaties dan zal de BMSi lager zijn. In hoofdstuk 5 wordt er een uit-
gebreid overzicht gegeven over de ontwikkeling van IMI en over de klinische studies 
die tot op heden zijn gepubliceerd.
In hoofdstuk 6 wordt een studie beschreven waarin de BMSi waarde is gemeten van 
90 patiënten met een lage botmassa (osteopenie en osteoporose) en zowel met als 
zonder fracturen. Patiënten met een fractuur hebben gemiddeld een lagere BMSi 
waarde dan patiënten zonder een fractuur. Verder zagen wij een sterke omgekeerde 
relatie tussen BMSi en de leeftijd van de patiënt. Deze gegevens impliceren dat de 
materiaal eigenschappen van bot bij mensen met een fractuur afwijkend zijn en dat 
BMSi metingen parameters van botsterkte omvatten die niet worden omvat door een 
botdichtheidsmeting.
Nadat de studie beschreven in hoofdstuk 6 was afgerond en gepubliceerd, werden 
er twee studies gepubliceerd waarin de relatie tussen BMSi en wervelfracturen werd 
onderzocht. De resultaten van deze twee studies waren echter tegenstrijdig. Om meer 
inzicht te krijgen of BMSi inderdaad inzicht kan geven in materiaaleigenschappen van 
het gehele skelet in plaats van alleen corticaal bot, onderzochten wij de relatie tussen 
BMSi en verscheidene typen fracturen, waaronder wervelfracturen, waarvan de resul-
taten staan beschreven in hoofdstuk 7. Er werden in totaal 132 patiënten geïncludeerd 
in deze studie, waaronder 101 patiënten met een fractuur. De fractuurpatiënten kon-
den worden verdeeld in 14 patiënten met een wervelfractuur, 53 met een niet-wervel 
fractuur en 34 met zowel een wervelfractuur als een ander fractuurtype. De BMSi 
van de patiënten met de verschillende fractuurtypen was onderling niet verschillend, 




daarom zien dat BMSi een weergave is van botsterkte in het gehele skelet en niet 
alleen van botsterkte van het corticale bot.
Met het doel te onderzoeken of de IMI techniek in staat is patiënten met een hoog 
risico op wervelfracturen te identificeren hebben wij een studie uitgevoerd waarin 
BMSi waarden bij 48 patiënten met acromegalie werden gemeten. De resultaten 
van dit onderzoek staan beschreven in hoofdstuk 8. Acromegalie is een zeldzame 
endocriene ziekte waarbij er een overproductie van groeihormoon bestaat met een 
scala van gevolgen, waaronder een hoge prevalentie wervelfracturen. De acrome-
galie patiënten werden vergeleken met 44 controle patiënten met vergelijkbare BMI 
en botdichtheid van de wervelkolom en het collum femoris. Er werd een gemiddeld 
lagere BMSi waarde gezien bij patiënten met acromegalie dan bij de controle patiën-
ten. In de vergelijking tussen acromegalie patiënten met en zonder wervelfracturen 
werd er geen verschil in BMSi gezien. De resultaten van deze studie impliceren dat de 
materiaal eigenschappen van het bot bij patiënten met acromegalie afwijkend zijn wat 
mogelijk bijdraagt aan het hoge risico op wervelfracturen.
In de periode waarin de studies werden uitgevoerd die staan beschreven in dit proef-
schrift, werd eveneens door andere onderzoeksgroepen onderzoek uitgevoerd met 
de IMI methode. Deze studies hebben allen bijgedragen aan een ruimere ervaring met 
de methode maar leidden ook tot een aantal vragen die reeds werden benoemd in 
verschillende review artikelen. Het gaat om de volgende aandachtspunten: de iden-
tificatie van foutmetingen, de variabiliteit van afzonderlijke metingen op het botop-
pervlakte en de voorkeurslocatie van de metingen op het bot (oftewel het dominante 
of het niet-dominante been). Deze vraagstukken worden allen onderzocht in de studie 
beschreven in hoofdstuk 9, waarin wij BMSi metingen hebben uitgevoerd op beide 
tibiae bij patiënten met de ziekte van Paget gelokaliseerd in de tibia en bij patiënten 
zonder afwijkingen in de tibia. Er werd een minimale variantie van de uitgevoerde 
afzonderlijke botmetingen gezien bij de meerderheid van de patiënten zonder pa-
thologie aan de tibia. Een grotere variantie werd ook gezien, maar dit leidde bij geen 
van de patiënten tot een significant verschil in de gemiddelde BMSi waarde van de 
contralaterale tibia. Er was geen significant verschil in BMSi tussen de dominante en 
niet-dominante tibia in deze patiënten. Bij de patiënten met de ziekte van Paget was 
de BMSi waarde van de tibia waarin de Paget laesie was gelokaliseerd lager dan de 
BMSi waarde van de contralaterale tibia zonder afwijkingen, dit verschil was echter 
niet significant lager. Laatstgenoemd resultaat bij de patiënten met de ziekte van 
Paget was onverwachts aangezien de ziekte gepaard gaat met forse afwijkingen in 
microarchitectuur van het aangedane bot en met een verhoogd risico op fracturen. 
Ondanks het ontbreken van een significant verschil in BMSi, was er wel een grotere 
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variabiliteit van sequentiële metingen bij de aangedane tibiae dan bij de tibiae zonder 
afwijkingen. Deze studie laat zien dat de variabiliteit van de metingen als een nieuwe 
parameter voor materiaal eigenschappen van bot kan worden gebruikt en suggereert 
dat metingen als foutief moeten worden beoordeeld door een ervaren operator in 
plaats van door een geautomatiseerd algoritme waarin pre-gedefinieerde afkapwaar-
den worden gehanteerd.
TOEkOMSTPERPECTIEF
Impact microindentatie is een veelbelovende techniek die parameters van botsterkte 
weergeeft die niet worden weergegeven door een botdichtheidsmeting. Eerdere 
studies hebben aangetoond dat IMI kan differentiëren tussen patiëntgroepen met 
een aandoening die gepaard gaat met een verhoogd fractuurrisico zoals diabetes 
mellitus type 2, het gebruik van glucocorticoïden en de aanwezigheid van een frac-
tuur, en controle patiënten. Ondanks dat de kennis en de ervaring van deze techniek 
toeneemt bestaan er een aantal vragen en discussiepunten die nog onduidelijk zijn, 
zoals de relatie tussen BMSi en leeftijd of de botdichtheid van de patient, en de relatie 
tussen BMSi en klassieke mechanische parameters. Het is noodzakelijk dat deze 
onduidelijkheden inzichtelijk worden gemaakt. Het is opmerkelijk dat de gemiddelde 
BMSi waarden van de controle patienten in de gepubliceerde studies erg varieren, 
namelijk van 70 tot 85. Een studie toonde eerder een significant verschil in BMSi aan 
tussen vrouwen uit Noorwegen en uit Spanje. Deze resultaten suggereren dat het no-
dig zal zijn om referentiewaarden te implementeren waarin wordt gecorrigeerd voor 
karakteristieken zoals leeftijd en geografische achtergrond voordat uitkomstwaarden 




AFF Atypical femoral fractures
BMD  Bone Mineral Density
BMI Body Mass Index
BMSi Bone Material Strength index
BMSu Unnormalized Bone Material Strength
BPiv Intravenous bisphosphonates
BPor Oral bisphosphonates
BTM Bone turnover marker
CAG Chronic atrophic gastritis
CA/D Calcium/vitamin D supplementation
CKD Chronic kidney disease
CMI Cyclic reference point microindentation
CTX C-terminal crosslinked telopeptide of type I collagen
CV Coefficient of variation
DALY Disability Adjusted Life Years
Dmab Denosumab
DXA Dual Energy X-ray Absorptiometry
eGFR estimated glomerular filtration rate
EM early menopause
ER  Emergency Room
FLS Fracture Liaison Service
FN Femoral neck
FU Follow-up




HIV Human Immunodeficiency Virus
HT Hyperthyroidism
HRpQCT High Resolution peripheral Quantitative Computed Tomography
IDI Indentation Distance Increase




LUMC Leiden University Medical Center
MDRD Modification of diet in renal disease
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MGUS Monoclonal Gammopathy of Undetermined Significance





P1NP Procollagen 1 N-terminal extension peptide
RA Rheumatoid arthritis
RPI Reference Point Indentation
RSN Risedronate
SD Standard deviation
SEM Standard error of the mean
SERMs  Selective estrogen receptor modulators
TBS Trabecular Bone Score
TPTD Teriparatide
T2DM Type 2 Diabetes Mellitus
VFA Vertebral Fracture Assessment
VF+/Fx+  Vertebral and non-vertebral fracture
VF+/Fx- Only vertebral fracture
VF-/Fx+ Only non-vertebral fracture
WHO World Health Organization
1° HPT  Primary hyperparathyroidism
2° HPT  Secondary hyperparathyroidism
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